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About seven million years ago one of the most important moments of the human 
evolution occurred when a group of new beings, descendents of the chimpanzees, 
emerged from the tropical forests to the open savannas of Africa. These new beings 
had one major prevailing characteristic: they were capable of standing and walking 
upright. Over a period of millions of years the modern human being, Homo sapiens, 
evolved some two hundred thousand years ago. Over this period the modern human 
being evolved to a full erected posture when standing and walking, completing the 
evolutionary transition from quadruped to bipedal human being.
The upright posture enhanced mobility, but at the same time it greatly 
challenged the control of blood pressure regulation by making it highly sensitive to 
gravitational forces. The blood pressure regulation systems in most animals are quite 
similar with a large pump, the heart, circulating the blood to a large system of blood 
vessels. However, in most quadrupeds about 70% of blood volume is at o r above heart 
level in contrast to humans where approximately 70% of blood volume is below  heart 
level (1). This means that in quadrupeds the hydrostatic and gravitational impact on 
blood pressure regulation is significantly less than in humans. To maintain blood 
pressure in the upright posture, blood pressure regulation systems in humans evolved 
over time to accommodate for gravitational and hydrostatic forces (1).
The autonomic nervous system, through sympathetic nervous system activity, 
plays a principal role in maintaining blood pressure during the upright position (2-4). 
It is, therefore, thought that an alteration of the function of the autonomic nervous 
system may result in a decrease in blood pressure when adopting the upright posture, 
known as orthostatic hypotension (2,4). The aim of this thesis is to examine the role of 
peripheral vascular control systems in individuals with autonomic failure. In this 
chapter the function of the autonomic nervous system in the blood pressure 
regulation will be summarised with special emphasis on the sympathetic nervous 
system mediated peripheral vascular control.
BLOOD PRESSURE REGULATION
Maintaining blood pressure during the upright posture is essential for our well being. 
It is socially not desirable or even not accepted that individuals cannot stand-up or 
stand upright for a certain amount of time. This is only possible when the blood 
pressure is maintained during the upright posture by regulating mechanisms. Blood
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pressure is defined as the product of cardiac output (heart rate times stroke volume) 
and total peripheral resistance (Figure 1). The effect of the upright posture on cardiac 
output has been extensively studied. In contrast, the effect of the upright posture on 
peripheral vascular resistance is scarcely studied.
Figure 1. Schematic representation of baroreflex control of blood pressure through 
changes in sympathetic nervous system activity.
Vasoconstrictor mechanisms
The upright posture in humans results in a gravitational displacement of ~500-1000 
ml of blood into the dependent vasculature below the diaphragm, leading to a 
decrease in venous return to the heart with a consequent decrease in cardiac output 
and an immediate drop in blood pressure (Figure 1) (3,4). The autonomic nervous 
system plays a principal role in the blood pressure regulation and the maintenance of 
blood pressure during changes in posture (2-4). The blood pressure drop during the 
upright posture will unload the baroreceptors resulting in an increased sympathetic 
nerve activity and decreased vagal outflow, i.e. baroreflex activation (2). The 
baroreceptors are stretch receptors located in the carotid sinus and ascending aorta. In 
order to maintain blood pressure, the baroreceptor mediated activation of the 
sympathetic nervous system will increase heart rate, cardiac contractility and 
peripheral vascular resistance (Figure 1) (2,3). The primary role of the baroreflex is a
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rapid adjustment of blood pressure on a beat-to-beat basis. Changes in peripheral 
vascular resistance rather than changes in cardiac output are thought to be primarily 
responsible for maintaining blood pressure during orthostatic challenges (3,5,6).
Although the baroreflex mediated increase in peripheral resistance is important 
in the maintenance of blood pressure during orthostatic challenges, there are also 
other mechanisms which can increase peripheral vascular resistance (4). During the 
initial adjustments to the change in posture, local vasoconstrictor mechanisms can 
contribute to the increased peripheral vascular resistance. These local vasoconstrictor 
mechanisms are the veno-arteriolar axon reflex (VAR) (7) and the myogenic response 
(8,9). It is thought that they may contribute to 45% of leg vasoconstriction during 
orthostatic challenges (7). Both are triggered by an increase in pressure caused by the 
gravitational displacement of blood during the upright posture. The VAR is triggered 
by an increase in venous pressure resulting in a vasoconstriction of the corresponding 
arteriole (7). Whereas the myogenic response is triggered by an increase in transmural 
pressure across an arteriole (8,9). During prolonged orthostatic stress, the baroreflex 
mediated increase in sympathetic activity remains important (4), but also humoral 
factors, such as angiotensin II, contribute to the increased peripheral resistance (4,10). 
The renin-angiotensin-aldosterone system is activated during orthostatic challenges 
via increased sympathetic activity to the kidneys and renal hypoperfusion. The 
released renin will catalyse the conversion of angiotensinogen to angiotensin I, which 
w ill be converted to angiotensin II, via the angiotensin converting enzyme (ACE) 
(11,12). Angiotensin II  can induce vasoconstriction via binding to angiotensin II  type 
1 receptors (11,12). Vasopressin and atrial natriuretic factor seem to play only a minor 
role in the maintenance of blood pressure during orthostatic challenges (4,10). Also 
the local endothelium derived vasoconstrictor endothelin-1 does not seem to play a 
role in maintaining blood pressure during orthostatic challenges (13).
Orthostatic hypotension
Failure of these regulating mechanisms to maintain blood pressure during the upright 
position can result in (a)symptomatic orthostatic hypotension (2,4,14-16). This is 
defined as a decrease in systolic blood pressure of at least 20 mmHg or a decrease in 
diastolic blood pressure of at least 10 mmHg within 3 minutes of standing or a 60° 
head-up tilt test (17). Orthostatic hypotension is often the most disabling symptom in 
patients and negatively related to daily life activities and quality of life (4,18-22). It
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increases the risk of falls (23-25) and is associated with cardiovascular morbidity and 
mortality in elderly (26-30). Even in the general population it is estimated that 
orthostatic hypotension occurs in 0.5% (31), with a higher incidence of 5-30% in the 
elderly (29,32-34). Characteristic symptoms of orthostatic hypotension are mostly due 
to cerebral hypoperfusion and include feelings of weakness, fatigue, blurred vision, 
light headedness, dizziness and loss of consciousness (2,17,19).
AUTO NO M IC NERVOUS SYSTEM
The autonomic nervous system, through sympathetic nervous system activity, plays a 
principal role in maintaining blood pressure during the upright position (2-4). 
Orthostatic hypotension in patients with autonomic disorders is thought to be related 
to baroreflex failure (4 ,14-16). A normal function of the autonomic nervous system 
and particularly the sympathetic mediated increase in peripheral vascular resistance is, 
therefore, essential to maintain blood pressure. In this chapter we will focus on the 
sympathetic nervous system regulation of blood pressure.
Anatomy and physiology
The autonomic nervous system has a central and peripheral part. The central part 
exists of multiple brain areas, such as the hypothalamus and ‘limbic system’, including 
the hippocampus, amygdale and insula cortex. Within the brainstem the input and 
output of the central and peripheral autonomic nervous system are integrated to 
control vasomotor tone and cardiac function from the ventrolateral medulla in the 
brainstem. The peripheral autonomic nervous system consists of two complementary 
system, e.g. the sympathetic and parasympathetic nervous system. The sympathetic 
nervous system is also known as the ‘fight and flight’ system, whereas the 
parasympathetic nervous system is known as the ‘rest and digest’ system.
The sympathetic nervous system exists of pre- and postganglionic fibres 
(Figures 2 and 3). The preganglionic axons derive from cell bodies located within the 
spinal cord between the first thoracic (T 1) and the second or third lumbar spinal 
segment (L2-3). These efferent preganglionic fibres innervate sympathetic neurons 
located in para- and prevertebral ganglia. Efferent postganglionic axons from these 
ganglia innervate the target organs. The paravertebral ganglia are paired at both sides 
of the vertebral column forming the sympathetic trunk. The heart is innervated from
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the preganglionic axons derived from the first to fourth thoracic spinal segment (T 1- 
4). Smooth muscle cells of peripheral blood vessels are innervated from their 
corresponding spinal cord segments, for example blood vessels of the trunk at thoracic 
segments and of the lower limbs from low thoracic and lumbar spinal segments. 
Preganglionic axons innervating the splanchnic organs pass through the sympathetic 
trunk to prevertebral ganglia and derive from spinal segments below the sixth thoracic 
spinal segment (T6).
Figure 2. The sympathetic autonomic nervous system with outflow to various organs.
Modified with permission from BMJ Publising Group Ltd from Mathias, Neurol Neurosurg 
Psychiatry 2003 (35).
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Figure 3. The sympathetic nervous system.
Spinal oord
_____________________________ II____________ I
Post ganglionic axon_____________________ Preganglionic axon
Via pre- and postganglionic axons, an electrical potential releases noradrenaline (•)  from the nerve 
terminal into the synaptic cleft where it binds to adrenoceptors (a1 and fi2) of the smooth muscle cell 
of the target organ. The presynaptic a 2-adrenoceptor will inhibit noradrenaline release and the 
noradrenaline transporter (NET) will reuptake noradrenaline from the synaptic cleft.
In the sympathetic nervous system, noradrenaline is the effective neurotransmitter 
released from the postganglionic nerve terminals, whereas acetylcholine is the 
neurotransmitter at the preganglionic nerve terminals, with exception of the sweat 
glands where acetylcholine is the effective neurotransmitter. The biosynthesis of 
noradrenaline occurs in the sympathetic neuron and starts with the amino acid 
tyrosine which is conversed into dihydroxyphenylalanine (DOPA) catalysed by 
tyrosine hydroxylase (Figure 3). In the second step, L-aromatic amino acid 
decarboxylase catalyses the conversion of DOPA to dopamine. Finally, dopamine is
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conversed into noradrenaline which is catalysed by dopamine-fi-hydroxylase. 
Noradrenaline will be released from the nerve terminal into the synaptic cleft 
triggered by electrical action potentials. Binding of noradrenaline to the a- and fi- 
adrenergic receptors of target organs will cause the major sympathetic actions (Figure
3).
Besides noradrenaline also non-adrenergic neurotransmitters, such as 
adenosine triphosphate (ATP) and neuropeptide Y (NPY), are released from the 
sympathetic nerve terminal (36,37). These neurotransmitters are co-stored with 
noradrenaline, simultaneously released into the synaptic cleft and thought to have a 
coordinated action with noradrenaline (36,37). ATP acts on the purinoceptor P2X of 
the target organ and has been demonstrated to be a vasoconstrictor in animal studies 
(36). Neuropeptide Y modulates the action of noradrenaline and ATP, and does not 
seem to be a vasoconstrictor itself (36).
Autonomic disorders
There are many different disorders which can result in autonomic failure (Table 1). 
We distinguish primary autonomic disorders, with unknown aetiology, from 
secondary disorders (38). The primary autonomic disorders are subdivided in acute 
and chronic autonomic failure syndromes. Pure autonomic failure, multiple system 
atrophy, formerly known as the Shy-Drager syndrome, and autonomic failure with 
Parkinson’s disease are classified as primary chronic autonomic disorders. Secondary 
autonomic disorders cover a wide range of causes from common disorders, such as 
diabetes mellitus, via quite specific disorders, such as spinal cord injuries, to very rare 
hereditary disorders, such as dopamine-fi-hydroxylase deficiency. There are also 
various drugs, chemicals, poisons and toxins which can cause autonomic failure. 
Besides these generalised autonomic disorders, there are also some localised 
autonomic disorders of which the most familiar is the Horner’s syndrome. The 
autonomic disorders studied in this thesis will be discussed in more detail.
P u re autonom ic fa ilu re
The first cases of pure autonomic failure (PAF) were described by Bradbury and 
Eggleston in 1925 as ‘idiopathic orthostatic hypotension’ (39). In PAF there is a 
postganglionic lesion of the sympathetic nervous system with a generalised los of 
sympathetic fibres in the body and consequently reduced supine plasma
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noradrenaline levels (Table 2) (16,40,41). PAF is one of the chronic primary 
autonomic disorders (Table 1) and characterised by persistent orthostatic hypotension 
in the absence of signs of central nervous system disease or other known causes of 
orthostatic hypotension (17,38,39). Besides orthostatic hypotension also other 
symptoms of widespread autonomic failure are usually present. The cause of PAF is 
still unknown, but it seems not to be inherited nor infectious (42). It occurs in middle- 
aged or elderly individuals with no preference for sex or race (15,42). PAF is a chronic 
and disabling disorder, but is thought not to be lethal.(15,42)
Table 1. Primary and secondary autonomic disorders.
Secondary autonomic disorders
Congenital
Nerve growth factor deficiency 
Hereditary
Familial amyloid neuropathy 
Dopamine-fi-hydroxylase deficiency 
Familial dysautonomia 
M etabolic diseases 
Diabetes mellitus 
Chronic renal failure 
Chronic liver disease 
Alcohol induced 
Vitamin Bi2 deficiency 
Inflam m atory
Guillain-Barre syndrome 
Transverse myelitis 
Infections
Bacterial: Tetanus 
Parasitic: Chagas’disease 
Viral: HIV 
Neoplasia
Brain tumors 
Paraneoplastic 
Connective tissue disorders 
Rheumatoid arthritis 
Surgery
Sympathectomy 
Traum a
Spinal cord injury 
Drugs, chemicals, poisons and toxins 
For the secondary autonomic disorders only the subdivisions and some examples are given.
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Primary autonomic disorders
Acute/subacute dysautonomias 
Pure cholinergic dysautonomia 
Pure pandysautonomia 
Pandysautonomia with neurological features
C hronic autonom ic fa ilu re  syndromes 
Pure autonomic failure 
Multiple system atrophy 
Autonomic failure with Parkinson’s disease 
Dementia with Lewy bodies
Table 2 . Pathophysiological classification of the different autonomic disorders
PAF PD DBH SCI
SNS lesion Postganglionic Postganglionic Postganglionic Central
Sympathetic nerves Degenerative Degenerative Intact Intact
Baseline noradrenaline Low Low Absent Normal
Noradrenaline release Low Low Absent Low
Response to noradrenaline Increased Increased Increased Increased
Spinal cord injury (SCI), Parkinson’s disease with autonomic failure (PD), pure autonomic failure 
(PAF) and dopamine-fi-hydroxylase deficiency (DBH). SNS, sympathetic nervous system.
P a rk in so n ’s disease
James Parkinson, in 1817, accurately described the motor problems of what was later 
called Parkinson’s disease (PD), but also noted several non-motor symptoms (43). PD 
is a neurodegenerative disorder caused by the loss of dopaminergic neurons in the 
substantia nigra and characterised by typical motor symptoms, i.e. bradykinesia or 
even akinesia, tremor and muscle rigidity (44). In the last decade it has become clear 
that PD also affects the sympathetic nervous system. Lewy bodies were found within 
the sympathetic ganglia (45,46) and there is sympathetic denervation of the heart 
(47,48), indicating a more generalised involvement (Table 2). Besides the typical 
motor symptoms also non-motor symptoms may be present, such as autonomic 
failure (47,49-53). Symptomatic and asymptomatic orthostatic hypotension occurs in 
up to 60% of PD patients (54-56) and was thought to be caused by levodopa treatment 
(57,58). However, PD patients off levodopa treatment or never treated with levodopa 
also demonstrate orthostatic hypotension (47,58,59). Orthostatic hypotension in PD, 
therefore, reflects autonomic failure and PD is now classified as a chronic primary 
autonomic disorder (42,47). PD usually occurs in older individuals with no preference 
for sex or race.
D opam ine-fi-hydroxylase deficiency
In the mid-eighties of the last century, the first two reported cases of dopamine-fi- 
hydroxylase (DBH) deficiency were published almost simultaneously by Robertson et 
al. (60) and Man in’t Veld et al. (61). DBH deficiency is an extremely rare (less than 20 
cases worldwide) autosomal recessive hereditary disorder (Table 1) (20). DBH 
deficiency is characterised by a complete absence of noradrenaline with an intact 
sympathetic nervous system (Table 2) (20). Since these patients lack the DBH enzyme,
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they cannot convert dopamine into noradrenaline (20,60,61). As a result, 
noradrenaline levels are undetectable and dopamine levels are high (20,60-62). 
Autonomic failure in these patients is caused by a lack of sympathetic 
neurotransmitter, and not by a decreased or absent sympathetic activity, since the 
sympathetic nerves are intact (20). DBH deficiency patients suffer from severe 
orthostatic hypotension (20,60,61). DBH deficiency patients can be treated with L- 
threo-dihydroxyphenylserine (L-DOPS or droxidopa) (20,63), a synthetic prodrug of 
noradrenaline (64).
Spinal cord in ju ry
The incidence of spinal cord injuries in the Netherlands varies between 10-27 per 
million individuals (65,66), mostly caused by trauma (67). Disruption of the spinal 
cord results in a complete or incomplete paralysis of motor, sensory and autonomic 
function below the level of the lesion. A spinal cord injury has dramatic consequences 
on the cardiovascular control by the sympathetic nervous system (68-70). The severity 
of the autonomic failure is depending on the completeness and level of the spinal cord 
lesion (68,69,71). At the level of the spinal cord lesion sympathetic denervation might 
take place, although sprouting of nerve cells might result in preservation of 
sympathetic nerves (72-74). Below the spinal cord lesion sympathetic nerves are 
preserved (69), however they are without central supraspinal control, depending the 
completeness of the lesion. Orthostatic hypotension is frequently demonstrated 
directly after the spinal cord lesion and persists over time in cervical and high thoracic 
spinal cord lesions (68-70,75). In lower thoracic spinal cord lesions orthostatic 
hypotension might resolve or become less important.
One of the cardiovascular consequences of a spinal cord injury is the increased 
basal leg vascular resistance (76), which might contribute to the development of 
pressure sores and poor wound healing in SCI individuals due to decreased perfusion 
(77). Previous research of our department has demonstrated that the increased basal 
leg vascular resistance in SCI individuals is not explained by adaptations in a- 
adrenergic vascular tone (78) or in endothelium derived nitric oxide (79). Endothelin- 
1 does contribute to the increased basal leg vascular resistance, however it cannot fully 
explain the total increase in leg vascular resistance in SCI individuals (80). Other 
vasoconstrictors might, therefore, contribute to the increased basal leg vascular 
resistance. Of special interest is angiotensin II, which is closely linked with
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endothelin-1 (81-83) and SCI individuals have an increased renin-angiotensin II 
system activity (84,85). However, the role of angiotensin II  in the increased basal leg 
vascular resistance in SCI individuals is unknown.
Figure 4 . Schematic representation of autonomic dysreflexia in a spinal cord-injured 
individual with a spinal cord lesion above the sixth thoracic spinal segment (T6).
Modified with permission from the Canadian Medical Association from Blackmer, CMAJ 2003 (87).
Because of the intact sympathetic nervous system below the spinal cord lesion with no 
influence of supraspinal inhibitory pathways (69), the interesting clinical 
phenomenon of autonomic dysreflexia can occur in spinal cord-injured (SCI) 
individuals. Autonomic dysreflexia is a potentially life-threatening episode of 
hypertension that can develop in up to 80% of SCI individuals with a spinal cord
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lesion at or above the sixth thoracic spinal segment (T6) (68). This phenomenon 
occurs in SCI individuals since a large part of the sympathetic nervous system has no 
central inhibitory pathways to limit the increase in blood pressure (69,70). Autonomic 
dysreflexia is characterised by a blood pressure increase, with levels as high as 300 
mmHg systolic and 200 mmHg diastolic (68,69,71). The increase in blood pressure is 
induced by exaggerated sympathetic activity caused by visceral, noxious or nociceptive 
stimuli entering the spinal cord below the level of the lesion (Figure 4) (68-70,86,87). 
Daily trivialities in SCI individuals such as catheterization, bladder distension, and 
bowel evacuation can initiate autonomic dysreflexia (68-70,86,87). The increased 
blood pressure will result in a vasodilator response above the spinal cord lesion 
through loading of the baroreflex (Figure 4) (68-70,86,87). This results in the 
accompanying symptoms such as sweating, flushing and a pounding headache (68,86). 
Autonomic dysreflexia can lead to severe morbidity and even mortality in SCI 
individuals (88-91). Clinically, autonomic dysreflexia is well documented, but the 
mechanisms that mediate autonomic dysreflexia remain unclear (92). Because 
autonomic dysreflexia is induced by exaggerated sympathetic activity, it is thought to 
be a-adrenergic mediated (69,70,86).
The management of autonomic dysreflexia exist of non-pharmacological and 
pharmacological measures. The non-pharmacological measures are removing the 
trigger evoking autonomic dysreflexia and placing the SCI individual in a more 
upright position (86,93). Several pharmacological agents, mostly anti-hypertensives, 
have been used in an attempt to manage autonomic dysreflexia (93). In earlier days, a- 
adrenoceptor antagonists were used (86) and are a rational first choice in autonomic 
dysreflexia management considering the supposed mechanism. Nowadays, nifedipine, 
a calcium channel blocker, is most commonly used (86,93). Also the use of an 
angiotensin-converting enzyme (ACE) inhibitor, captopril, has been proposed as the 
primary pharmacological agent in the management of autonomic dysreflexia (94). The 
management of autonomic dysreflexia in clinical practice, therefore, remains a 
challenge (87,93).
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OUTLINE OF THE THESIS
Aim  of the present studies
Maintaining blood pressure during changes in posture has been an important human 
evolutionary achievement. The Autonomic nervous system plays a principal role in 
the control of blood pressure regulation via changes in sympathetic nervous system 
activity. Baroreflex mediated increases in sympathetic nervous system activity lead to 
changes in heart rate, cardiac contractility and peripheral vascular resistance. 
Surprisingly, the changes in peripheral vascular resistance are scarcely studied. 
Therefore, the general aim of this thesis is to examine the role of the peripheral 
vascular control in individuals with autonomic failure, with a special interest in 
individuals with a spinal cord lesion.
Head-up tilt is a frequently used test to establish orthostatic hypotension and to 
diagnose autonomic failure. To calculate peripheral vascular resistance during head- 
up tilt it is necessary to assess the changes in the arterial-venous pressure gradient. 
We, therefore, measured intravenous pressure during head-up tilt in Ch apter 2 . We 
hypothesize that leg venous pressure is similar to the calculated hydrostatic pressure 
and, therefore, that hydrostatic pressure makes an equal contribution to leg arterial as 
well as to leg venous pressure during head-up tilt.
SCI individuals with a complete spinal cord transsection have lost supraspinal control 
of the sympathetic nervous system below the spinal cord lesion. In Ch apter 3 we assess 
the leg vascular resistance changes in SCI individuals during head-up tilt. We 
hypothesize that SCI individuals have an attenuated leg vasoconstriction during head- 
up tilt caused by the loss of supraspinal sympathetic control.
Angiotensin II  might contribute to the increased basal leg vascular resistance in SCI 
individuals. Moreover, during head-up tilt renin levels rise more quickly and to higher 
levels in SCI individuals than in controls, suggesting a role for angiotensin II  in 
peripheral vasoconstriction during head-up tilt. Therefore, the role of angiotensin II 
in the increased leg vascular resistance in SCI individuals is assessed in Chapter 4 . We 
hypothesize that angiotensin II  contributes to the increased leg vascular resistance as 
well as to the leg vasoconstriction during head-up tilt in SCI individuals.
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The clinical phenomenon of autonomic dysreflexia in SCI individuals is induced by 
exaggerated sympathetic activity and thought to be a-adrenergic mediated. In Chapter
5  the a-adrenergic contribution to the increased leg vascular resistance during 
autonomic dysreflexia in SCI individuals is assessed. We hypothesize that a- 
adrenergic blockade during autonomic dysreflexia abolishes the increase in leg 
vascular resistance.
In C hapter 6 we assess the leg vasoconstriction during head-up tilt in older men. An 
important characteristic in older men is the chronically elevated sympathetic nervous 
system activity. However, total peripheral vascular resistance is augmented in older 
men during head-up tilt. We hypothesize that leg vasoconstriction is also augmented 
in older men during head-up tilt, despite their already chronically elevated 
sympathetic activity.
Parkinson’s disease is a primary autonomic disorder with pre- and postganglionic 
autonomic failure. In contrast to SCI individuals, it is assumed that Parkinson’s 
disease patients have sympathetic denervation. In Chapter 7  we assess the leg vascular 
resistance changes during head-up tilt in Parkinson’s disease patients with and 
without orthostatic hypotension. We hypothesize that leg vasoconstriction during 
head-up tilt w ill be attenuated in Parkinson’s disease patients with orthostatic 
hypotension.
Autonomic failure can be caused by lesions in different parts of the sympathetic 
nervous system, depending on the pathophysiology of the autonomic disorder. In 
Chapter 8, leg vascular responses during head-up tilt are assessed in two distinctive 
autonomic disorders with postganglionic autonomic failure, i.e. pure autonomic 
failure and dopamine-C-hydroxylase deficiency. We hypothesize that leg 
vasoconstriction during head-up tilt w ill be present in pure autonomic failure and 
dopamine-C-hydroxylase deficient patients despite their loss of sympathetic mediated 
vascular control, because of compensatory vasoconstrictor mechanisms.
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Methods applied in this thesis
B lood pressure
Blood pressure is measured continuously using a non-invasive blood pressure device 
(Portapres, TNO, The Netherlands; Nexfin, BMEYE, The Netherlands) with an 
infrared finger photoplethysmograph. A finger cuff is attached to the middle phalanx 
of the right third finger in order to measure finger arterial blood pressure, which 
accurately reflects intra-arterial blood pressure changes (95). A built-in heart 
reference system was in operation to correct for hydrostatic influences. Mean arterial 
blood pressure is derived beat-to-beat and heart rate is the inverse of the interbeat 
interval. Modelflow, a pulse-contour method (96) is used to calculate stroke volume 
(97), cardiac output and total or systemic peripheral resistance (98).
Venous occlusion plethysm ography
Leg resistance arterial blood flow is measured by electrocardiography-triggered 
venous occlusion plethysmography (99), using electrically calibrated mercury-in- 
silastic strain gauges (100). The leg is positioned approximately 5 cm above heart level 
to facilitate venous outflow between venous occlusions (101). For upper leg (thigh) 
blood flow measurements the strain gauge is placed around the upper leg, 10 cm 
above the patella. A venous occlusion cuff, placed around the upper leg 5 cm above the 
strain gauge, is rapidly inflated with a rapid cuff inflator (Hokanson E-20, Hokanson, 
USA), within 1 second, to 50 mmHg (102). Occlusion pressures are sustained for 8 
heart cycles after which the cuff was deflated instantaneously for 10 heart cycles. 
Blood flow is calculated as the slope of the volume change over a 4 seconds interval 
using a customized computer program (103). Measurement of upper leg blood flow 
using venous occlusion plethysmography has a coefficient of variation between 6 and 
9% in our laboratory ( 103).
Similarly, lower leg (calf) blood flow can be measured using venous occlusion 
plethysmography (99). The strain gauge is placed around the thickest part of the calf 
and a venous occlusion cuff is placed around the distal part of the upper leg. 
Measurement of calf blood flow using venous occlusion plethysmography has a 
coefficient of variation between 13 and 14% in our laboratory ( 103).
We used venous occlusion plethysmography in the supine and head-up tilt 
position. During head-up tilt, the leg blood flow measurement with venous occlusion
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plethysmography could be influenced by venous compliance. Venous occlusion 
plethysmography is assumed to require an empty venous system to guarantee full 
venous compliance (99,101). However, leg blood flow measured using venous 
occlusion plethysmography during head-up tilt is in good agreement with superficial 
femoral artery blood flow measured by Doppler ultrasound (correlation coefficient of 
0.86) (104). This indicates that venous occlusion plethysmography during head-up tilt 
represents arterial inflow and is not significantly affected by venous compliance ( 104).
U ltrasound measurements
Baseline red blood cell velocity and diameter of the superficial femoral artery are 
measured using an Doppler ultrasound device (H D I 5000 Ultrasound System, ATL 
Ultrasound, USA; Megas, ESAOTE, Italy; ARTLAB system, Pie Medical, The 
Netherlands; W AKI, Atys Medical, France; ) with a 5-7.5 Mhz broadband linear array 
transducer (105,106). Mean red blood cell velocity (Vmean) and systolic and diastolic 
diameter of the superficial femoral artery are measured, approximately 2 cm distal of 
the bifurcation, are measured. Vmean is calculated as the average of 20 Doppler 
waveforms. Automated software was used for operator-independent analyses of 
waveforms. For diameter measurements, the average of 6 consecutive mean diameters 
is obtained. Leg blood flow is calculated with the following formula: (n-r2-Vmean)-60 (r 
= ^  diameter of the superficial femoral artery.
The perfused leg model
The technique of leg blood flow measurements in combination with drug infusions 
into the femoral artery is developed collectively by the departments of physiology and 
pharmacology-toxicology (78). A cannula (Angiocath 16-gauge, Becton Dickinson, 
USA) is introduced into the femoral artery of the leg using a modified Seldinger 
technique. The intra-arterial cannula is used for drug administration (Type P2000, 
IVA C Medical System, USA) and for blood pressure measurements (HP monitor type 
78353B, Hewlett Packard, Germany). Leg blood flow is measured with bilateral venous 
occlusion plethysmography, as described earlier.
Apart from the aforementioned hemodynamic measurements, we also examined 
neurotransmitter and humoral parameters. We assessed plasma levels of 
noradrenaline, adrenaline, renin and angiotensin II. Furthermore, in chapter 7  we
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assessed plasma volume by indicator dilution method using radio-labelled albumin
(125I-HSA) ( 107).
REFERENCES
1. Rowell LB. Passive effects of gravity. In: Rowell LB, editor. Human cardiovascular control. New 
York: Oxford University Press; 1993. p. 1-36.
2. Freeman R. Clinical practice. Neurogenic orthostatic hypotension. N Engl J Med 2008;358:615- 
624.
3. Rowell LB. Reflex control during orthostasis. In: Rowell LB, editor. Human cardiovascular 
control. New York: Oxford University Press; 1993. p. 37-80.
4. Smit AA, Halliwill JR, Low PA, Wieling W. Pathophysiological basis of orthostatic hypotension 
in autonomic failure. J Physiol 1999;519:1-10.
5. Tyden G. Aspects of cardiovascular reflex control in man. An experimental study. Acta Physiol 
Scand Suppl 1977;448:1-62.
6. Cooper VL, Hainsworth R. Effects of head-up tilting on baroreceptor control in subjects with 
different tolerances to orthostatic stress. Clin Sci (Lond) 2002;103:221-226.
7. Henriksen O, Sejrsen P. Local reflex in microcirculation in hum an skeletal muscle. Acta Physiol 
Scand 1977;99:19-26.
8. Folkow B. Myogenic mechanisms in the control of systemic resistance. Introduction and 
historical background. J Hypertens Suppl 1989;7:S1-4.
9. Imadojemu VA, Lott MEJ, Gleeson K, Hogeman CS, Ray CA, Sinoway LI. Contribution of 
perfusion pressure to vascular resistance response during head-up tilt. Am J Physiol Heart Circ 
Physiol 2001;281:H371-375.
10. Sander-Jensen K, Secher NH, Astrup A, Christensen NJ, Giese J, Schwartz TW, W arberg J, Bie P. 
Hypotension induced by passive head-up tilt: endocrine and circulatory mechanisms. Am J 
Physiol 1986;251:R742-748.
11. Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Renin-angiotensin system and 
cardiovascular risk. Lancet 2007;369:1208-1219.
12. W atanabe T, Barker TA, Berk BC. Angiotensin II and the endothelium: diverse signals and 
effects. Hypertension 2005;45:163-169.
13. Galatius S, Wroblewski H, Sorensen VB, Bie P, Kastrup J. Regional blood flow in the calf and 
plasma endothelin during prolonged orthostasis in humans. Scand J Clin Lab Invest 1999;59:305- 
313.
14. Mathias CJ. Orthostatic hypotension: causes, mechanisms, and influencing factors. Neurology 
1995;45:S6-11.
15. Medow MS, Stewart JM, Sanyal S, M umtaz A, Sica D, Frishman WH. Pathophysiology, diagnosis, 
and treatm ent of orthostatic hypotension and vasovagal syncope. Cardiol Rev 2008;16:4-20.
16. Ziegler MG, Lake CR, Kopin IJ. The sympathetic-nervous-system defect in prim ary orthostatic 
hypotension. N Engl J Med 1977;296:293-297.
17. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and 
multiple system atrophy. The Consensus Committee of the American Autonomic Society and the 
American Academy of Neurology. Neurology 1996;46:1470.
25
18. Magerkurth C, Schnitzer R, Braune S. Symptoms of autonomic failure in Parkinson's disease: 
prevalence and impact on daily life. Clin Auton Res 2005;15:76-82.
19. Mathias CJ, Mallipeddi R, Bleasdale-Barr K. Symptoms associated with orthostatic hypotension 
in pure autonomic failure and multiple system atrophy. J Neurol 1999;246:893-898.
20. Robertson D, Haile V, Perry SE, Robertson RM, Phillips JA, 3rd, Biaggioni I. Dopamine beta- 
hydroxylase deficiency. A genetic disorder of cardiovascular regulation. Hypertension 1991;18:1-
8.
21. Stefanova N, Bucke P, Duerr S, W enning GK. Multiple system atrophy: an update. Lancet Neurol 
2009;8:1172-1178.
22. Sloane P, Blazer D, George LK. Dizziness in a community elderly population. J Am Geriatr Soc 
1989;37:101-108.
23. Bloem BR. Postural instability in Parkinson's disease. Clin Neurol Neurosurg 1992;94 Suppl:S41-
45.
24. Bloem BR, Overeem S, van Dijk JG. Syncopal falls, drop attacks and their mimics. In: Bronstein 
AM, Brandt T, Woollacott MH, Nutts JG, editors. Clinical Disorders of Balance, Posture and 
Gait. London: Arnold; 2004. p. 286-316.
25. Gray P, Hildebrand K. Fall risk factors in Parkinson's disease. J Neurosci Nurs 2000;32:222-228.
26. Eigenbrodt ML, Rose KM, Couper DJ, Arnett DK, Smith R, Jones D. Orthostatic hypotension as 
a risk factor for stroke: the atherosclerosis risk in communities (ARIC) study, 1987-1996. Stroke 
2000;31:2307-2313.
27. Elmstahl S, Rosen I. Postural hypotension and EEG variables predict cognitive decline: results 
from a 5-year follow-up of healthy elderly women. Dement Geriatr Cogn Disord 1997;8:180-187.
28. Luukinen H, Koski K, Laippala P, Kivela SL. Prognosis of diastolic and systolic orthostatic 
hypotension in older persons. Arch Intern Med 1999;159:273-280.
29. Masaki KH, Schatz IJ, Burchfiel CM, Sharp DS, Chiu D, Foley D, Curb JD. Orthostatic 
hypotension predicts mortality in elderly men: the Honolulu Heart Program. Circulation 
1998;98:2290-2295.
30. Rose KM, Tyroler HA, Nardo CJ, A rnett DK, Light KC, Rosamond W, Sharrett AR, Szklo M. 
Orthostatic hypotension and the incidence of coronary heart disease: the Atherosclerosis Risk in 
Communities study. Am J Hypertens 2000;13:571-578.
31. Hollister AS. Orthostatic hypotension. Causes, evaluation, and management. West J Med 
1992;157:652-657.
32. Lipsitz L. Orthostatic hypotension in the elderly. N Engl J Med 1989;321:952-957.
33. Low PA, Singer W. Management of neurogenic orthostatic hypotension: an update. Lancet 
Neurol 2008;7:451-458.
34. Low PA. Prevalence of orthostatic hypotension. Clin Auton Res 2008;18 Suppl 1:8-13.
35. Mathias CJ. Autonomic diseases: clinical features and laboratory evaluation. J Neurol Neurosurg 
Psychiatry 2003;74:iii31-41.
36. Burnstock G. Physiology and pathophysiology of purinergic neurotransmission. Physiol Rev 
2007;87:659-797.
37. Mathias CJ. Role of sympathetic efferent nerves in blood pressure regulation and in 
hypertension. Hypertension 1991;18:III22-30.
38. Bannister R, mathias CJ. Introduction and classification of autonomic disorders. In: Mathias CJ, 
Bannister R, editors. Autonomic failure: a textbook of clinical disorders of the autonomic 
nervous system. fourth ed. New York: Oxford University Press; 2006. p. xvii-xxii.
39. Bradbury S, Eggleston C. Postural hypotension: a report of three cases. Am Heart J 1925;1:73-86.
26
40. Goldstein DS, Holmes C, Cannon RO, 3rd, Eisenhofer G, Kopin IJ. Sympathetic 
cardioneuropathy in dysautonomias. N Engl J Med 1997;336:696-702.
41. Goldstein DS, Polinsky RJ, Garty M, Robertson D, Brown RT, Biaggioni I, Stull R, Kopin IJ. 
Patterns of plasma levels of catechols in neurogenic orthostatic hypotension. Ann Neurol 
1989;26:558-563.
42. Goldstein DS. The autonomic nervous system in health and disease. New York: Marcel Dekker 
Inc.; 2001.
43. Parkinson J. An essay on the shaking palsy. 1817. J Neuropsychiatry Clin Neurosci 2002;14:223- 
236; discussion 222.
44. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999;56:33-
39.
45. Braak H, Sastre M, Bohl JR, de Vos RA, Del Tredici K. Parkinson's disease: lesions in dorsal horn 
layer I, involvement of parasympathetic and sympathetic pre- and postganglionic neurons. Acta 
Neuropathol 2007;113:421-429.
46. Sharabi Y, Imrich R, Holmes C, Pechnik S, Goldstein DS. Generalized and neurotransm itter- 
selective noradrenergic denervation in Parkinson's disease with orthostatic hypotension. Mov 
Disord 2008;23:1725-1732.
47. Goldstein DS. Dysautonomia in Parkinson's disease: neurocardiological abnormalities. Lancet 
Neurol 2003;2:669-676.
48. Goldstein DS, Holmes C, Li ST, Bruce S, M etman LV, Cannon RO, 3rd. Cardiac sympathetic 
denervation in Parkinson disease. Ann Intern Med 2000;133:338-347.
49. Adler CH. N onm otor complications in Parkinson's disease. Mov Disord 2005;20 Suppl 11:S23-
29.
50. Dubow JS. Autonomic dysfunction in Parkinson's disease. Dis Mon 2007;53:265-274.
51. Oka H, Yoshioka M, Onouchi K, M orita M, Mochio S, Suzuki M, Hirai T, Ito Y, Inoue K. 
Characteristics of orthostatic hypotension in Parkinson's disease. Brain 2007;130:2425-2432.
52. Witjas T, Kaphan E, Azulay JP, Blin O, Ceccaldi M, Pouget J, Poncet M, Cherif AA. Nonmotor 
fluctuations in Parkinson's disease: frequent and disabling. Neurology 2002;59:408-413.
53. Chaudhuri KR, Healy DG, Schapira AH. N on-m otor symptoms of Parkinson's disease: diagnosis 
and management. Lancet Neurol 2006;5:235-245.
54. Allcock LM, Ullyart K, Kenny RA, Burn DJ. Frequency of orthostatic hypotension in a 
comm unity based cohort of patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 
2004;75:1470-1471.
55. Goldstein DS. Orthostatic hypotension as an early finding in Parkinson's disease. Clin Auton Res 
2006;16:46-54.
56. Senard JM, Rai S, Lapeyre-Mestre M, Brefel C, Rascol O, Rascol A, M ontastruc JL. Prevalence of 
orthostatic hypotension in Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;63:584-589.
57. Hoehn MM. Levodopa-induced postural hypotension. Treatment with fludrocortisone. Arch 
Neurol 1975;32:50-51.
58. Senard JM, Brefel-Courbon C, Rascol O, M ontastruc JL. Orthostatic hypotension in patients with 
Parkinson's disease: pathophysiology and management. Drugs Aging 2001;18:495-505.
59. Senard JM, Verwaerde P, Rascol O, Montastruc JL. Effects of acute levodopa administration on 
blood pressure and heart variability in never treated parkinsonians. Hypertens Res 1995;18 Suppl 
1:S175-177.
27
60. Robertson D, Goldberg MR, Onrot J, Hollister AS, Wiley R, Thompson JG, Jr., Robertson RM. 
Isolated failure of autonomic noradrenergic neurotransmission. Evidence for impaired beta- 
hydroxylation of dopamine. N Engl J Med 1986;314:1494-1497.
61. Man in 't Veld AJ, Boomsma F, Moleman P, Schalekamp MA. Congenital dopamine-beta- 
hydroxylase deficiency. A novel orthostatic syndrome. Lancet 1987;1:183-188.
62. Man in 't Veld A, Boomsma F, Lenders J, vd Meiracker A, Julien C, Tulen J, Moleman P, Thien T, 
Lamberts S, Schalekamp M. Patients with congenital dopamine beta-hydroxylase deficiency. A 
lesson in catecholamine physiology. Am J Hypertens 1988;1:231-238.
63. Man in 't Veld AJ, Boomsma F, van den Meiracker AH, Julien C, Lenders J, Schalekamp MA. d,l- 
threo-3,4-dihydroxyphenylserine restores sympathetic control and cures orthostatic hypotension 
in dopamine beta-hydroxylase deficiency. J Hypertens Suppl 1988;6:S547-549.
64. Goldstein DS. L-Dihydroxyphenylserine (L-DOPS): a norepinephrine prodrug. Cardiovasc Drug 
Rev 2006;24:189-203.
65. Schonherr MC, Groothoff JW, M ulder GA, Eisma WH. Rehabilitation of patients with spinal 
cord lesions in The Netherlands: an epidemiological study. Spinal Cord 1996;34:679-683.
66. van Asbeck FW, Post MW, Pangalila RF. An epidemiological description of spinal cord injuries 
in The Netherlands in 1994. Spinal Cord 2000;38:420-424.
67. de Groot S, Dallmeijer AJ, Post MW, van Asbeck FW, Nene AV, Angenot EL, van der Woude 
LH. Demographics of the Dutch multicenter prospective cohort study 'Restoration of mobility in 
spinal cord injury rehabilitation'. Spinal Cord 2006;44:668-675.
68. Krassioukov A, Claydon VE. The clinical problems in cardiovascular control following spinal 
cord injury: an overview. Progr Brain Res 2006;152:223-229.
69. Mathias CJ, Frankel HL. Autonomic disturbances in spinal cord lesions. In: Mathias CJ, 
Bannister R, editors. Autonomic failure: a textbook of clinical disorders of the autonomic 
nervous system. fourth ed. New York: Oxford University Press; 2006. p. 494-513.
70. Teasell RW, Arnold JMO, Krassioukov A, Delaney GA. Cardiovascular consequences of loss of 
supraspinal control of the sympathetic nervous system after spinal cord injury. Arch Phys Med 
Rehabil 2000;81:506-516.
71. Krassioukov AV, Karlsson AK, Wecht JM, W uermser LA, Mathias CJ, Marino RJ. Assessment of 
autonomic dysfunction following spinal cord injury: rationale for additions to International 
Standards for Neurological Assessment. J Rehabil Res Dev 2007;44:103-112.
72. Llewellyn-Smith IJ, Weaver LC. Changes in synaptic inputs to sympathetic preganglionic 
neurons after spinal cord injury. J Comp Neurol 2001;435:226-240.
73. Llewellyn-Smith IJ, Weaver LC, Keast JR. Effects of spinal cord injury on synaptic inputs to 
sympathetic preganglionic neurons. Prog Brain Res 2006;152:11-26.
74. Rabchevsky AG. Segmental organization of spinal reflexes mediating autonomic dysreflexia after 
spinal cord injury. Prog Brain Res 2006;152:265-274.
75. Claydon VE, Steeves JD, Krassioukov A. Orthostatic hypotension following spinal cord injury: 
understanding clinical pathophysiology. Spinal Cord 2006;44:341-351.
76. Hopman MT, Groothuis JT, Flendrie M, Gerrits KH, Houtman S. Increased vascular resistance 
in paralyzed legs after spinal cord injury is reversible by training. J Appl Physiol 2002;93:1966- 
1972.
77. Deitrick G, Charalel J, Bauman W, Tuckman J. Reduced arterial circulation to the legs in spinal 
cord injury as a cause of skin breakdown lesions. Angiology 2007;58:175-184.
78. Kooijman M, Rongen GA, Smits P, Hopman MT. Preserved alpha-adrenergic tone in the leg 
vascular bed of spinal cord-injured individuals. Circulation 2003;108:2361-2367.
28
79. Bleeker MW, Kooijman M, Rongen GA, Hopman MT, Smits P. Preserved contribution of nitric 
oxide to baseline vascular tone in deconditioned human skeletal muscle. J Physiol 2005;565:685- 
694.
80. Thijssen DH, Ellenkamp R, Kooijman M, Pickkers P, Rongen GA, Hopman MT, Smits P. A 
causal role for endothelin-1 in the vascular adaptation to skeletal muscle deconditioning in spinal 
cord injury. Arterioscler Thromb Vasc Biol 2007;27:325-331.
81. Imai T, Hirata Y, Emori T, Yanagisawa M, Masaki T, Marumo F. Induction of endothelin-1 gene 
by angiotensin and vasopressin in endothelial cells. Hypertension 1992;19:753-757.
82. M ontanari A, Biggi A, Carra N, Ziliotti M, Fasoli E, Musiari L, Perinotto P, Novarini A. 
Endothelin-A receptors mediate renal hemodynamic effects of exogenous Angiotensin II in 
humans. Hypertension 2003;42:825-830.
83. Rajagopalan S, Laursen JB, Borthayre A, Kurz S, Keiser J, Haleen S, Giaid A, Harrison DG. Role 
for endothelin-1 in angiotensin II-mediated hypertension. Hypertension 1997;30:29-34.
84. Mathias CJ, Christensen NJ, Corbett JL, Frankel HL, Goodwin TJ, Peart WS. Plasma 
catecholamines, plasma renin activity and plasma aldosterone in tetraplegic man, horizontal and 
tilted. Clin Sci Mol Med 1975;49:291-299.
85. Mathias CJ, Christensen NJ, Frankel HL, Peart WS. Renin release during head-up tilt occurs 
independently of sympathetic nervous activity in tetraplegic man. Clin Sci 1980;59:251-256.
86. Karlsson A. Autonomic dysreflexia. Spinal cord 1999;37:383-391.
87. Blackmer J. Rehabilitation medicine: 1. Autonomic dysreflexia. Can Med Assoc J 2003;169:931- 
935.
88. Dolinak D, Balraj E. Autonomic dysreflexia and sudden death in people with traum atic spinal 
cord injury. Am J Forensic Med Pathol 2007;28:95-98.
89. Eltorai I, Kim R, Vulpe M, Kasravi H, Ho W. Fatal cerebral hemorrhage due to autonomic 
dysreflexia in a tetraplegic patient: case report and review. Paraplegia 1992;30:355-360.
90. Valles M, Benito J, Portell E, Vidal J. Cerebral hemorrhage due to autonomic dysreflexia in a 
spinal cord injury patient. Spinal Cord 2005;43:738-740.
91. Yarkony GM, Katz RT, W u Y-C. Seizures secondary to autonomic dysreflexia. Arch Phys Med 
Rehabil 1986;67:834-835.
92. Weaver LC. W hat causes autonomic dysreflexia after spinal cord injury? Clin Auton Res 
2002;12:424-426.
93. Krassioukov A, W arburton DE, Teasell R, Eng JJ. A systematic review of the management of 
autonomic dysreflexia after spinal cord injury. Arch Phys Med Rehabil 2009;90:682-695.
94. Esmail Z, Shalansky KF, Sunderji R, Anton H, Chambers K, Fish W. Evaluation of captopril for 
the management of hypertension in autonomic dysreflexia: A pilot study. Arch Phys Med 
Rehabil 2002;83:604-608.
95. Imholz BPM, Wieling W, van Montfrans GA, Wesseling KH. Fifteen years experience with finger 
arterial pressure monitoring:: assessment of the technology. Cardiovasc Res 1998;38:605-616.
96. Wesseling KH, Jansen JR, Settels JJ, Schreuder JJ. Computation of aortic flow from pressure in 
humans using a nonlinear, three-element model. J Appl Physiol 1993;74:2566-2573.
97. Harms MP, Wesseling KH, Pott F, Jenstrup M, Van Goudoever J, Secher NH, Van Lieshout JJ. 
Continuous stroke volume m onitoring by modelling flow from non-invasive measurement of 
arterial pressure in humans under orthostatic stress. Clin Sci (Lond) 1999;97:291-301.
98. Jansen JR, Wesseling KH, Settels JJ, Schreuder JJ. Continuous cardiac output m onitoring by 
pulse contour during cardiac surgery. Eur Heart J 1990;11 Suppl I:26-32.
29
99. Joyner MJ, Dietz NM, Shepherd JT. From Belfast to Mayo and beyond: the use and future of 
plethysmography to study blood flow in hum an limbs. J Appl Physiol 2001;91:2431-2441.
100. Brakkee AJ, Vendrik AJ. Strain-gauge plethysmography; theoretical and practical notes on a new 
design. J Appl Physiol 1966;21:701-704.
101. Barendsen GJ, Venema H, van den Berg J. Semicontinuous blood flow measurement by triggered 
venous occlusion plethysmography. J Appl Physiol 1971;31:288-291.
102. Groothuis JT, van Vliet L, Kooijman M, Hopman MTE. Venous cuff pressures from 30 m m Hg to 
diastolic pressure are recommended to measure arterial inflow by plethysmography. J Appl 
Physiol 2003;95:342-347.
103. Thijssen D, Bleeker M, Smits P, MTE H. Reproducibility of blood flow and post-occlusive 
reactive hyperaemia as measured by venous occlusion plethysmography. Clin Sci 2005; 108:151­
157.
104. Kooijman M, Poelkens F, Rongen GA, Smits P, Hopman MT. Leg blood flow measurements 
using venous occlusion plethysmography during head-up tilt. Clin Auton Res 2007;17:106-111.
105. De Groot PC, Van Kuppevelt DH, Pons C, Snoek G, Van Der W oude LH, Hopman MT. Time 
course of arterial vascular adaptations to inactivity and paralyses in humans. Med Sci Sports 
Exerc 2003;35:1977-1985.
106. de Groot PCE, Poelkens F, Kooijman M, Hopman MTE. Preserved flow-mediated dilation in the 
inactive legs of spinal cord-injured individuals. Am J Physiol Heart Circ Physiol 2004;287:H374- 
380.
107. Recommended methods for measurement of red-cell and plasma volume: International 
Committee for Standardization in Haematology. J Nucl Med 1980;21:793-800.
30
Leg intravenous pressure during head-up tilt
Jan Groothuis 
Fleur Poelkens 
Stijn Wouters 
Miriam Kooijman 
Maria Hopman
Journal of Applied Physiology 2008;105:811-815

ABSTRACT
Leg vascular resistance is calculated as the arterial - venous pressure gradient divided 
by blood flow. During orthostatic challenges it is assumed that the hydrostatic 
pressure contributes equally to leg arterial as well as to leg venous pressure. Because of 
venous valves, one may question whether, during orthostatic challenges, a continuous 
hydrostatic column is formed and if leg venous pressure is equal to the hydrostatic 
pressure. The purpose of this study was, therefore, to measure intravenous pressure in 
the great saphenous vein of 12 healthy individuals during 30° and 70° head-up tilt and 
compare this with the calculated hydrostatic pressure. The height difference between 
the heart and the right medial malleolus level represented the hydrostatic column. The 
results demonstrate that there were no differences between the measured intravenous 
pressure and the calculated hydrostatic pressure during 30° (47.2 ± 1.0 and 46.9 ± 1.5 
mmHg, respectively) and 70° head-up tilt (83.9 ± 0.9 and 85.1 ± 1.2 mmHg, 
respectively). Steady state levels of intravenous pressure were reached after 95 ± 12 s 
during 30° and 161 ± 15 s during 70° head-up tilt. In conclusion, the measured leg 
venous pressure is similar to the calculated hydrostatic pressure during orthostatic 
challenges. Therefore, the assumption that hydrostatic pressure contributes equally to 
leg arterial as well as to leg venous pressure during orthostatic challenges can be made.
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INTRODUCTION
The increase in leg vascular resistance, by a baroreflex induced increase in 
sympathetic tone and by local mechanisms such as the veno-arteriolar axon ‘reflex’ 
(VAR) (1) and the myogenic response (2), are important to withstand orthostatic 
challenges (3). Peripheral vascular responses to orthostatic challenges, quantified by 
leg vascular resistance, have been studied in healthy individuals as well as in 
individuals with autonomic dysfunction (2,4-14).
In supine position, leg vascular resistance is calculated as the arterial - venous 
pressure gradient (Pa - Pv) divided by blood flow. In supine position, most studies 
(2,5-8,10) assume that venous pressure equals 0 mmHg and use mean arterial blood 
pressure (MAP) to replace the arterial - venous pressure gradient, while others (4,11­
14) have estimated venous pressure in the leg using venous occlusion 
plethysmography. During orthostatic challenges a hydrostatic pressure is added to leg 
arterial as well as to leg venous pressure due to gravitational translocation of blood 
(3,15). One may question how upright posture will affect the arterial - venous pressure 
gradient. The veins have valves that close at the onset of orthostatic challenges and 
thereby interrupt the development of a continuous hydrostatic column. When an 
orthostatic challenge persist, the veins will continue to fill with blood and 
consequently the venous valves will open to form a continuous hydrostatic column 
(15-17). At this time the assumption can be made that the hydrostatic pressure 
contributes equally to leg arterial as well as to leg venous pressure (15) and vascular 
resistance can be calculated as MAP (- Pv supine) divided by blood flow (2,4-14).
Surprisingly, only a few studies have tested this assumption by measuring 
intravenous pressure. Unfortunately, these studies were done in a small number of 
individuals (18) and/or during relaxed (motionless) standing (18,19), which still could 
cause considerable (in)voluntary muscle contractions (19). Recent studies on leg 
vascular responses use passive head-up tilt (HUT) to diminish these (in)voluntary 
muscle contractions. Others (4,11,12), have tested the assumption during passive 
HUT, but they used an indirect, non-invasive method (20) that could only be used in 
(HUT) angles up to 35°.The purpose of this study was, therefore, to measure leg 
venous pressure during 30 ° and 70 ° HUT. We hypothesized that the measured leg 
venous pressure is similar to the calculated hydrostatic pressure and, therefore, that 
the assumption can be made that the hydrostatic pressure makes an equal
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contribution to leg arterial as well as to leg venous pressure during orthostatic 
challenges. 2
METHODS
Subjects
Twelve healthy individuals (6 males and 6 females) volunteered to participate in this 
study (Table 1). Subjects never smoked, were normotensive (< 140/90 mmHg), free of 
overt cardiovascular diseases and did not report orthostatic intolerance. None of the 
subjects used any medication, except from oral contraceptives in female subjects. The 
study has been carried out in accordance with the Declaration of Helsinki (2000) and 
was approved by the medical ethical committee of our institution. All subjects gave 
written informed consent.
Table 1. Subject characteristics.
Mean±SD Range
Age (yrs) 22 ± 2 2 0 1 2 00
Height (cm) 176 ± 6 168 -  187
Weight (kg) 69 ± 7 2855
Calf circumference (cm) 37 ± 1 9353
Systolic BP (mmHg) 119 ± 6 105 -  130
Diastolic BP (mmHg) 72 ± 7 5 8
Tj-6
MAP (mmHg) 88 ± 7 78 -  97
Values represent mean±SD. BP, blood pressure. MAP, mean arterial blood pressure.
Experimental procedures and protocol
All subjects refrained from caffeine-containing food and beverages, vitamin C 
supplements, and alcohol for at least 12 hours prior to the experiment and refrained 
from heavy physical activity for at least 24 hours prior to the experiment. Room 
temperature was controlled at 23 ±1  °C. After completing a health questionnaire, 
subjects were comfortably placed in the supine position on a manually controlled tilt 
table with footboard. A chest belt was used to prevent them from falling down in case 
of vasovagal syncope. The right leg was placed in such a way that the right medial 
malleolus was on heart level, mid-thoracally at the second intercostal space, in the 
supine position. The subjects supported their body weight during HUT by standing 
on the left leg, allowing the right leg to be relaxed for venous pressure measurements.
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The experimental procedures started after a supine resting period of at least 30 
minutes after placement of an intravenous catheter in the right great saphenous vein.
First, baseline venous pressure was measured for 5 minutes in the supine 
position. Subsequently, subjects were tilted manually, within 5 seconds, to passive 30° 
HUT position for 5 minutes, during which venous pressure was continuously 
measured. After returning to the supine position and venous pressure returned to 
baseline values, the same procedure was repeated with a passive 70° HUT.
Measurements
Blood pressure (BP) was measured auscultatory at the right brachial artery using a 
sphygmomanometer. Mean arterial blood pressure (MAP) was calculated as diastolic 
BP + 1/3(systolic BP - diastolic BP).
A 20-gauge venous catheter was placed in the right great saphenous vein at the 
level of the medial malleolus and connected to a continuous pressure monitoring 
system (Edwards Life sciences Services Gmbh, Germany). Throughout the entire 
protocol the venous catheter was fixed in the same position, e.g. in the saphenous vein 
at the level of the right medial malleolus. Figure 1 shows a typical intravenous 
pressure recording of one subject. Intravenous pressure (mmHg) was determined as 
the average of the last minute in each position. The time to reach a steady state 
intravenous pressure was determined.
Figure 1. A typical intravenous pressure recording of one single subject during the 
complete experimental protocol.
The hydrostatic column was determined by measuring the vertical height difference 
(cm) between heart level, midthoracally at the second intercostal space, and the right 
medial malleolus where intravenous pressure was monitored. To convert to units of 
mmHg, the height difference was multiplied by a factor 0.766, which includes a 
correction for the specific gravity of blood (= 1.055) (4,13,21). The determination of 
the hydrostatic column was done in duplicate, with a coefficient of variation less than 
4%.
Statistical analysis
Data are presented as mean ± SEM, unless otherwise stated. A paired Student’s t-test 
was used to determine the effect of HUT and a Pearson correlation coefficient was 
calculated to determine the correlation between intravenous pressure and calculated 
hydrostatic pressure. Bland-Altman plots were constructed to show the distribution of 
the individual data. The level of statistical significance was set at a  = 0.05.
RESULTS
Supine intravenous pressure
Venous pressure in the great saphenous vein in supine position varied between 6 to 13 
mmHg (Table 2), and did not differ between supine positions before 30° and 70° 
HUT. The mean value of supine venous pressure was 8.7 ± 0.3 mmHg, with a 95% 
confidence interval (CI) between 8.0 -  9.3 mmHg.
Table 2. Head-up tilt induced changes in intravenous pressure, calculated hydrostatic 
pressure during head-up tilt and time till steady state intravenous pressure.
Venous pressure 
(mmHg)
Hydrostatic pressure 
(mmHg)
Time till steady state 
(s)
30° Head-up tilt
Supine 8.8 ± 0.5
30° Head-up tilt 47.2 ± 1.0* 46.9 ± 1.5 95 ± 12
70° head-up tilt
Supine 8.5 ± 0.5
30° Head-up tilt 83.9 ± 0.9* 85.1 ± 1.2 161 ± 15
Values represent mean±SE. HUT, head-up tilt. *, significantly different from supine.
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Figure 2. Correlation for measured intravenous pressure and calculated hydrostatic 
pressure for 30° and 70° head-up tilt.
1.0). HUT, head-up tilt
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Figure 3. Bland-Altman analysis of measured venous pressure and calculated 
hydrostatic pressure for each individual (n=12) during 30° and 70° head-up tilt.
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Intravenous and hydrostatic pressure during head-up tilt
During both 30° and 70° HUT, the venous pressure increased in the great saphenous 
vein and reached steady state levels (Table 2 and Figure 1). The intravenous pressures 
during 30° HUT ranged from 41 to 51 mmHg and during 70° HUT from 80 to 91 
mmHg. These steady state levels were reached between 37 and 168 s for 30° and 
between 64 and 247 s for 70° HUT. The calculated hydrostatic pressures ranged from
39 to 55 mmHg during 30° HUT and from 79 to 93 mmHg during 70° HUT (Table 2). 
No differences were found between the measured intravenous pressure and the 
calculated hydrostatic pressure during both 30° HUT (47.2 ± 1.0 and 46.9 ± 4.5 
mmHg, respectively) and 70° HUT (83.9 ± 0.9 and 85.1 ± 1.2 mmHg, respectively) 
(Table 2).
The measured intravenous pressure and the calculated hydrostatic pressure 
during 30° and 70° HUT correlated well, with a correlation coefficient (r) of 0.937 (p < 
0.001) for 30° HUT and a correlation coefficient of 0.813 (p < 0.001) for 70° HUT 
(Figure 2). In figure 3 Bland-Altman plots are shown for 30° and 70° HUT, 
demonstrating the distribution of the individual data.
DISCUSSION
The major finding of the present study is that the measured intravenous pressure in 
the great saphenous vein corresponds with the calculated hydrostatic pressure during 
30° and 70° HUT. So, the assumption that hydrostatic pressure contributes equally to 
leg arterial as well as to leg venous pressure during orthostatic challenges seems to be 
correct for both 30° and 70° HUT. Therefore, the arterial - venous pressure gradient 
during orthostatic challenges is equal to MAP, and leg vascular resistance can be 
calculated as MAP divided by blood flow.
Supine intravenous pressure
Although most studies (2,5-8,10) assume that supine leg venous pressure equals 0 
mmHg, the results of the present study demonstrate that venous pressure ranges 
between 6-13 mmHg. This must be due to a combination of static and dynamic 
pressure (16), since the hydrostatic pressure component was alienated through 
placement of the right leg on heart level. The above mentioned studies (2,5-8,10), 
therefore, underestimate supine leg venous pressure and as a consequence
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overestimate leg vascular resistance, since vascular resistance is calculated as the 
arterial - venous pressure gradient divided by blood flow. The studies that indirectly 
derive supine leg venous pressure (4,11-14), do not seem to underestimate leg venous 
pressure, as previously demonstrated by Christ et al. (21). The measured supine 
venous pressure in our study is in agreement with a recent study of Calbet et 
al.(22),who found a leg venous pressure of 7.1 ± 0.1 mmHg (mean ± SD). However, 
they measured venous pressure in the femoral vein, which may not be compared 
directly to venous pressures values in the saphenous vein.
Nevertheless, supine leg venous pressure cannot be assumed to equal 0 mmHg 
because it was 8.7 (8.0 -  9.3) mmHg (mean (95% CI). A venous pressure within this 
95% CI should be assumed when leg vascular resistance is calculated in supine 
position unless leg venous pressure is measured intravenously.
Intravenous pressure during head-up tilt
Intravenously measured leg venous pressure corresponded and correlated well with 
the calculated hydrostatic pressure in 30° and 70° HUT. It seems, therefore, correct to 
make the assumption that during an orthostatic challenge the hydrostatic pressure 
contributes equally to leg arterial as well as to leg venous pressure. Consequently, the 
leg vascular resistance during orthostatic challenges can be calculated as MAP (­
supine Pv) divided by blood flow.
However, two important remarks have to be made to this assumption. First, 
because of venous valves the forming of a continuous hydrostatic column in the veins 
is not instantaneously, as compared to the arteries. When an orthostatic challenge 
persists, the veins will continue to fill with blood and the venous valves will open 
allowing the formation of a continuous hydrostatic column (15-17). A gradual 
increase in intravenous pressure was seen directly after the onset of HUT and a steady 
state, indicating equilibrium, was seen after 37-168 s during 30° and after 64-247 s 
during 70° HUT. So, the remark has to be made that the assumption can only be used 
when this equilibrium is achieved, because from that moment on, a continuous 
hydrostatic column has been formed in the veins.
Secondly, according to the assumption that during orthostatic challenges 
hydrostatic pressure contributes equally to leg arterial as well as to leg venous 
pressure, supine leg venous pressure should be added to the calculated hydrostatic 
pressure. The results of this study, however, demonstrate that leg venous pressure
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during orthostatic challenges equals hydrostatic pressure, without adding the supine 
leg venous pressure. A possible explanation could be that venous tone is reduced 
during HUT, although this seems unlikely and one would expect the opposite to occur 
during HUT. Another explanation could be that the decrease in leg blood flow during 
HUT (5-7,9,10) lowers venous pressure. Although, this is an interesting question the 
present study was not designed to answer that question.
Consequently, in the calculation of leg vascular resistance during orthostatic 
challenges, the arterial -  venous pressure gradient can be replaced by MAP, without 
accounting for supine leg venous pressure.
Limitations
One may argue that the pressure in the great saphenous vein, a superficial vein, does 
not reflect the pressure in the deep veins (21), which drain most of the blood from the 
lower limbs (23). However, the pressure gradient between the deep and superficial 
veins is small, because blood is drained through low resistance valves (24). Moreover, 
venous pressure measured at various cannulation sites varies by 1-2 mmHg, when 
measured after an equilibration time of 120 seconds (24). We, therefore, believe that 
the measured venous pressure in the great saphenous vein represents superficial as 
well as deep venous pressure.
From the Bland-Altman plot for 30° HUT (Figure 3), one could argue that 
there might be an overestimation of intravenous pressure from the hydrostatic 
pressure for low pressures only (< 48 mmHg). However, there were no differences 
between the intravenous and hydrostatic pressure and no systematic errors for both 
HUT positions. We are, therefore, convinced that the measured intravenous pressure 
corresponds with the calculated hydrostatic pressure during 30° and 70° HUT.
In this study we did not measure leg arterial pressure, because the hydrostatic 
column is immediately formed in the arteries (3,15) and the added hydrostatic 
pressure to leg arterial pressure is calculated in the exact same manner as hydrostatic 
pressure is calculated in the present study for leg venous pressure (16).
Recommendations
From the results of this study, some important methodological recommendations can 
be made.
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1) We recommend using a supine leg venous pressure of 8.7 (8.0-9.3) mmHg (mean 
(95% CI) when the measured leg is placed on heart level.
2) The assumption that hydrostatic pressure contributes equally to leg arterial as well 
as to leg venous pressure during orthostatic challenges is correct. However, supine 
leg venous pressure should not be added to the hydrostatic pressure and the 
assumption can only be made after a continuous hydrostatic column is formed, 
for 30° HUT this is after 3 min and for 70° HUT after 4 min.
3) It is essential that arterial and venous measurements are at the same level 
compared to the heart, otherwise a correction equal to the hydrostatic column 
difference should be made.
When these recommendations are taken into account, leg vascular resistance during 
orthostatic challenges can be calculated as MAP divided by (leg) blood flow.
Conclusion
During orthostatic challenges the leg venous pressure, measured intravenously in the 
great saphenous vein, is similar to the calculated hydrostatic pressure. Therefore, the 
assumption can be made that the hydrostatic pressure contributes equally to leg 
arterial as well as to leg venous pressure. Although this assumption can only be made 
when a continuous hydrostatic column has been formed in the veins, the time until 
this column has been formed is depending on the performed orthostatic challenge.
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ABSTRACT
Despite loss of centrally mediated sympathetic vasoconstriction to the legs, spinal 
cord-injured individuals cope surprisingly well with an orthostatic challenge. This 
study assessed changes in leg vascular resistance following head-up tilt in healthy (C) 
and in paraplegic (P) individuals. After 10 min of supine rest, subjects were tilted 30° 
head-up. Mean arterial pressure (MAP) and total peripheral resistance (TPR) 
increased in C (MAP from 76.7±6.6 mmHg to 80.6±8.2 mmHg; TPR from 1.12±0.26 
AU to 1.19±0.31 AU) while both remained unchanged in P. Echo Doppler ultrasound 
determined red blood cell velocity in the femoral artery, which decreased (P from 
18.9±6.2 cm/s to 12.5±4.5 cm/s, P=0.001; C from 16.3±6.2 cm/s to 10.8±5.0 cm/s, 
P=0.001) and leg vascular resistance, which increased (P from 402±137 AU to 
643±274 AU, P=0.001; C from 238±68 AU to 400±122 AU, P=0.003) from supine to 
upright. The present study shows that independent of supraspinal sympathetic 
control, humans are able to increase leg vascular resistance and maintain blood 
pressure during head-up tilt.
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INTRODUCTION
Spinal cord-injured individuals have part of their sympathetic nervous system isolated 
from brain stem control. Consequently, they show an attenuated or absent increase in 
sympathetic activity during orthostatic challenges (1). Nevertheless, individuals with 
paraplegia maintain blood pressure during orthostatic stress (2,3), suggesting an 
increase in peripheral vascular resistance. Sympathetic reflexes below the level of the 
lesion induce vasoconstriction independent of brain stem control (4,5). Other local 
mechanisms contributing to vasoconstriction are the veno-arteriolar axon reflex and 
the myogenic response. The veno-arteriolar reflex is triggered by venous distension of 
small veins and probably runs through a sympathetic axon, that innervates both an 
arteriole and a small vein (6), and may be responsible for ~50% of the vasoconstriction 
elicited during head-up tilt (7). However, plasma noradrenaline, which normally 
increases by 80- 100% from supine to head-up tilt, hardly increases in spinal cord- 
injured individuals (8). A myogenic response is a muscle vasoconstrictor response to 
increments in transmural pressure. Imadojemu et al. (9) suggest that the myogenic 
response might be engaged in the head-up tilt induced leg vasoconstriction in healthy 
individuals.
Despite the fact that Skagen et al. (10) and Andersen et al. (11) demonstrated a 
vasoconstrictor response in tetraplegic individuals to head-up tilt, tetraplegics still 
show a marked drop in mean arterial pressure (MAP) during tilt, the latter in contrast 
to paraplegic individuals and controls. This study measured changes in the central and 
peripheral vascular responses following head-up tilt in paraplegic and healthy-control 
individuals in order to assess the necessity of intact supraspinal sympathetic control to 
increase in leg vascular resistance.
METHODS 
Subjects
Ten healthy male control (C) and eleven paraplegic (P) individuals participated in this 
study. P (T4-L1 lesions), eight males and three females, had complete spinal cord 
lesions (AIS A (12)), except for one male who had a sensory incomplete spinal cord 
lesion (AIS B) and one who had a motor incomplete but non functional spinal cord 
lesion (AIS C). In all P individuals, sweating was disturbed under the level of the
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lesion, indicating loss of autonomic control of the skin. After completion of the study, 
six P-males and two P-females returned to the laboratory to assess the completeness of 
the sympathetic lesion by a cold pressor test of the hand and a separate control group 
was assembled with similar age and gender profile (39±2 years (mean±SD); seven 
males and two females).
Three P smoked and two used atenolol for hypertension and one used tofranil 
to control bladder spasms. One C smoked but none used medication, and all exercised 
between 0 h/week and 5 h/week (Table 1). The study was approved by the Faculty of 
Ethics Committee and conformed with the principles outlined in the Declaration of 
Helsinki. All the subjects gave their written informed consent prior to the study.
Table 1. Physical characteristics.
C(n=10) P (n=11)
Age (yrs) 31.1±11.5 36.1±9.4
Height (cm) 179±7 182±8
Weight (kg) 72.7±7.2 71.9±15.2
Calf circumference (cm) 37.2±2.8 31.3±3.9*
Spinal Cord Injury duration (yrs) 9.1±6.9
Values represent means±SD. C, control group. P, paraplegic group. *, significantly different from C.
Protocol
All individuals refrained from caffeine, nicotine and alcohol for 3 h prior to the study. 
They were studied in a quiet room at 24- 26° C on a manually driven tilt table with 
non-skid in order to prevent sliding and P individuals were supported by a strap 
around their chest. After at least 15 min in the supine position, the subjects were 
instrumented. Ten minutes in the supine position was followed, in 5 s, by 10 min in a 
passive 30° head-up tilt position in order to induce a significant cardiovascular 
response (13). In the common femoral artery, red blood cell velocity and its diameter 
were measured after 5 min in the supine and upright position by echo Doppler (HDI 
5000 Ultrasound System, ATL Ultrasound, Bothell, USA). Heart rate (HR) and MAP 
were measured by Portapres (TNO, Amsterdam, The Netherlands) and calf volume 
changes by strain-gauge plethysmography (Instrumental service, UMC, Nijmegen, 
The Netherlands).
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Measurements
Blood flow in the left common femoral artery was measured using a 5 MHz 
broadband linear array transducer. The transducer was placed 2.0 cm proximal to the 
bifurcation of the common femoral artery, with a sample size of 1.5 mm. The 
transducer was kept at an angle below 60° and in the middle of the vessel. Maximal 
(Vmax) and minimal red blood cell velocity (Vmin) were determined. The systolic 
and diastolic diameter of the artery were measured and the mean diameter was 1/3 
systolic + 2/3 diastolic diameter. The mean red blood cell velocity (Vmean) was 
((1/4Vmax) +(1/6Vmin))1/HR) (HR, beats per second) (14). Blood flow in the artery 
was 1/2(p-r2-Vmean) (r = 1/2 mean diameter).
The MAP and HR were measured with a finger cuff attached to the middle 
phalanx of the third finger of the right hand during head-up tilt. Finger arterial blood 
pressure reflects accurately the intra-arterial pressure changes (15,16). Data were 
collected beat to beat at 200 Hz and MAP was calculated. Modelflow, a pulse-contour 
method, was used to calculate stroke volume (SV) (17-19) and cardiac output was SV 
times HR. Leg vascular resistance was MAP divided by femoral blood flow and total 
peripheral resistance was MAP divided by cardiac output. Strain-gauge 
plethysmography used two mercury-filled tubes of silicon rubber around the thickest 
part of the left calf, while the foot and knee were supported by pillows, and was 
calibrated electrically (20).
Data analysis
Variables were analysed off-line every tenth second. The average of each variable was 
calculated from 7.5 min to 9.5 min while supine and upright.
Cold pressor test
The hand was immersed into water of 4° C for 3 min while calf blood flow was 
measured using venous occlusion plethysmography and MAP by Finapres.
Statistical analysis
A two-tailed paired Student’s t-test was used to assess differences within the groups in 
vessel diameter, Vmean, blood flow, leg vascular resistance and HR, MAP, SV and 
total peripheral resistance between supine and head-up tilt. Between the groups the 
differences in cardiovascular responses from supine to head-up tilt levels were
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analysed using ANOVA. P-values less than 0.05 were considered to represent a 
statistical significant difference.
RESULTS
Individual responses in calf vascular resistance of 8 P and 9 controls are shown in 
Figure 1. The increase in calf vascular resistance was less in P than in the controls. 
Three P individuals could not participate in the cold pressor test, but they had 
complete spinal lesions at midthoracic level. No differences in SV, MAP and total 
peripheral resistance in supine position were seen between groups, whereas HR was 
higher in P compared with C (Table 2).
Figure 1. Individual and mean responses of relative calf vascular resistance to the cold 
pressor test of the hand in spinal cord-injured and control individuals.
In the supine position, no differences in Vmean were seen between the groups. The 
diameter of the common femoral artery in P was lower than in C and also leg blood 
flow was lower and leg vascular resistance higher (Table 3). No differences in diameter
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were observed between supine and upright. Since the quality of the measurements was 
better in the supine position, these diameters were used for all further analysis, both 
supine and upright.
From supine to head-up tilt, SV decreased 9% in C, but not in P, while HR 
increased by 9% in C and 5% in P. The MAP in C increased 5%in head-up tilt 
compared to supine, whereas in P it did not change (Figure 2a). Total peripheral 
resistance increased 7% in C in head-up tilt compared to supine with no changes in P 
(Table 2).
From supine to head-up tilt, leg blood flow decreased in both P (34%) and in C 
(34%) and leg vascular resistance increased in P (60%) and in C (75%) (Figure 2b). 
Also, calf volume increased from supine to head-up tilt in P and C (Table 3 and Figure
3).
Table 2. Steady state values of systemic parameters.
C(n=10) P(n=11)
Heart rate (bpm) Supine 58.96.9 68.1±10.7*
Head-up tilt 64.5±12.0 71.5±8.7
P-value 0.040 0.036
SV (ml) Supine 73.3±11.9 70.7±18.0
Head-up tilt 66.9±10.6 63.0±20.6
P-value 0.004 0.067
MAP (mmHg) Supine 76.7±6.6 83.4±12.8
Head-up tilt 80.6±8.2 84.6±13.2
P-value 0.027 0.454
TPR (AU) Supine 1.12±0.26 1.17±0.36
Head-up tilt 1.19±0.31 1.27±0.47
P-value 0.028 0.208
Values represent mean±SD. P -values indicate differences between supine and head-up tilt within 
each group. C, control group. P, paraplegic group. SV, stroke volume. MAP, mean arterial blood 
pressure. TPR, total peripheral resistance. AU, arbitrary units. *, significantly different from controls.
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Figure 2. Mean arterial blood pressure (A) and leg vascular resistance (B) during 
head-up tilt in paraplegic and controls.
Values represent group-average. The dashed lines represent head-up tilt, preceded by supine rest. 
MAP, mean arterial blood pressure. LVR, leg vascular resistance. P, paraplegic. C, control.
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Table 3. Steady state values of leg variables.
C  (n = 1 0 a) P ( n = 1 1 )
D iam eter (cm) Supine 1 .01±0.11 0 .7 2 ± 0 .1 3 *
V m ean (cm /s) Supine 16.3±6.2 18.9±6.2
H ead-up tilt 10 .8±5.0 12.5±4.5
P-value 0.001 0.001
Blood flow (l/m in) Supine 0 .3 5 ± 0 .0 9 0 .2 2 ± 0 .0 5 *
H ead-up tilt 0 .2 3 ± 0 .0 7 0 .1 5 ± 0 .0 5 *
P-value 0.002 0.001
L V R  (m m H g/l/m in) Supine 283 .3±68 .6 4 0 1 .6 ± 1 3 6 .5 *
H ead-up tilt 399 .5 ± 1 2 2 .0 6 4 2 .9 ± 2 7 4 .1 *
P-value 0.003 0.001
C alf volum e change (vol%) H ead-up tilt 1 .31±0 .70 0 .8 5 ± 0 .8 5
P-value 0.003 0.040
Values represent mean±SD. P-values indicate differences between supine and head-up tilt within each 
group. C, control group. P, paraplegic group. Vmean, mean red blood cell velocity. LVR, leg vascular 
resistance. *, significantly different from controls. a, n=9 for diameter and blood flow in C.
Figure 3. Changes in calf volume upon head- up tilt measured by plethysmography.
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P, paraplegic individuals. C, controls.
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DISCUSSION
The major finding of the present study is that paraplegic individuals show an increase 
in leg vascular resistance during head-up tilt comparable with that demonstrated by 
control subjects.
In healthy individuals, immediately upon head-up tilt, central volume or pressure 
receptors detect an unloading due to a blood shift from central to peripheral vascular 
beds (21). The latter is confirmed in the present study by the initial rapid calf volume 
increase, which results in a reduced venous return and, consequently, in a decrease in 
SV and, transiently, in MAP. Within a heartbeat, HR increases and within 10 to 12 s, 
peripheral vasoconstriction is manifest. The response in vascular resistance seems to 
be of importance to restore MAP, or in C to enhance MAP.
The P individuals were able to increase their leg vascular resistance in the 
upright posture, despite lack of centrally mediated sympathetic control, and thus, no 
sympathetic efferent of the baroreflex to the leg blood vessels. The spinal cord injury 
may have been incomplete or supraspinal control of sympathetic outflow to the leg 
may have been restored. However, in all P individuals, sweating was disturbed under 
the level of the lesion, indicating loss of autonomic control of the skin (22). In 
addition, in 8 of the 11 P individuals, a cold pressor test was performed (23). All these 
P subjects showed no vasoconstriction in the calf during a cold pressor test of the 
hand, indicating disrupted supraspinal sympathetic outflow to the leg vasculature.
Blood pressure was maintained at the pre-tilt levels in the P population and this 
response was not different from C, which confirms data presented by Grimm et al. (2). 
Leg vasoconstriction in P may result from spinal sympathetic reflex activity, veno- 
arteriolar reflexes or myogenic responses. As in C, P showed a rapid increase of calf 
volume (assessed by strain-gauge plethysmography) immediately upon head-up tilt. 
The shifted blood volume is located mainly in the venous vascular system leading to 
stretch on the venous vascular walls (24). An increase in pressure of 25 mmHg in the 
venous vascular system will result in a 40- 50% increase in arterial vascular resistance 
via the veno-arteriolar reflexes, which runs via a sympathetic axon (6,7,25-27). 
However, against the hypothesis of veno-arteriolar reflexes or spinal sympathetic 
reflex activity (the latter normally induced by specific triggers like pain and bladder 
distension rather than by head-up tilt; (28)) seems to be the fact that noradrenaline
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hardly shows an increase in P individuals (8) suggesting that the activity of the 
sympathetic nervous system has not increased. This is in accordance with the lack of 
an increase in sympathetic activity, as has been assessed by low frequency power in 
HR variability, in P during head-up tilt (1,2). Crandall et al. (29) showed that the 
cutaneous veno-arteriolar reflex is not mediated by adrenergic mechanisms but may 
be due to other local mechanisms. Myogenic mechanisms, associated with changes in 
vascular pressure, may account to a large extend for the observed vasoconstriction in 
P. According to Bayliss (30) and Folkow (31), the myogenic response is a potent and 
powerful vasoconstriction mechanism. With an intact baroreflex mechanism, 
excitatory influences from extrinsic origin may overrule the slow depolarization 
response, i.e., the myogenic response. However, when the normal regulatory 
mechanisms fail, the myogenic response may come into play (31). Imadojemu et al. 
(9) reported that the myogenic response may contribute in parallel with sympathetic 
nerve activity to vasoconstriction in healthy individuals during head-up tilt.
Leg vascular resistance rose in both groups, but total vascular resistance only in 
C, which indicates that the vasoconstriction response in P is a local mechanism 
triggered by vascular pressure changes, and therefore, not as generalized as in C with 
an overall vasoconstrictor response. Skagen and Bonde-Petersen (26) showed that 
proximal nervous blockade in healthy human subjects can block the vasoconstriction 
in the arms but not in the legs, indicating that leg vasoconstriction is not induced by 
centrally mediated sympathetic activity.
Besides the neurogenic and myogenic mechanisms, humoral mediated control 
may contribute to cardiovascular responses upon head-up tilt (32). Ten minutes after 
30° head-up tilt, Sander-Jensen et al. (33) found no change in renin, angiotensin, 
vasopressin, aldosterone and adrenaline in healthy individuals. Wall et al. (34) found 
no change in vasopressin levels and renin activity during 30° head-up tilt in normal 
individuals. In tetraplegic individuals, the renin angiotensin system activity is elevated 
and Mathias et al. (8) showed that renin levels rose more quickly and to higher levels 
in tetraplegic individuals upon head-up tilt than in healthy controls. Sved et al. (35) as 
Ozcan et al. (36) showed that vasopressin levels increased rapidly in tetraplegic 
individuals upon head-up tilt and were doubled within 3 min after tilt. Aldosterone 
and adrenaline do not appear to play an important role in cardiovascular responses 
upon head-up tilt in tetraplegic individuals (8). In contrast in P, Wall et al. (34) found
56
no change in renin and vasopressin activity during 30° head-up tilt. Therefore, a role 
for humoral-induced vasoconstriction upon tilt in P is less likely.
We speculate that the venous vascular atrophy, as reported in P (37,38), is 
beneficial for their orthostatic tolerance, although the relationship between venous 
blood pooling and orthostatic tolerance is controversial (39). Individuals with low 
thoracic lesions may be able to induce splanchnic vasoconstriction, which will 
contribute to their orthostatic tolerance, although Halliwil et al. (40) demonstrated 
that the splanchnic area may not be important in blood redistribution during head-up 
tilt. However, neither vascular atrophy nor splanchnic innervation, can explain the leg 
vasoconstriction observed during head up tilt in P.
Vasoconstrictor reserve affects orthostatic tolerance (41,42). Leg vascular 
resistance in P is higher than in C in the supine position, which implicates that the 
vasoconstrictor reserve is attenuated in P.
Although we cannot distinguish between veno-arteriolar reflex activity and 
myogenic responses or other local mechanisms, the results suggest that local 
regulatory mechanisms come into play and are able to induce leg vasoconstriction 
when centrally mediated vasoconstrictor mechanisms fail.
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ABSTRACT
Objective: Spinal cord-injured (SCI) individuals demonstrate an increased baseline 
leg vascular resistance. In addition, despite the lack of sympathetic control, an increase 
in leg vascular resistance is observed during orthostatic challenges. Based on the 
vasoconstrictive characteristics of angiotensin II, we examined the hypothesis that 
angiotensin II contributes to the leg vascular resistance at baseline and during head- 
up tilt in SCI individuals.
Methods: Supine baseline leg and forearm blood flow were measured using venous 
occlusion plethysmography and leg blood flow during 30° head-up tilt using duplex 
ultrasound. Measurements were performed before and 4 hours after an angiotensin II 
antagonist (irbesartan; 150 mg) in 8 SCI individuals and 8 age- and gender matched 
able-bodied controls. Vascular resistance was calculated as the arterial-venous 
pressure gradient divided by blood flow.
Results: Angiotensin II blockade significantly decreased baseline leg vascular 
resistance in SCI individuals (p=0.02) but not in controls, whilst no changes in 
forearm vascular resistance were found in both groups. Angiotensin II blockade did 
not alter the increase in leg vascular resistance during head-up tilt in SCI individuals 
nor in controls.
Conclusion: Our results indicate that angiotensin II contributes to the increased 
baseline leg vascular resistance in SCI individuals. As angiotensin II does not 
contribute to forearm vascular resistance, the contribution to leg vascular resistance 
may relate to the extreme inactivity of the legs in SCI individuals. Angiotensin II does 
not contribute to the increase in leg vascular resistance during head-up tilt in SCI 
individuals nor controls.
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INTRODUCTION
Angiotensin II plays an important role in the regulation of vascular tone and blood 
pressure via binding to the angiotensin II subtype 1 (ATi; vasoconstriction) and 2 
(AT2; vasodilation) receptor (1,2). Whilst angiotensin II does not contribute to 
vascular tone in healthy controls (3,4), angiotensin II plays a pivotal role in the 
increased forearm vascular resistance in individuals with an increased renin- 
angiotensin system (RAS) activity (3-5) (6).
Spinal cord-injured (SCI) individuals demonstrate an increased RAS activity, 
supported by elevated renin levels (7,8), but also show an increased leg vascular 
resistance (9-13). Vascular resistance is regulated by various factors, including 
angiotensin II. Previous studies demonstrated that the increased leg vascular 
resistance in SCI individuals cannot be explained through the sympathetic nervous 
system (10) or via endothelium derived nitric oxide (9), whilst endothelin-1 partly 
contributes to the increased leg vascular resistance (11). In SCI individuals, less 
angiotensin II is necessary to achieve a similar increase in blood pressure compared 
with controls (14), which suggests an increased angiotensin II responsiveness in SCI 
individuals. Angiotensin II might, therefore, play an important role in the increased 
leg vascular resistance in SCI individuals. SCI individuals offer a unique model of 
nature to assess peripheral vascular adaptations to inactivity since the skeletal muscles 
below the lesion are paralyzed and, therefore, extremely inactive. Furthermore, 
supraspinal sympathetic cardiovascular control is importantly impaired, which could 
lead to serious complications such as hypotension, orthostatic intolerance and 
episodic hypertension (autonomic dysreflexia) (15). Understanding the regulation of 
peripheral vascular tone is of special interest since an increased leg vascular resistance 
may contribute to the development of pressure sores and pour wound healing due to 
decreased perfusion in SCI individuals (16).
Despite their spinal cord lesion and concomitant sympathetic disruption, SCI 
individuals demonstrate an increase in leg vascular resistance during orthostatic 
challenges to the same extent as controls (12,17). This indicates that in SCI individuals 
other vasoconstrictive mechanisms contribute to the increase in leg vascular 
resistance. In SCI individuals, renin levels rise more quickly and to higher levels 
during orthostatic challenges compared with controls (7,8). Therefore, Angiotensin II
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might play a role in the increase in leg vascular resistance during orthostatic 
challenges in SCI individuals.
The aim of this study was to assess the contribution of angiotensin II to leg and 
forearm vascular resistance at baseline and during an orthostatic challenge in SCI 
individuals and controls. We hypothesized that angiotensin II contributes to the 
increased baseline leg vascular resistance as well as to the increase in leg vascular 
resistance during an orthostatic challenge in SCI individuals, but not in controls.
METHODS 
Subjects
Eight male SCI individuals and eight age- and gender matched able-bodied controls 
participated in this study (Table 1). All subjects were normotensive (<140/90 mmHg; 
auscultary blood pressure measurement), free of overt cardiovascular diseases and 
none of the individuals smoked. Four SCI individuals used medication, none of which 
is known to substantially interfere with vascular reactivity or the RAS. SCI individuals 
had longstanding (>5 years) traumatic spinal cord injury with a motor and sensory 
complete spinal cord lesion (American Spinal Injury Association Impairment Scale 
(AIS) A (18)) below the fourth thoracic spinal segment (T4). All included SCI 
individual had a complete paralysis with extremely inactive and deconditioned lower 
limbs and normal function and activity of the upper limbs. The level of spinal cord 
injury was assessed by clinical examination. The study was carried out in accordance 
with the declaration of Helsinki and approved by the medical ethical committee of our 
institution (Radboud University Nijmegen Medical Centre). All subjects gave written 
informed consent.
Experimental procedures and protocol
Three days preceding the experiment, subjects followed a sodium-defined diet (2000­
2400 mg sodium/day) to control the sodium intake. All subjects refrained from 
caffeine-containing food and beverages, vitamin C supplements and alcohol for >12 
hours and from heavy physical activity for >24 hours prior to the experiment. Subjects 
fasted for >2 hours and had emptied their bladder in the hour before the experiments. 
All experiments were performed in the morning in a quiet, temperature-controlled 
(23±1 °C) room.
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Table 1. Subject characteristics of the spinal cord-injured individuals.
SCI DOI Age Height Weight MAP Medication
Subject Level (yrs) (yrs) (cm) (kg) (mmHg)
SCI 1 T7 17 39 180 84 91 trimethoprim
SCI 2 T11 8 36 185 90 85
SCI 3 T7 24 55 187 83 104 methenamine,
nitrofurantoin,
oxazepam
CI 4 T8 14 49 178 78 83 solifenacin
SCI 5 T12 22 45 186 63 95 pregabalin
SCI 6 T6 5 32 173 53 80
SCI 7 T12 14 46 185 70 106
SCI 8 T4 6 28 175 75 77
SCI (n=8) 14±7 41±9 181±5 75±12 90±11
Controls (n=8) 42±11 179±7 76±9 91±8
Values represent mean±SD. SCI, spinal cord injury. DOI, duration of injury. MAP, mean arterial 
blood pressure. T, thoracic spinal segment.
Subjects were positioned comfortably on a manually driven tilt table and supported by 
a chest belt to prevent them from sliding down during the experiment. The 
experiment started after a supine resting period of >30 minutes. First, baseline leg and 
forearm blood flow were measured in supine position using venous occlusion 
plethysmography over a 5-minute period. To examine blood flow responses during 
orthostatic challenges, we first measured baseline superficial femoral artery blood flow 
using duplex ultrasound. Subsequently, subjects were tilted manually, within 5 
seconds, to a 10-minute passive 30° head-up tilt (HUT). In the last minute of 30°HUT 
superficial femoral artery blood flow was measured using duplex ultrasound. After the 
30°HUT, subjects were returned to the supine position (Figure 1). Subjects then 
received an oral dose of 150 mg of irbesartan (Aprovel, Sanofi-Aventis), a non­
competitive selective angiotensin II subtype 1 (ATi) receptor antagonist with a high 
affinity (IC50= 1.3 nmol/l) and high mean bioavailability (60-80%) (19,20). The 
measurements were repeated 4 hours after ingestion of irbesartan, to match the 
measurements with the peak blood pressure response to irbesartan (21-23). 
Measurements were performed under the same conditions as described earlier (i.e.>2 
hours fasting and bladder emptying >1 hour before the experiments) (Figure 1).
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Figure 1. Schematic representation of the experimental protocol.
V e n o u s b lo o d  sam ple Ven o u  s blood sam p le
Supine resting period
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30 35 45 255 285 290 300 min.0
30°HUT, 30° head-up tilt.
Measurements
Blood pressure was measured continuously using a non-invasive blood pressure 
device (Nexfin, BMEYE). A finger cuff was attached to the middle phalanx of the right 
third finger in order to measure finger arterial blood pressure, which accurately 
reflects intra-arterial blood pressure changes (24). A build-in heart reference system 
was in operation to correct for hydrostatic influences. Mean arterial blood pressure 
(MAP) values were derived beat to beat and heart rate was the inverse of the interbeat 
interval.
Leg and forearm resistance arterial blood flow were measured by ECG- 
triggered venous occlusion plethysmography, using electrically calibrated (25) 
mercury-in-silastic strain gauges (Hokanson, Inc.), with a coefficient of variation 
(CV) between 6-13% (26). In the supine position, the right leg and left arm were 
positioned ~5 cm above heart level to facilitate venous outflow between venous 
occlusions (27). Strain gauges were placed around the upper leg, 10 cm above the 
patella, and around the widest circumference of the forearm. Venous occlusion cuffs, 
placed on the thigh ~5 cm above the strain gauge and around the upper arm, were 
simultaneously inflated with a rapid cuff inflator (Hokanson, Inc.), within 1 s, to 50 
mmHg (28). Occlusion pressures were sustained for 8 heart cycles after which the cuff 
was deflated instantaneously (for 10 heart cycles). Blood flow was calculated as the 
slope of the volume change over a 4-second interval using a customized computer 
program (Matlab 6.1; Mathworks) (26).
Superficial femoral arterial blood flow during supine rest and 30°HUT was 
measured using duplex ultrasound, with a CV of 14% (29). Mean red blood cell 
velocity (Vmean) and systolic and diastolic diameter of the right superficial femoral 
artery, ~2 cm distal of the bifurcation, were measured with a duplex ultrasound device 
(ARTLAB system, Pie Medical; WAKI, Atys Medical). Vmean was calculated as the 
average of 20 Doppler waveforms. Automated software was used for operator-
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independent analyses of waveforms (Matlab 6.1; Mathworks). For diameter 
measurements the average of six consecutive mean diameters was obtained. Real-time 
automated analyses were performed using the ARTLAB system (Pie Medical). Leg 
blood flow was calculated with the following formula: (n • r2 • Vmean) • 60 (r = ^  • 
diameter of the superficial femoral artery).
Venous blood samples were drawn from the right antecubital vein in supine 
rest before and after ATi receptor blockade (Fig. 1). Plasma levels of sodium, 
creatinine, renin and angiotensin II levels were measured before ATi receptor 
blockade and plasma levels of renin and angiotensin II were measured after AT1 
receptor blockade. Plasma renin was measured by immunoradiometric assay (CISbio 
International) and angiotensin II levels in medium were measured by 
radioimmunoassay (detection limit 0.5 pmol/l) as described previously (30).
Urine excretion was collected over a 24-hour period preceding the experiment 
and urine sodium and creatinine concentrations were determined, which enabled the 
calculation of 24-hour sodium urine output and creatinine clearance.
Data analysis
Leg and forearm vascular resistance were calculated as the arterial-venous pressure 
gradient (Pa-Pv) divided by blood flow. Supine venous pressure was set at 9 mmHg 
and during 30°HUT the arterial-venous pressure gradient was replaced by MAP, since 
hydrostatic pressure makes an identical contribution to leg venous as well as leg 
arterial pressure (31). Leg and forearm vascular resistance measured using venous 
occlusion plethysmography are expressed in arbitrary units (AU).
Statistical analysis
Statistical analyses were performed using SPSS 16.0 (SPSS) software. Data are 
presented as mean±SD, unless otherwise stated. The level of statistical significance was 
set at a<0.05. Independent t-tests were used to assess differences at baseline. Repeated 
measures ANOVAs were used to examine whether the impact of AT1 receptor 
blockade differed between SCI individuals and controls for angiotensin II and renin 
levels, and leg and forearm vascular resistance. Repeated measures ANOVAs were also 
used to assess the effect of AT1 receptor blockade on the increase in leg vascular 
resistance during 30°HUT within SCI individuals and controls. Post-hoc t-tests were
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performed when the ANOVA reported a significant main or interaction effect. 
Bonferroni’s correction was used to correct for multiple comparisons.
RESULTS
Baseline plasma angiotensin II and renin levels were significantly higher in SCI 
individuals compared with controls (Table 2). ATi receptor blockade similarly 
increased angiotensin II and renin levels in SCI individuals and controls (ANOVA 
ATi blockade p=0.03, interaction p=0.35; ATi blockade p=0.01, interaction p=0.40, 
respectively) (Table 2). Creatinine clearance and 24-hour sodium excretion were 
similar between SCI individuals and controls, indicating similar sodium load (Table 
2).
Table 2. Plasma renin and angiotensin II levels, 24-hour sodium and urine excretion 
and creatinine clearance in spinal cord-injured and control individuals.
S C I (n = 8 ) C o n tro l (n = 8 ) P -value
Renin (m E/l)
Baseline 19±9 11±8 0.04
A T i blockade 10 3±115* 5 6 ± 7 2 * 0 .17
A ngiotensin II (pm ol/l)
Baseline 4 .8 ± 1 .9 2 .7±2 .6 0.05
A T 1  blockade 25 .9 ± 1 5 .2 * 14 .9±20 .0* 0.13
24-hou r sodium  excretion (m m ol) 164±43 141±43 0.40
24-hou r urine excretion (ml) 2 5 4 5 ± 9 8 4 1981±702 0.30
C reatinine clearance (m l/m in) 139±45 140±24 0.93
Values represent mean±SD. SCI, spinal cord-injured. ATi blockade, angiotensin II subtype 1 receptor 
blockade with irbesartan. *, post-hoc significantly different from baseline.
Contribution of angiotensin II to baseline vascular resistance
Leg vascular resistance (LVR) was significantly (p=0.01) higher in SCI individuals 
(39±10 AU) compared with controls (25±8 AU), whereas baseline forearm vascular 
resistance (FVR) was comparable between both groups (44±13 and 32±17 AU, 
respectively) (Figure 2). ATi receptor blockade significantly (post hoc p=0.02) 
decreased leg vascular resistance in SCI individuals (32±10 AU), but not in controls 
(29±11 AU) (Figure 2). No changes in forearm vascular resistance were observed after 
ATi receptor blockade in both groups (46±13 and 42±25 AU, respectively) (Figure 2).
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Baseline MAP and heart rate were comparable between groups and did not change 
after ATi receptor blockade (ANOVA ATi blockade p=0.07, interaction p=0.29; ATi 
blockade p=0.88; interaction p=0.71, respectively) (Table 3). Leg blood flow was 
similar between groups and significantly increased (post hoc p=0.02) in SCI 
individuals after ATi receptor blockade (ANOVA ATi blockade p=0.06, interaction 
p<0.01) (Table 3). Baseline superficial femoral artery diameter was significantly lower 
in SCI individuals compared to controls and did not change after ATi receptor 
blockade (ANOVA ATi blockade p=0.27, interaction p=0.7i) (Table 3).
Table 3. Effect of angiotensin II blockade on leg vascular parameters measured using 
duplex ultrasound in spinal cord-injured and control individuals in supine and during 
30° head-up tilt.
P o sitio n S C I ind iv id u als (n = 8 ) C o n tro ls  (n = 8 )
Baseline ATi blockade Baseline ATi blockade
SFA  diam eter (mm ) supine 5 .3 ± 0 .9 5 .3 ± 0 .9 7 .7 ± 0 .8 f 7 .6 ± 0 .8 f
30° HUT 5 .3 ± 0 .7 5 .2±0 .8 7 .5 ± 0 .8 f 7 .5 ± 0 .8 f
LBF (m l/m in) supine i i 2 ± 6 4 i6 0 ± 7 5 * i i 7 ± i 9 i0 6 ± 3 5
30° HUT 84 ± 5 7 * i i i ± 5 8 * 8 0 ± 3 0 * 86 ± 3 5 *
L V R  (m m H g/m l/m in) supine i . i7 ± 0 .8 3 0 .65±0.30* 0 .7 9 ± 0 .i4 0 .9 5 ± 0 .5 7
30° HUT i .8 0 ± i . i 7 * i . i6 ± 0 .7 9 * i.4 9 ± 0 .8 9 * i.3 4 ± 0 .6 6 *
M A P (m m H g) supine 9 8 ± i5 9 6 ± i6 9 8 ± 8 9 3 ± 9
30° HUT i0 3 ± 2 2 9 7 ± i7 i0 0 ± 9 9 7 ± 9 *
H eart rate (bpm) supine 6 9 ± i0 7 i ± i 3 59 ± 8 5 9 ± i0
30° HUT 7 3 ± i i * 7 5 ± i3 6 2 ± i0 6 i± 9
Values represent mean±SD. SCI, spinal cord-injured. ATi, angiotensin II subtype i receptor. SFA, 
superficial femoral artery. LBF, leg blood flow. LVR, leg vascular resistance. MAP, mean arterial blood 
pressure. 30° HUT, 30° head-up tilt. *, post-hoc significantly different from supine. f, significantly 
different from SCI individuals. *, post-hoc significantly different from baseline.
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Figure 2. Leg (A) and forearm (B) vascular resistance in spinal cord-injured 
individuals and controls before and after angiotensin II subtype 1 receptor blockade.
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Figure 3. Supine and 30° head-up tilt leg vascular resistance in spinal cord-injured 
individuals (A) and controls (B) before and after angiotensin II subtype 1 receptor 
blockade.
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Contribution o f angiotensin II to changes in vascular resistance during 30° head- 
up-tilt
30°HUT significantly increased leg vascular resistance in SCI individuals and controls 
(Figure 3). ATi receptor blockade did not alter the increase in leg vascular resistance 
during 30°HUT in both groups (Figure 3). MAP did not change during 30°HUT in 
SCI individuals (ANOVA 30°HUT p=0.10, interaction p=0.17), but significantly 
increased in controls after ATi receptor blockade (ANOVA 30°HUT p=0.01, 
interaction p=0.26) (Table 3). Heart rate significantly increased during 30°HUT in 
SCI individuals before ATi receptor blockade (ANOVA 30°HUT p<0.01, interaction 
p=0.91), but not in controls (ANOVA 30°HUT p=0.08, interaction p=0.96) (Table 3). 
Leg blood flow decreased during 30°HUT in both groups and the decrease was 
comparable before and after AT1 receptor blockade within SCI individuals and 
controls (ANOVA 30°HUT p<0.01, interaction p=0.29 and 30°HUT p<0.01, 
interaction p=0.14, respectively) (Table 3).
DISCUSSION
This study examined the contribution of angiotensin II, a strong vasoconstrictor, to 
the leg and forearm vascular resistance in SCI individuals and controls. The major 
findings are that: 1) angiotensin II contributes to the increased vascular resistance of 
the paralyzed legs, but not to the vascular resistance of the normally innervated 
forearms in SCI individuals; 2) angiotensin II does not contribute to leg or forearm 
vascular resistance in controls; and 3) AT1 receptor blockade does not significantly 
contribute to the increase in leg vascular resistance during 30°HUT in SCI individuals 
or controls.
This study is the first to demonstrate a decrease in baseline leg vascular resistance in 
SCI individuals after selective AT1 receptor blockade. This indicates that angiotensin 
II contributes, at least partly, to the increased vascular resistance in the extremely 
inactive legs of SCI individuals. In contrast, AT1 receptor blockade did not alter 
forearm vascular resistance in SCI individuals. These observations demonstrate a 
localized effect of angiotensin II, which suggests that the extreme physical inactivity in 
the deconditioned legs of SCI individuals relates to the increased contribution of 
angiotensin II to vascular resistance. This notion is supported by increased
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angiotensin II levels after bed rest (32,33), whereas exercise training reduces 
angiotensin II levels in heart failure (34) and angiotensin II mediated vasoconstriction 
in coronary artery disease (35). To further support the idea that physical inactivity 
relates to the increased vascular resistance, we have consistently demonstrated that 
electrical stimulation-assisted exercise training of the paralyzed lower limbs in SCI 
individuals can normalize the vascular adaptations caused by the SCI (11,13,36). 
Electrical stimulation-assisted exercise could even completely reverses the 
contribution of endothelin-1 to the increased leg vascular resistance in SCI individuals 
(11).
Our observations raise questions about the mechanism behind the increased 
contribution of angiotensin II to the leg vascular resistance in SCI individuals. A 
potential explanation relates to the elevated angiotensin II and renin levels in SCI 
individuals compared to controls in our study, a finding similar to previous studies in 
SCI individuals with high cervical lesions (7,8). However, the circulating angiotensin
II levels in SCI individuals were certainly not excessive (37), and angiotensin II 
blockade did not affect forearm vascular resistance. This argues against a major role 
for plasma angiotensin II per se. A local phenomenon is therefore more likely to 
underlie our observations. Angiotensins are known to be produced locally in the 
vascular wall (38). Such production depends entirely on the uptake of renal renin 
(37,39). Potentially, the leg vasculature of SCI individuals may display a larger renin 
uptake compared to the arms. Alternatively, an increase in angiotensin-converting 
enzyme (ACE) availability could increase the local formation of angiotensin II (39). 
However, individuals carrying the D-allele of the ACE gene did not have higher 
angiotensin II levels, despite having 60% higher ACE levels (40). The simplest 
explanation might be an alteration at the level of the angiotensin II receptors..
Since binding of angiotensin II to the AT1 receptor mediates vasoconstriction 
(1,2), an increased sensitivity or density of the AT1 receptors in the legs would be 
sufficient to explain our observation in SCI individuals. The exaggerated blood 
pressor response to angiotensin II in SCI individuals (14) supports this concept. 
However, a downregulation or a decreased sensitivity of the AT2 receptors, which 
mediate vasodilation (2), may also contribute to our findings. Although the effect of 
inactivity on AT2 receptors is unknown, exercise training increases AT2 receptor 
expression (35). Since vascular changes due to inactivity seem to mirror the effects of 
exercise, inactivity might decrease AT2 receptor expression. Future studies should
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further examine the exact mechanism explaining the contribution of angiotensin II to 
the increased leg vascular resistance in SCI individuals.
We recently reported that endothelin-1 contributes to the increased leg 
vascular resistance in SCI individuals, probably through the endothelin A (ETa) 
receptor (11). Interestingly, endothelin-1 and angiotensin II are closely connected. 
Angiotensin II stimulates the endothelin-1 release in cultured endothelial cells (41) 
and might mediate hypertensive effects in humans by stimulation of renal 
endothelium ET a receptors (42). Furthermore, angiotensin II-induced hypertension 
in rats can be attenuated by ET a receptor blockade (43). Whilst angiotensin II and 
endothelin-1 play an important role in the increased leg vascular resistance in SCI 
individuals, the link between both vasoconstrictor mechanisms in SCI individuals 
remains unknown.
Angiotensin II levels did not contribute to baseline vascular resistance in 
healthy controls. Whilst this finding reinforces previous observations in the forearm 
of healthy controls (3,4), our data adds to the current knowledge that angiotensin II 
does not contribute to the leg vascular resistance in healthy controls either. This 
observation is of special interest, since the magnitude of the effect of endothelium- 
dependent and independent dilators are limb dependent (44). Suggesting a limb 
dependent balance between vasoconstrictors and -dilators in controls, which 
determines the vascular tone in upper and lower limbs.
During orthostatic challenges a baroreflex mediated increase in sympathetic 
activity will increase heart rate, cardiac contractility and peripheral resistance in order 
to maintain blood pressure (45). Despite their spinal cord lesion and concomitant 
sympathetic disruption, our SCI individuals demonstrate a similar increase in leg 
vascular resistance during 30°HUT compared with controls, which is in agreement 
with previous studies (12,17). This indicates that other vasoconstrictor mechanisms 
compensate for the lack of sympathetic control. Although renin levels increase more 
rapidly in SCI individuals compared with controls (7,8), we found no impact of AT1 
receptor blockade on the vascular responses during 30°HUT in both groups. We 
studied SCI individuals with (low) thoracic spinal lesions compared to high cervical 
lesions in previous studies (7,8). All SCI individuals in our study demonstrated 
increased baseline renin and angiotensin II levels, indicating an increased RAS 
activity. Our observations indicate that angiotensin II does not contribute to the 
increase in leg vascular resistance during 30°HUT. One explanation relates to an
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insufficient orthostatic stress. However, a 30°HUT causes significant cardiovascular 
effects (12,17), which are comparable to higher HUT angles (46). Another explanation 
relates to the duration of our orthostatic challenge (10 minutes), as angiotensin II only 
contributes to vascular responses during prolonged orthostatic challenges (>25 
minutes) in controls (47). During 10-minute orthostatic challenges, angiotensin II 
does not contribute to the increase in leg vascular resistance in controls (47) and our 
SCI individuals. The observed increase in leg vascular resistance, therefore, is 
mediated by other vasoconstrictor mechanisms. The vasoconstrictors endothelin-1, 
vasopressin and aldosterone unlikely contribute to our observations, since they do not 
increase or during prolonged orthostatic challenges only (47,48). In a recent study, we 
demonstrated that the myogenic response, at least partly, contributes to the increase 
in leg vascular resistance during orthostatic challenges in SCI individuals (17).
Limitations
Since AT1 receptor blockers for intra-arterial human use are not available, we used an 
oral selective AT1 receptor blocker. SCI individuals and controls demonstrated similar 
increases in angiotensin II and renin levels after ingestion, indicating successful AT1 
receptor blockade. A single dose of irbesartan (150 mg) has a receptor occupancy of 
~90% (21,22), which means that AT1 receptors were not fully blocked. Nonetheless, 
we found a localized impact on the leg vasculature in SCI individuals.
Our experiments took place in the morning with a 4-hours difference between 
before and after AT1 receptor blockade measurements (Fig. 1). The diurnal rhythm of 
RAS activity, with a peak in the early morning (2-8 a.m.) and a relatively stable plateau 
during the awake hours(49), could have influenced our measurements. We started the 
experiments between 9-10 a.m. in both controls and SCI individuals. The diurnal 
rhythm of RAS activity, therefore, unlikely explains the localized impact of AT1 
receptor blockade on the leg vascular resistance in SCI individuals.
Since venous occlusion plethysmography is suggested to require an empty 
venous system to guarantee full venous compliance, we measured leg vascular 
resistance during 30°HUT using duplex ultrasound. In supine position we used 
venous occlusion plethysmography, since simultaneous measurements of different 
limbs is possible with a single device. Both methods have a good reproducibility 
(26,29) and there is a good agreement between the two methods with a correlation 
coefficient of 0.86 (46). Possible differences at baseline and in the magnitude of
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angiotensin II contribution to leg vascular resistance might be explained by the fact 
that both methods measure a different part of the cardiovascular system. Whilst 
venous occlusion plethysmography measures blood flow in resistance arteries, duplex 
ultrasound measures conduit artery blood flow. Distinct adaptations at both levels 
have been documented in response to exercise as well as physical inactivity (36).
Perspectives
SCI individuals are prone to develop pressure sores and suffer from poor wound 
healing below the level of the spinal cord lesion, which are associated with the 
increased leg vascular resistance (16). Based on the vasodilator effect in the paralyzed 
legs of SCI individuals, ATi receptor antagonists may improve or even prevent these 
secondary complications. Moreover, prolonged treatment may even improve 
cardiovascular function and health (1). Finally, our results suggest a detrimental role 
for physical inactivity to increase the angiotensin II-mediated vascular tone. 
Accordingly, physical inactivity may contribute, at least partly, to the increased 
angiotensin II-mediated tone in other disease states, such as heart failure and 
cirrhosis.
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ABSTRACT
Autonomic dysreflexia is a hypertensive episode in spinal cord-injured individuals 
induced by exaggerated sympathetic activity and thought to be a-adrenergic mediated. 
a-adrenoceptor antagonist have been a rational first choice, nevertheless calcium 
channel blockers are primarily used in autonomic dysreflexia management. However, 
a-adrenoceptor blockade may leave a residual vasoconstrictor response to sympathetic 
non-adrenergic transmission unaffected. The aim was to assess the a-adrenergic 
contribution and, in addition, the role of supraspinal control to leg vasoconstriction 
during exaggerated sympathetic activity provoked by autonomic dysreflexia in spinal 
cord-injured and by a cold pressure test in control individuals. Upper leg blood flow 
was measured using venous occlusion plethysmography during supine rest and during 
exaggerated sympathetic activity in 6 spinal cord-injured individuals and 7 able­
bodied control individuals, without and with phentolamine (a-adrenoceptor 
antagonist) and nicardipine (calcium channel blocker) infusion into the right femoral 
artery. Leg vascular resistance was calculated. In spinal cord-injured individuals, 
phentolamine significantly reduced the leg vascular resistance increase during 
autonomic dysreflexia (8±5 versus 24±13 arbitrary units, p=0.04) in contrast to 
nicardipine (15±10 versus 24±13 arbitrary units, p=0.12). In controls, phentolamine 
completely abolished the leg vascular resistance increase during a cold pressure test 
(1±2 versus 18±14 arbitrary units, p=0.02). The noradrenaline increase during 
phentolamine infusion was larger (p=0.04) in control than in spinal cord-injured 
individuals. These results indicate that the leg vascular resistance increase during 
autonomic dysreflexia in spinal cord-injured individuals is not entirely a-adrenergic 
mediated and is partly explained by non-adrenergic transmission which may, in 
healthy subjects, be suppressed by supraspinal control.
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INTRODUCTION
Autonomic dysreflexia (AD) is a potentially life-threatening episodic hypertension 
that develops in 80-90% of spinal cord-injured (SCI) individuals with a spinal cord 
lesion at or above the sixth thoracic spinal segment (T6) (1). AD occurs in these SCI 
individuals because a large part of the sympathetic nervous system is without central 
inhibitory pathways (2,3). An arterial pressure increase is induced by exaggerated 
sympathetic activity caused by visceral, noxious or nociceptive stimuli entering the 
spinal cord below the level of the lesion and can be initiated by catheterization, 
bladder distension and bowel evacuation (1-4). AD is accompanied by sweating, 
flushing and a pounding headache (1,4), and can lead to severe morbidity and even 
mortality (5-8).
Clinically, AD has been well documented, but the mechanisms that mediate AD 
remain unclear (9). Because AD is induced by exaggerated sympathetic activity it is 
thought to be a-adrenergic mediated (2-4). Therapy with an a-adrenoceptor blocker 
has, therefore, been a rational first choice in AD management (4). However, a- 
adrenoceptor blockers may leave a residual vasoconstrictor response to sympathetic 
co-transmitters such as adenosine triphosphate (ATP) and neuropeptide Y  (NPY) 
unaffected (10). These neurotransmitters may still cause a vasoconstrictor response 
during a-adrenoceptor blockade, although their exact role during exaggerated 
sympathetic activity is unclear. Because SCI individuals lack supraspinal sympathetic 
control, their responses could differ from able-bodied individuals in the contribution 
of non-adrenergic transmission during exaggerated sympathetic reflexes. Nowadays, a 
calcium channel blocker (nifedipine) is most commonly used as primary agent in the 
management of AD (4). A calcium channel blocker may be useful to prevent or 
control AD, indicated by a lower blood pressure response (11). However, the effect of 
calcium channel blockers on the vasoconstrictor response during AD is unknown.
The first aim was to assess the a-adrenergic contribution to leg vasoconstriction 
during AD in SCI individuals by a-adrenoceptor blockade. A second aim was to assess 
whether an a-adrenoceptor antagonist would be more effective than a calcium 
channel blocker in reducing the leg vasoconstriction during AD. We hypothesized 
that an a-adrenoceptor antagonist would abolish the leg vasoconstriction during AD 
and would, therefore, be more effective than a calcium channel blocker. To test this 
hypothesis the effect of the a-adrenoceptor antagonist phentolamine on leg
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vasoconstriction during AD in SCI individuals was compared with the calcium 
channel blocker nicardipine (intravenous equivalent of nifedipine). The third aim was 
to assess the role of the presence or absence of supraspinal control on sympathetic 
non-adrenergic transmission during exaggerated sympathetic activity by comparing 
the vascular responses of SCI with control individuals. We hypothesized that the 
contribution of a-adrenergic receptor stimulation would be more pronounced in SCI 
individuals. To test this hypothesis the effect of phentolamine on leg vasoconstriction 
during exaggerated sympathetic activity in SCI, by means of AD, was compared with 
control individuals, by means of a cold pressor test.
METHODS 
Subjects
Six male SCI individuals and seven healthy male able-bodied control individuals 
participated in this study (Table 1). All subjects were normotensive (<140/90 mmHg; 
auscultary blood pressure measurement), free of overt cardiovascular diseases and did 
not report orthostatic hypotension. Two SCI and two control individuals smoked, 
four SCI individuals used medication, none of which are known to substantially 
interfere with vascular reactivity (rectal laxantia (n=2), furosemide and tolterodine). 
All SCI individuals had longstanding traumatic spinal cord injury with a motor and 
sensory complete spinal cord lesion above T6 (AIS A, zone of partial preservation 
above T6 (12)). The level of spinal cord injury was assessed by clinical examination. 
The study was carried out in accordance with the declaration of Helsinki and was 
approved by the medical ethical committee of our institution. All subjects gave written 
informed consent.
Experimental procedures and protocol
All subjects refrained from caffeine-containing food and beverages, vitamin C 
supplements, nicotine and alcohol for >12 hours prior to the experiment and from 
heavy physical activity for >24 hours prior to the experiment. Subjects had been 
fasting for >12 hours and had emptied their bladder in the hour before the 
experiment. All experiments were performed in the morning in a quiet, temperature- 
controlled room (23±1 °C). Each subject was studied on two different occasions, 
separated by one week. On the first experimental day subjects were screened with a
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health questionnaire, physical examination and a resting electrocardiogram. 
Subsequently, a measurement of leg vascular resistance (LVR) in supine rest and 
during exaggerated sympathetic activity, i.e. AD in SCI and a cold pressor test of the 
hand (CPT) in control individuals. On the second experimental day nicardipine, a 
calcium ion influx inhibitor (calcium channel blocker), and phentolamine, a non- 
selective competitive antagonist of a-adrenergic receptors, were successively infused 
into the right femoral artery. LVR was measured during supine rest as well as during 
AD in SCI and during a CPT in control individuals.
Table 1. Subject characteristics, including the specific characteristics of the spinal 
cord-injured and control individuals.
Subject SCI
Level
DOI
(yrs)
Age
(yrs)
Height
(cm)
Weight
(kg)
SBP
(mmHg)
DBP
(mmHg)
SCI1 C5 17 46 181 105 130 78
SCI2 T5 28 46 198 65 108 78
SCI3 C7 45 69 179 81 108 60
SCI4 T5 10 39 178 70 106 62
SCI5 C7 34 52 182 92 108 62
SCI6 C7 12 36 183 58 110 50
SCI n=6 44±2 181±4 78±6 112±3 65±4
C1 22 180 67 118 76
C2 34 194 110 124 90
C3 46 174 65 118 82
C4 26 188 73 128 64
C5 42 188 88 118 78
C6 29 180 76 136 70
C7 54 187 85 138 70
Control n=7 36±4 184±2 81±5 126±3* 76±3
Values represent mean±SD. SCI, spinal cord-injured individuals. C, control individuals.DOI, 
duration of injury. SBP, systolic blood pressure. DBP, diastolic blood pressure. C, cervical spinal 
segment. T, thoracic spinal segment. *, significantly different from SCI.
On both days, subjects were positioned comfortably in supine position on a bed with 
an anti-ulcer mattress. Experimental procedures on the first experimental day started 
after a supine resting period of at least 30 minutes. First, baseline upper leg blood flow 
was measured for 10 minutes in supine position and, subsequently, AD was provoked 
in SCI individuals for 5 minutes. In control individuals, a CPT of the hand was 
applied for 3 minutes, during which upper leg blood flow was measured. On the
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second experimental day an intra-arterial cannula (Angiocath 16 gauge, Becton, 
Dickinson Infusion Therapy Systems Inc, USA) was introduced after local anesthesia 
(0.4 ml lidocainehydrochloride 10 mg/ml, Fresenius Kabi Nederland BV, The 
Netherlands) using a modified Seldinger technique into the right femoral artery at the 
level of the inguinal ligament for arterial blood pressure measurement (HP monitor 
type 78353B, Hewlett Packard GmbH, Germany) and intra-arterial drug 
administration by an automatic syringe infusion pump (Type P2000, IVAC Medical 
Systems, England). The measurements started after a supine resting period of at least 
30 minutes after cannulation of the right femoral artery. First, baseline upper leg 
blood flow was measured during a 5-minute saline (NaCl 0,9%, Baxter BV, The 
Netherlands) infusion period, followed by nicardipine infusion (Cardene, 1 mg/ml, 
Astellas Pharma BV, The Netherlands) during 10 minutes in a dose of 0.5 
^g/min/100ml of leg volume (13,14). In a pilot study higher dosages of nicardipine did 
not further increase blood flow in a control individual. In the last 5 minutes of 
nicardipine infusion, AD was provoked in SCI and a CPT in control individuals. After 
a resting period of at least 30 minutes with only saline infusion, the same protocol was 
performed but this time with phentolamine infusion (Regitine, 10 mg/ml, Novartis 
Pharma BV, The Netherlands) in a dose of 12 ^g/min/100ml of leg volume (15). 
Nicardipine was infused first because of the short half-life time of 2-5 min (16), in 
contrast to the unclear half-life time of phentolamine. The schedule of the protocol is 
shown in figure 1.
AD in SCI individuals was provoked by inflating a blood pressure cuff to 220 
mmHg on the contra-lateral upper leg, which gives a nociceptive stimulus (2,3). 
According to the literature, AD was achieved when there was a systolic blood pressure 
response to the stimulus of at least 20mmHg (3,17,18) or a 20% increase in blood 
pressure with visualized vasoconstriction (4). On the first experimental day we 
attempted to provoke AD with different stimuli (bladder percussion, CPT of the foot 
and inflating a blood pressure cuff) to see which stimulus would result in the highest 
increase in blood pressure and would fulfill the criteria (3,4,17,18). Bladder percussion 
could not be performed in all SCI individuals (sacral rhizotomy and electrical bladder 
stimulator) and the frequency and pressure of the bladder percussion was difficult to 
standardize. A CPT of the foot did not increase MAP in 5 consecutive SCI individuals 
and was therefore considered an inappropriate stimulus. Inflating a blood pressure 
cuff to 220 mmHg on the contra-lateral leg resulted in the highest increases in blood
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pressure, was consistent in provoking AD, appeared easy to standardize and was 
applicable for each SCI individual. Inflating a blood pressure cuff to 220 mmHg did 
not result in heamodynamic changes or in LVR of the contra-lateral leg in control 
individuals. We therefore decided to use this stimulus to provoke AD in SCI 
individuals.
To elevate sympathetic activity in control individuals, a CPT of the hand was 
applied (19). A CPT consisted of immersion of the right hand into ice-water (4°C) for 
a period of 3 minutes (19).
Figure 1. Schematic representation of the experimental protocol.
Day 1: non-invasive measurement
venous blood samples
Supine AD/CPT 
H-----------L --------- H
0 5 10 min
Day 2: invasive measurement
cannulation arterial blood samples arterial blood samples
Saline Nicardipine Saline Phentolam ine
1— //—
Supine AD/CPT
------//------
Supine AD/CPT
-30 10 15 45 50 55 60 min0 5
AD, autonomic dysreflexia in spinal cord-injured (SCI) individuals. CPT, cold pressor test of the hand 
in control individuals. Saline, NaCl 0,9%. Nicardipine, 0.5 |ig/min/100 ml of leg volume. 
Phentolamine, 12 |ig/min/100 ml of leg volume.
Measurements
Bilateral upper leg blood flow was measured by ECG-triggered venous occlusion 
plethysmography, using mercury-in-silastic strain gauges (D.E. Hokanson, Bellevue, 
Wash), and electrically calibrated (20). In supine position, the legs were positioned ~5 
cm above heart level to facilitate venous outflow between venous occlusions (21). 
Strain gauges were placed 10 cm above the patella and 12 cm width occlusion cuffs, 
placed on the thigh above the strain gauge, were inflated with a rapid cuff inflator 
(D.E. Hokanson), within 1 second, to 50 mmHg (22). Occlusion pressures were 
sustained for 8 heart cycles after which the cuff was deflated instantaneously (for 10 
heart cycles).
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Arterial blood pressure was measured continuously using a non-invasive blood 
pressure device (Portapres, TNO, The Netherlands) on day 1. A finger cuff was 
attached to the middle phalanx of the left third finger in order to measure finger 
arterial blood pressure, which accurately reflect intra-arterial blood pressure changes 
(23). On day 2 arterial blood pressure was continuously measured intra-arterial using 
the femoral artery cannula. MAP values were derived beat to beat and heart rate was 
the inverse of the interbeat interval.
Leg volume was determined by anthropometry as described and validated by 
Jones and Pearson (24).
Venous (day 1) and arterial (day 2) blood samples were taken to determine 
noradrenaline levels in SCI and control individuals. In SCI individuals, renin and 
angiotensin II levels were determined as well to establish a possible role of the renin- 
angiotensin system in AD. The blood samples were taken at rest, before infusion of 
nicardipine and phentolamine, and directly after AD in SCI and after a CPT in control 
individuals (Figure 1). The samples were collected in prechilled glass tubes on melting 
ice containing glutathione and EDTA for determination of noradrenaline levels and 
non-chilled glass tubes for determination of renin and angiotensin II levels. Samples 
were processed immediately in a refrigerated centrifuge and stored at -80°C until 
further analysis. Plasma noradrenaline was measured by sensitive and specific high­
performance liquid chromatography (HPLC) with fluorometric detection as described 
previously (25). Plasma renin was measured by immunoradiometric assay (IRMA) 
provided by CISbio International (Gif-sur-Yvette, France) and angiotensin II levels in 
medium were measured by radioimmunoassay (detection limit 0.5 pmol/l) as 
described previously (26).
Data analysis
A data acquisition system digitalized the data with a sample frequency of 100 Hz 
(MIDAC, Instrumentation Department, RUNMC, The Netherlands). Upper leg blood 
flow was calculated as the slope of the volume change over a 4-second interval using a 
customized computer program (Matlab 6.1; Mathworks, USA). MAP and heart rate 
values over the same intervals were averaged.
LVR was calculated as the arterial-venous pressure gradient divided by upper 
leg blood flow. For these calculations, we assumed that central venous pressure was 9
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mmHg in supine position (27). During AD and during a CPT the average of the 
highest three consecutive measurements was taken to determine LVR.
Statistical analysis
Statistical analyses were performed using SPSS 16.0 (SPSS) software. Data are 
presented as mean±SD, unless otherwise stated. The level of statistical significance was 
set at a=0.05. To assess differences in baseline values between SCI and control 
individuals unpaired t-tests were used. Repeated measurements ANOVAs were used 
to assess the effect of AD within the SCI group and of a CPT within the control group 
on the first day and the effect of infusion of nicardipine or phentolamine on the 
second day. Post-hoc t-tests were performed when the ANOVA reported a significant 
main or interaction effect. Bonferroni’s correction was used to correct for multiple 
comparisons.
RESULTS
Baseline values
Supine resting systolic blood pressure and MAP in SCI were lower (p=0.02) and LVR 
was higher (p<0.01) compared with control individuals. Provoking AD in SCI and 
performing a CPT in control individuals on day 1 resulted in an increase in MAP 
(p<0.01 and p=0.01, respectively) and LVR (p<0.01 and p=0.01, respectively), whereas 
heart rate did not change in either group. The LVR increase during AD in SCI was 
similar to the increase during a CPT in control individuals (Tables 1, 2 and 3, Figure
2).
Phentolamine and nicardipine infusion during AD in SCI individuals
LVR in SCI individuals was lower (p=0.02) during saline infusion on day 2 compared 
with the baseline value on day 1. Infusion of phentolamine did not change MAP and 
heart rate, but did lower LVR (p=0.04). Provoking AD during phentolamine infusion 
did not change MAP and heart rate, however LVR increased (p=0.02). The increase in 
LVR was significantly lower (p=0.04) during phentolamine infusion (8.0±4.5 AU) 
compared with the LVR increase on day 1 (23.6± 13.4 AU). Nicardipine infusion did 
not change MAP, heart rate or LVR. Provoking AD during nicardipine infusion 
resulted in an increase in MAP (p=0.03) and LVR (p=0.04) with no change in heart
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rate. The increase in MAP during AD was significantly lower (p=0.03) during 
nicardipine infusion (11.9±8.4 mmHg) compared with the MAP increase on day 1 
(21.3± 10.9 mmHg). Nicardipine did not significantly attenuate the LVR increase 
during AD (p=0.12), whereas the LVR increase provoked by AD was significantly 
lower (p<0.05) during phentolamine (8.0±4.5 AU) compared with nicardipine 
infusion (15.1±9.9 AU). In the non-infused leg no change in LVR was seen during 
infusion of phentolamine (31.3± 10.3 vs. 30.0± 10.0 AU), nor during nicardipine 
(33.0± 15.8 vs. 33.8± 16.8 AU) (Tables 2 and 3, Figure 2).
Table 2. Systemic hemodynamic variables and leg vascular resistance reactions during 
autonomic dysreflexia in spinal cord-injured individuals and cold pressure test in 
control individuals without and with phentolamine or nicardipine infusion.
Intervention SCI individuals (n=6) Control individuals (n=7)
MAP
(mmHg)
HR
(bpm)
LVR
(AU)
MAP
(mmHg)
HR
(bpm)
LVR
(AU)
baseline 82±6 55±7 32.7±3.1 96±6* 57±6 22.3±6.6*
AD/CPT 103±8* 52±6 56.3±13.8* 112±14* 59±6 40.1±17.8*
Phentolamine infusion
saline 77±9 51±10 23.8±7.2 90±13 61±7 21.9±5.7
phentolamine 75±12 54±10 18.9±6.2* 86± 11 66±8* 12.4±1.9*
AD/CPT 84±11 53±10 26.9±8.2f 91±3 68±4 13.1±2.5
Nicardipine infusion
saline 79±10 53±11 23.6±6.3 86±12 57±7 19.8±5.5
nicardipine 78±11 53±11 21.3±6.0 85±11 62±8* 13.8±4.1*
AD/CPT 90±11t 51±10 36.4±15.5t 94±13t 65±4 18.1±7.3t
Values represent mean±SD. SCI, spinal cord-injured. MAP, mean arterial blood pressure. HR, heart 
rate. LVR, leg vascular resistance. AD, autonomic dysreflexia. CPT, cold pressor test. AU, arbitrary 
units. *, significantly different from baseline or saline. f, significantly different from nicardipine or 
phentolamine. *, significantly different from SCI individuals.
Phentolamine and nicardipine during CPT in control individuals
Phentolamine infusion in control individuals did not change MAP but did increase 
heart rate (p=0.02) and resulted in a decrease in LVR (p=0.01). Phentolamine infusion 
completely abolished the LVR increase in response to a CPT without affecting MAP or 
heart rate. Infusion of nicardipine did not change MAP but increased heart rate 
(p=0.02) and decreased LVR (p<0.05) in control individuals. A CPT during 
nicardipine infusion increased MAP and LVR (p=0.04 and p=0.03, respectively) with
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no change in heart rate. The MAP and LVR increase were significantly less 
pronounced (p=0.04 and p=0.03, respectively) during nicardipine infusion compared 
with day 1. In the non-infused leg no change in LVR was seen during phentolamine 
infusion (23.0±8.6 vs. 21.1±8.0 AU) and the LVR increase during a CPT to 27.2± 11.9 
AU was lower compared to day 1, probably due to spill-over of phentolamine to the 
non-infused leg. LVR in the non-infused leg did not change during nicardipine 
infusion (21.1±7.6 vs. 21.8±8.0 AU) and during a CPT the LVR increased (37.2± 16.0 
AU) similar to day 1. (Tables 2 and 3, Figure 2).
Table 3. Individual increase in mean arterial blood pressure and leg vascular 
resistance during autonomic dysreflexia in spinal cord-injured individuals and cold 
pressure test in control individuals without and with phentolamine or nicardipine
infusion.
Subject Day 1 Phentolamine infusion Nicardipine infusion
4  MAP 4  LVR 4  MAP 4  LVR 4  MAP 4  LVR
mmHg (%) AU (%) mmHg (%) AU (%) mmHg (%) AU (%)
SCI during AD
SCI1 12 (13) 4 (13) 2 (2) 14 (87) 8 (8) 9 (57)
SCI2 15 (16) 43 (142) 4 (4) 3 (16) 9 (10) 9 (50)
SCI3 33 (44) 20 (54) 8 (12) 9 (30) 17 (25) 21 (72)
SCI4 6 (8) 19 (67) 1 (2) 10 (64) 4 (5) 24 (101)
SCI5 30 (40) 33 (95) 36 (58) 11 (58) 27 (39) 25 (98)
SCI6 29 (36) 22 (67) 3 (4) 3 (14) 8 (11) 2 (12)
SCI 21±11 24±13 9±13* 8±5* 12±8* 15±9t
(n=6) (26±15) (73±40) (14±22) (45±27) (16±13) (65±30)
Control during CPT
C1 4 (5) 7 (51) 8 (10) 1 (9) 13 (16) 11 (58)
C2 14 (15) 8 (54) -15 (-14) -3 (-23) 13 (12) 5 (27)
C3 9 (9) 12 (41) 6 (7) 3 (26) 3 (4) 1 (13)
C4 6 (6) 14 (54) 10 (13) 2 (19) -2 (-3) 1 (8)
C5 15 (15) 17 (58) 6 (7) 0 (3) 6 (7) 1 (10)
C6 34 (36) 47 (175) 14 (19) 0 (3) 16 (21) 10 (82)
C7 31 (32) 21 (110) 7 (9) 0 (4) 13 (16) 1 (14)
Control 16±12 18±13 5±9* 1±2* 9±6* 4±4*
(n=7) (17±12) (78±45) (7±10) (6±14) (10±8) (30±26)
Values represent mean±SD. SCI, spinal cord-injured individuals. C, controls individual. MAP, mean 
arterial blood pressure. LVR, leg vascular resistance. A, increase. %, percentage increase. AU, arbitrary 
units. *, significantly different from day 1 . f, significantly different from phentolamine infusion.
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Figure 2. Leg vascular resistance in spinal cord-injured individuals (n=6, upper 
graph) and control individuals (n=7, lower graph).
80 SCI individuals □  S u p in e  rest■  intra-arterial infusion
■  A utonom ic dysreflexia
<  40
0
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■  Cold p ressor test
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*
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5
Leg vascular resistance during supine rest, infusion of phentolamine and nicardipine and during 
autonomic dysreflexia in spinal cord-injured (SCI) and cold pressor test in control individuals with 
and without infusion. Values represent mean+SE. AU, arbitrary units. *, significant difference.
Blood samples
Baseline noradrenaline levels were significantly lower (p<0.01) in SCI compared with 
control individuals. During AD noradrenaline did not significantly increase in SCI in 
contrast to control individuals during a CPT (p=0.01). Noradrenaline increased 
significantly during AD in combination with phentolamine and nicardipine infusion 
in SCI (p=0.04 and p=0.03, respectively) and during a CPT in control individuals
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(p<0.01, both conditions). The increase in noradrenaline during phentolamine 
infusion was significantly more pronounced (p=0.04) in control than in SCI 
individuals. There were no significant increases in renin and angiotensin II levels 
during AD in SCI individuals without or with phentolamine or nicardipine infusion 
(Table 4).
Table 4. Noradrenaline, renin and angiotensin II levels at baseline and during 
autonomic dysreflexia in spinal cord-injured and a cold pressure test in control 
individuals without and with phentolamine or nicardipine infusion.
Intervention SCI individuals (n=6) Control (n=7)
NA
(nmol/l)
Renin
(mE/l)
A T  II
(pmol/l)
NA
(nmol/l)
baseline 0.66±0.31 10±5 1.96±1.00 1.09±0.18t
AD/CPT 0.93±0.21 10±7 2.02±1.38 1.93±0.71*t
Phentolam ine infusion 
saline 0.76±0.74 9±4 1.20±0.32 1.14±0.29
AD/CPT 1.49±1.44* 9±4 1.46±0.58 3.22±1.11*
Nicardipine infusion
saline 0.60±0.60 7±5 1.34±0.65 0.90±0.15
AD/CPT 1.00±0.92* 7±5 0.96±0.47 1.67±0.41*
Values represent mean±SD. Control, control individuals. NA, noradrenaline. AT II, angiotensin II. 
AD/CPT, autonomic dysreflexia in SCI individuals or cold pressure test in control individuals. *, 
significantly different from baseline or saline. f, significantly different from SCI individuals.
DISCUSSION
The major finding of this study is that AD in SCI individuals is not entirely mediated 
through the a-adrenergic pathway, indicated by presence of a remaining residual leg 
vasoconstrictor response during AD in SCI individuals during phentolamine infusion. 
Nevertheless, a more pronounced attenuation of the LVR increase during AD was 
present during phentolamine infusion compared with a nicardipine infusion. In 
contrast to SCI individuals, phentolamine infusion completely abolished the 
vasoconstriction response to a CPT in control individuals which could indicate that 
the presence of supraspinal sympathetic control in control individuals may suppress 
the role of non-adrenergic transmission during exaggerated sympathetic activity.
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Contribution of non-adrenergic transmission
The LVR increase during AD in SCI individuals did not differ from the LVR increase 
during a CPT in control individuals. Nevertheless, phentolamine completely abolished 
the LVR increase in control individuals during a CPT, whereas a significant residual 
leg vasoconstrictor response occurred in SCI individuals during AD with 
phentolamine infusion. These results suggest that non-adrenergic transmission 
contributes to the leg vasoconstriction during exaggerated sympathetic activity in SCI 
but not in control individuals. This interpretation is supported by the more 
pronounced increase in plasma noradrenaline levels in control individuals compared 
with SCI individuals in response to exaggerated sympathetic activity. This observation 
challenges the widespread view that the vasoconstrictor response during AD in SCI 
individuals is entirely a-adrenergic mediated (2-4,28).
Since phentolamine is a non-selective competitive a-adrenoceptor antagonist, 
incomplete a-adrenoceptor blockade could, in theory, explain the residual LVR 
increase in SCI individuals. A similar intra-arterial dose of phentolamine has 
previously been used and achieved a maximal vasodilator effect in both SCI and 
control individuals indicating complete a-adrenoceptor blockade (15,29,30). 
Moreover, the LVR increase during a CPT in control individuals was completely 
abolished during phentolamine infusion, despite a larger increase in plasma 
noradrenaline compared with SCI individuals. This confirms that intra-arterial 
infusion of phentolamine achieved effective intrasynaptic drug concentrations (30) 
and excludes incomplete a-adrenergic blockade as an explanation for the residual 
vasoconstrictor response in SCI individuals in the present study.
Since vasoconstriction during AD occurs rapidly, it is not likely that other 
vasoconstrictor mechanisms play an important role, such as the renin-angiotensin 
system (RAS). The RAS is a slow acting vasoconstriction mechanism and, therefore, 
unlikely to cause immediate arterial vasoconstriction upon a visceral, noxious or 
nociceptive stimulus. Moreover, there was no increase in renin and angiotensin II 
levels during AD in SCI individuals supporting the notion that there was no activation 
of the RAS. However, the local angiotensin system could still play a role since we did 
not have an additional angiotensin II subtype I receptor blockade. It is unlikely that 
vasopressin plays a role since vasopressin levels are low in SCI individuals and do not 
increase during AD (31). The instant reaction to the triggering stimulus provoking 
AD in combination with the lack of supraspinal control in SCI individuals causing
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e x a g g e ra te d  sy m p a th e t ic  a c tiv ity  p ro v id e s  e n o u g h  e v id e n c e  fo r  a sy m p a th e tic  
m e d ia te d  m e c h a n ism . S in ce  a - a d r e n o c e p to r  b lo c k a d e  d id  n o t  a b o lish  th e  L V R  
in c re a se  d u r in g  A D , o th e r  s y m p a th e t ic  n e u ro t r a n s m it te r s  m ig h t b e  in v o lv ed , s u c h  as 
A T P  a n d  N P Y  (10). A T P , N P Y  a n d  n o ra d r e n a l in e  a re  c o -s to re d  in  th e  s y m p a th e tic  
sy n a p se  a n d  a re  s im u lta n e o u s ly  re le a se d  (32). R e c e p to rs  fo r  th e s e  n e u ro t r a n s m it te r s  
a re  lo c a te d  o n  s m o o th  m u sc le  a n d  e n d o th e l ia l  cells o f  b lo o d  vesse ls (32 ). I t  is th o u g h t  
t h a t  n o ra d r e n a l in e  a n d  A T P  h av e  a c o o rd in a te d  a c tio n  in  n e u ro g e n ic  v a s o c o n s tr ic tio n  
w h ic h  is m o d u la te d  b y  N P Y  (32). W e  d id  n o t  in v e s tig a te  th e  m e c h a n is m  b y  w h ic h  
sp in a l c o rd  in ju ry  in c re a se s  s y m p a th e t ic  n o n -a d re n e rg ic  t r a n s m is s io n . S in ce  th e  
s y m p a th e t ic  n e rv o u s  sy s tem  b e lo w  th e  le s io n  in  S C I in d iv id u a ls  is w ith o u t  c e n tra l 
in h ib i to ry  p a th w a y s  (2 ,3 ), in  c o n tr a s t  to  c o n tro l  in d iv id u a ls , w e  sp e c u la te  th a t  an  
in ta c t  s u p ra s p in a l c o n tro l  o f  sy m p a th e tic  o u tf lo w  p re fe re n tia lly  su p p re sse s  
sy m p a th e tic  n o n -a d re n e rg ic  t r a n s m is s io n . A lte rn a tiv e ly , sp in a l c o rd  in ju ry  a lte rs  th e  
re la tiv e  c o n c e n tra tio n s  o f  c o -s to re d  n e u ro tra n s m it te r s .  In  th is  re g a rd , a n  in te rm e d ia te  
ro le  fo r  e n d o th e l in  is w o r th  m e n t io n in g . W e  h av e  p re v io u s ly  sh o w n  th a t  th e  
c o n tr ib u t io n  o f  e n d o th e l in  in  L V R  is in c re a se d  in  S C I in d iv id u a ls  (33 ). In  ra ts  
e n d o th e l in -1  in fu s io n  in c re a se d  th e  re la tiv e  c o n tr ib u t io n  o f  A T P  as a  fu n c t io n a l 
s y m p a th e t ic  n e u ro t r a n s m it te r  (34). T h e re fo re , e n d o th e l in  m a y  m e d ia te  th e  in c re a se d  
c o n tr ib u t io n  o f  n o n -a d r e n e rg ic  n e u ro g e n ic  v a s o c o n s tr ic tio n  in  S C I in d iv id u a ls .
P h e n to l a m in e  e f f e c t  s u p e r io r  to  n ic a r d ip in e
P ro v o k in g  A D  in  S C I in d iv id u a ls  d u r in g  n ic a rd ip in e  in fu s io n  s till re s u lte d  in  a L V R  
in c re a se  w ith  a  c o n c u r r e n t  in c re a se  in  M A P . H o w ev e r, th e  M A P  in c re a se  w ith  
n ic a rd ip in e  in fu s io n  w as lo w e r c o m p a re d  w ith  d a y  1, in d ic a tin g  a n  a t te n u a t io n  o f  th e  
b lo o d  p re s s u re  re s p o n s e  d u r in g  A D  in  S C I in d iv id u a ls . T h is  is c o n s is te n t w ith  o n e  
p re v io u s  s tu d y  d e m o n s tr a t in g  a  lo w e r b lo o d  p re s s u re  re s p o n s e  d u r in g  o ra l n ife d ip in e  
p re - t r e a tm e n t  in  S C I in d iv id u a ls  w h o  e x h ib i te d  A D  d u r in g  e le c tro -e ja c u la t io n  (11). 
H o w ev e r, th e  L V R  in c re a se  w as  s im ila r  to  d ay  1 in d ic a tin g  a  m in o r  e ffec t o f  
n ic a rd ip in e  o n  leg  v a so c o n s tr ic tio n .
D e sp ite  th e  re s id u a l L V R  in c re a se  d u r in g  A D  in  S C I in d iv id u a ls  w ith  
p h e n to la m in e  in fu s io n , th is  L V R  in c re a se  w as s ig n if ic a n tly  lo w e r th a n  w ith  
n ic a rd ip in e  in fu s io n  a n d , m o re o v e r , w ith  p h e n to la m in e  th e re  w as n o  c h a n g e  in  M A P . 
T h e se  re s u lts  in d ic a te  a s u p e r io r  e ffec t o f  a n  a - a d r e n o c e p to r  a n ta g o n is t  c o m p a re d
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w ith  a c a lc iu m  c h a n n e l b lo c k e r  o n  leg  v a s o c o n s tr ic t io n  a n d  c o n c u r r e n t  b lo o d  p re s su re  
re s p o n s e  d u r in g  A D  in  S C I in d iv id u a ls .
A n  o b v io u s  e x p la n a tio n  fo r  th e  o b se rv e d  d if fe re n c e  in  e ffec t c o u ld  b e  an  
in e f f ic ie n t d o sa g e  o f  n ic a rd ip in e . In fu s io n  o f  n ic a rd ip in e  d id  n o t  r e s u lt  in  a s ig n if ic a n t 
d e c re a se  in  b a sa l L V R  in  S C I in d iv id u a ls . H o w ev e r, in  c o n tro l  in d iv id u a ls  b a sa l L V R  
d e c re a se d  w ith  th e  sa m e  d o se  a n d  in  a  p ilo t  s tu d y  h ig h e r  d o sag es  o f  n ic a rd ip in e  d id  
n o t  r e s u lt  in  a m o re  p r o n o u n c e d  v a s o d ila to ry  effec t. W e  a re , th e re fo re , c o n v in c e d  th a t  
w e  u s e d  a su ff ic ie n t d o se  o f  n ic a rd ip in e . T h e  v a s o d ila ta tio n  c a u se d  b y  n ic a rd ip in e  is, 
h o w e v e r, m o re  p r o n o u n c e d  in  h y p e r te n s iv e  c o m p a re d  w ith  n o rm o te n s iv e  in d iv id u a ls  
(16 ). S in ce  b lo o d  p re s s u re  in  S C I in d iv id u a ls  w as lo w e r c o m p a re d  w ith  c o n tro l 
in d iv id u a ls  th e  e ffec t o f  n ic a rd ip in e  o n  L V R  c o u ld  b e  sm a lle r  fo r  th is  re a so n .
B a s e lin e  v a lu e s
C o n s is te n t w ith  o u r  re su lts , S C I in d iv id u a ls  w ith  a  h ig h  sp in a l c o rd  le s io n  a re  p ro n e  to  
lo w  re s tin g  b lo o d  p re s su re s  (1 -3 ), w h ic h  is th o u g h t  to  b e  d u e  to  a d im in u t io n  in  
s y m p a th e t ic  n e rv o u s  ac tiv ity  b e lo w  th e  le s io n  as s u p p o r te d  b y  lo w  p la s m a  
n o ra d r e n a l in e  levels (1 ,2). A lth o u g h  th e  re d u c e d  n o ra d r e n a l in e  levels in  SC I 
in d iv id u a ls  m a y  a lso  b e  in f lu e n c e d  b y  th e  e ff ic ien cy  o f  th e  r e -u p ta k e  b y  th e  
n o ra d re n a l in e  t r a n s p o r te r  a n d  c h a n g e s  in  b lo o d  flo w  re d is tr ib u t io n  c a u se d  b y  
in a c t iv i ty  a n d  m u s c le  a tro p h y . D e sp ite  lo w e r s y m p a th e t ic  ac tiv ity , S C I in d iv id u a ls  
h a v e  a h ig h e r  re s tin g  L V R  (15 ,30 ,35), p ro b a b ly  d u e  to  a  c o m b in a tio n  o f  fu n c t io n a l 
(33) a n d  s t ru c tu ra l  v a sc u la r  ch a n g e s  (36 ). D u r in g  A D , SC I in d iv id u a ls  c a n  in c re a se  
th e i r  L V R  to  th e  sa m e  e x te n t as c o n tro l  in d iv id u a ls  d u r in g  a  C P T . A lth o u g h  a  C P T  is 
n o t  d ire c tly  c o m p a ra b le  w ith  A D , b o th  a re  s t ro n g  sy m p a th e tic  s tim u li, 
n o tw ith s ta n d in g  th e  p h y s io lo g ic a l a n d  n e u ro lo g ic a l d iffe ren ces , e sp ec ia lly  th e  ab sen ce  
(S C I) o r  p re s e n c e  (c o n tro l)  o f  s u p ra s p in a l c o n tro l  (2 ,3).
Lim i t a t i o n s
A lth o u g h  a -a d re n e rg ic  re s p o n s iv e n e s s  d e te r io ra te s  w ith  age  (37 ,38 ), a ll S C I a n d  
c o n tro l  in d iv id u a ls  d e m o n s tra te d  s im ila r  in c re a se s  in  L V R  d u r in g  A D  a n d  a  C P T , 
re sp ec tiv e ly , c o m p a re d  w ith  th e i r  p ee rs . M o re o v e r , th e  o ld e s t c o n tro l  in d iv id u a l (C 7, 
54  y rs ) h a d  a c o m p le te  a b o lish e d  L V R  in c re a se  d u r in g  a  C P T  w ith  p h e n to la m in e  
in fu s io n  a n d  th e  o ld e s t S C I in d iv id u a l (SC I3 , 69 y rs ) h a d  a n  a t te n u a te d  L V R  in c re a se  
d u r in g  A D  w ith  p h e n to la m in e  in fu s io n .
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In fu s io n  o f  sa lin e  in  S C I in d iv id u a ls  lo w e re d  su p in e  L V R  c o m p a re d  w ith  d ay  1. 
T h is  is p ro b a b ly  d u e  to  a m o re  p ro n o u n c e d  re a c t io n  to  a n  in c re a se  in  s h e a r  o n  th e  
v a sc u la r  w all, c a u se d  b y  th e  sa lin e  in fu s io n , d u e  to  fu n c t io n a l ch a n g e s  in  SC I 
in d iv id u a ls  (33). T h e  n o n - in fu s e d  leg  d id  n o t  d e m o n s tra te  a  lo w e r su p in e  LVR, 
in d ic a tin g  th a t  th e  lo w e r su p in e  L V R  in  th e  in fu s e d  leg  is p ro b a b ly  c a u se d  b y  th e  
sa lin e  in fu s io n . T h e  lo w e r su p in e  L V R  d id  n o t  h av e  a n y  e ffec t o n  M A P  a n d  h e a r t  ra te . 
S in ce  th e  fo c u s  o f  th e  s tu d y  w as  th e  e ffec t o f  p h e n to la m in e  a n d  n ic a rd ip in e  in fu s io n  
o n  th e  L V R  in c re a se  d u r in g  A D  a n d  a  C P T , w e  m a y  a ss u m e  th a t  th e  lo w e r b a sa l LV R  
d id  n o t  in f lu e n c e  o u r  re su lts .
P e r s p e c t iv e s
T h e  m a n a g e m e n t o f  A D  in  S C I in d iv id u a ls  re m a in s  a c h a lle n g e  in  c lin ica l p ra c tic e  
(18 ,39 ). O v e r  th e  y ea rs , m a n y  d if fe re n t a n ti-h y p e r te n s iv e  a g e n ts  h av e  b e e n  u se d  (4 ,18). 
I n  e a r l ie r  days a - a d r e n o c e p to r  a n ta g o n is ts  w e re  u s e d  (4), h o w e v e r, th e i r  u se  w as 
l im ite d  a n d  n o w a d a y s  n ife d ip in e  (c a lc iu m  c h a n n e l b lo c k e r )  is u se d  as a p r im a ry  ag e n t 
in  th e  m a n a g e m e n t o f  A D  (4). H o w e v e r, th e  p re s e n t s tu d y  d e m o n s tra te s  th a t  a n  a -  
a d re n o c e p to r  a n ta g o n is t  a p p e a rs  to  h a v e  a m o re  p r o n o u n c e d  e ffec tive  th a n  a c a lc iu m  
c h a n n e l b lo c k e r  o n  th e  L V R  a n d  c o n c u r r e n t  M A P  in c re a se  d u r in g  A D  in  SC I 
in d iv id u a ls . M o re o v e r , s e r io u s  a d v e rse  re a c t io n s  a f te r  th e  u se  o f  im m e d ia te  re le a se  
n ife d ip in e  in  h y p e r te n s iv e  e m e rg e n c ie s  in  n o n -S C I in d iv id u a ls  h a v e  b e e n  re p o r te d  
(40 ). T h e  p re s e n t s tu d y  d e m o n s tra te s  th a t  A D  in  S C I in d iv id u a ls  is n o t  e n tire ly  a -  
a d re n e rg ic  m e d ia te d  a n d  th a t  s y m p a th e t ic  n o n -a d re n e rg ic  tr a n s m is s io n  m a y  p a r t ly  
e x p la in  th e  L V R  in c re a se . T h e  d e v e lo p m e n t o f  a n ta g o n is ts  o f  n o n -a d re n e rg ic  
t r a n s m i t te r s  m a y  b e  a  ta rg e t fo r  fu tu re  A D  m a n a g e m e n t in  S C I in d iv id u a ls . P e rh a p s  
th e s e  a n ta g o n is ts  m a y  re d u c e  th e  b lo o d  p re s s u re  in c re a se  d u r in g  A D  w ith o u t  lo w e rin g  
th e  b lo o d  p re s s u re  in  th e  a b se n c e  o f  A D .
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ABSTRACT
Background Orthostatic hypotension is common in older men and associated with 
morbidity and mortality. During orthostatic challenges, older men maintain their 
blood pressure by an augmented increase in total peripheral resistance. Changes in the 
leg vascular bed contribute importantly to blood pressure regulation during 
orthostatic challenges, partly because of blood pooling in the legs. Little is known 
about the contribution of the leg vascular bed to the augmented increase in total 
peripheral resistance.
Objective To examine tilt-induced peripheral vasoconstriction in the leg vascular bed 
of young and older men.
Methods We measured forearm and calf blood flow in 12 young and 12 older men, 
using venous occlusion plethysmography during 30° head-up tilt (HUT). Forearm and 
calf vascular resistance were calculated as mean arterial blood pressure divided by 
blood flow.
Results During HUT, calf and forearm vascular resistance increased in older and 
young men. The increase in forearm vascular resistance was similar between older 
(40±6 %) and young men (51±12 %). However, the increase in calf vascular resistance 
was lower in older (96±15 %) than in young men (175±30 %).
Conclusion Advancing age leads to an attenuated tilt-induced increase in calf vascular 
resistance, which may contribute to age-related orthostatic hypotension.
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IN TRO D U CTIO N
Orthostatic hypotension is a common feature with advancing age, with a prevalence 
around 17 percent in persons aged 65 years and older (1,2), and is associated with falls 
(2), cognitive decline (3), cardiovascular morbidity (4) and mortality (2,5,6).
During orthostatic challenges venous blood is pooled in the lower limbs and 
abdomen, leading to a decreased venous return and a transient decrease in cardiac 
output and blood pressure. The drop in blood pressure activates the baroreflex, 
resulting in an increase in sympathetic activity. As a consequence, heart rate and 
vascular resistance are increased to restore cardiac output and blood pressure (7). In 
contrast to young men, during an orthostatic challenge older individuals demonstrate 
an attenuated cardiac output (8-10) which is compensated by an augmented increase 
in total peripheral resistance in order to maintain blood pressure (8-11).
Because venous blood pooling plays a major role during orthostatic challenges, 
changes in vascular resistance in the splanchnicus and lower limb vascular bed 
contribute importantly to the blood pressure regulation during orthostatic stress (7). 
Minson et al. (11), demonstrated an augmented increase in splanchnic vascular 
resistance during head-up tilt (HUT) in older compared with young men, which may 
account for the age-related augmented increase in total peripheral resistance. In 
addition, the lower limb vascular bed is also an important contributor to blood 
pressure regulation during orthostatic challenges (7). Nonetheless, changes in leg 
vascular resistance during an orthostatic challenge in older men have never been 
measured.
The purpose of this study is, therefore, to examine the tilt-induced peripheral 
vasoconstriction in the leg vascular bed of healthy young and healthy older men. We 
tested the hypotheses that the tilt-induced leg vasoconstriction is augmented in older 
men compared with young men, and thereby contributing to the previously reported 
augmented tilt-induced increase in total peripheral resistance.
METHODS
Subjects
Twelve healthy young (20-28 years) and twelve healthy older men (67-80 years) 
volunteered to participate in this study (Table 1). Subjects never smoked or stopped
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smoking at least 2 years ago. A ll subjects were normotensive (< 140/90 mmHg), had 
no signs of varicose veins and were free of overt chronic cardiovascular diseases as 
assessed by medical history and physical examination and did not report orthostatic 
hypotension. None of the subjects used medication known to interfere with the 
cardiovascular system. Individuals with ankle-brachial pressure index <0.90, and/or 
abnormalities in a 12-lead resting ECG were excluded. The study has been carried out 
in accordance with the Declaration of Helsinki (2000) and was approved by the 
medical ethical committee of our institution. A ll subjects gave written informed 
consent.
Table 1. General characteristics of young and older men.
Young men (n = 12) Older men (n = 12)
Age (yrs) 24 ± 1 71 ± 1*
Height (cm) 182 ± 2 175 ± 3
Body mass (kg) 73 ± 3 78 ± 3
Systolic BP (mmHg) 124 ± 3 131 ± 4
Diastolic BP (mmHg) 74 ± 2 77 ± 2
MAP (mmHg) 90 ± 2 95 ± 2
Values represent mean±SE. BP, blood pressure. MAP, mean arterial blood pressure. *, significantly 
different from young men.
Experimental procedures and protocol
A ll subjects refrained from caffeine-containing food and beverages, vitamin C 
supplements, and alcohol for at least 12 hours prior to the experiment and refrained 
from heavy physical activity for at least 24 hours prior to the experiment. Room 
temperature was controlled at 23 ± 1  °C. After completing a health questionnaire, 
subjects were positioned comfortably on a tilt table in the supine position. The 
experimental procedures started after a supine resting period of at least 30 minutes.
First, baseline forearm and calf blood flow were measured for 5 minutes in the 
supine position. Subsequently, subjects were tilted manually, within 5 seconds, to a 5 
minutes passive 30° HUT position in order to induce a significant cardiovascular 
response (12).
Measurements
Heart rate and arterial blood pressure were measured continuously using a non­
invasive portable blood pressure device (Portapres, TNO, Amsterdam, the
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Netherlands). A finger cuff was attached to the middle phalanx of the left third finger 
in order to measure finger arterial blood pressure. Finger arterial blood pressure 
measurements accurately reflect intra-arterial blood pressure changes during 
orthostatic stress (13). Data were collected during the experiment at a rate of 100 Hz. 
Mean arterial blood pressure (MAP) values were derived beat to beat and heart rate 
was the inverse of the interbeat interval.
Blood flow in the forearm and calf was measured using venous occlusion 
plethysmography. In the supine position, the right arm and leg were supported to 
ensure that they were positioned ~ 5 cm above heart level. A standard blood pressure 
cuff (10 cm width) was placed around the right upper arm and a 12 cm width 
occlusion cuff was placed just above the right knee. Mercury-in-silastic strain gauges 
(Hokanson, Inc, Bellevue, WA, USA) were placed at the widest girth of the right 
forearm and calf. Both cuffs were inflated simultaneously with a rapid cuff inflator 
(Hokanson, Inc, Bellevue, WA, USA), within 1 s, to 50 mmHg in the supine position 
(14) and to 65 mmHg in the 30° HUT position to correct for changes in hydrostatic 
pressure (15). The occlusion pressure was sustained for 7 seconds after which the cuffs 
were deflated instantaneously (for 9 seconds). Venous occlusion plethysmography is 
suggested to requisite an empty venous system to guarantee full venous compliance. 
Recently, it was shown that venous occlusion plethysmography measurements of calf 
blood flow during supine and up to 30° HUT correlates well (r2 = 0.86, p < 0.001) with 
superficial femoral artery blood flow measured with Doppler ultrasound (16). This 
indicates that venous occlusion plethysmography during 30° HUT represents arterial 
inflow and is not significantly affected by venous compliance.
Data analysis
Blood flow (in ml-min^-dl"1) was calculated from the slope of the volume change over 
a 4-seconds interval. To avoid artefacts, the initial first second was excluded from 
analysis. Vascular resistance was calculated as MAP divided by blood flow. For the 
calculation of vascular resistance, we assumed that venous pressure was ~ zero in the 
supine position. Furthermore, we assumed that hydrostatic pressure made an identical 
contribution to leg venous pressure as to leg arterial pressure during 30° HUT. Blood 
flow, vascular resistance, MAP and heart rate were averaged over the last two minutes 
of the supine and 30° HUT positions.
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Statistical analysis
Results are expressed as mean ± SEM. A paired Student’s t-test was used to determine 
the effect of 30° HUT in young and in older men and an unpaired Student’s t-test was 
used to compare the changes upon 30° HUT between young and in older men. The 
level of statistical significance was set at a  = 0.05.
RESULTS
No differences in physical characteristics between young and older men were present, 
with exception of the significant age difference. (Table 1)
Central cardiovascular responses
Young and older men demonstrated a significant increase in MAP during 30° HUT, 
which was significantly larger in young than in older men. During 30° HUT, heart rate 
increased significantly in young men only. (Table 2)
6
Table 2 . Central and peripheral parameters during supine and 30° head-up tilt in 
young and older men.
Supine 30° HUT P-value
Young men (n = 12)
MAP (mmHg) 85 ± 4 92 ± 4 < 0.001
Heart rate (bpm) 60 ± 2 66 ± 3 < 0.001
Calf BF (ml-min-1-dl-1) 3.3 ± 0.4 1.4 ± 0.1 < 0.001
Calf VR (mmHg-ml-1-min-1-dl-1) 28.8 ± 3.1 75.7 ± 8.7 < 0.001
Forearm BF (mLmin-1-dl-1) 4.9 ± 0.8 3.7 ± 0.6 < 0.001
Forearm VR (mmHg-ml-1-min-1-dl-1) 24.3 ± 4.2 33.7 ± 6.1 0.001
Older men (n = 12)
MAP (mmHg) 87 ± 3 90 ± 3 0.010
Heart rate (bpm) 61 ± 4 63 ± 4 0.326
Calf BF (ml-min-1-dl-1) 3.4 ± 0.2 1.9 ± 0.2 < 0.001
Calf VR (mmHg-ml-1-min-1-dl-1) 27.5 ± 2.5 55.0 ± 7.9 < 0.001
Forearm BF (mLmin-1-dl-1) 4.8 ± 0.6 3.5 ± 0.5 < 0.001
Forearm VR (mmHg-ml-1-min-1-dl-1) 22.4 ± 2.9 33.2 ± 4.4 0.003
Values represent mean±SE. 30° HUT, 30° head-up tilt. MAP, mean arterial blood pressure. BF, blood 
flow. VR, vascular resistance.
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Figure 1. 30° head-up tilt induced differences in calf and forearm vascular resistance 
in young and older men.
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Peripheral cardiovascular responses
In young and older men, calf and forearm blood flow demonstrated a significant 
decrease during 30° HUT, which were not different between both groups. Calf and 
forearm vascular resistance increased significantly during 30° HUT in young and 
older men. The increase in forearm vascular resistance was not different between both 
groups. However, the increase in calf vascular resistance was affected by age. A 
significantly larger increase in calf vascular resistance was found in young (175 ± 30 
%) compared with older men (96 ± 15 %). (Table 2 and Figure 1)
DISCUSSION
The major finding of the present study is that, in contrast to our hypothesis, an 
attenuated increase in calf vascular resistance during 30° HUT in older men is present 
compared with young men. The attenuated peripheral vasoconstriction in older men 
is present in the calf, but not in the forearm.
The lower limb vascular bed importantly contributes to the blood pressure 
regulation, especially during orthostatic stress (7). Hence, our results suggest that the 
age-related attenuated vasoconstriction in the calf vascular bed may be part of the 
explanation of orthostatic hypotension in older men.
We did not find a difference in baseline vascular tone between young and older men, 
which is in agreement with some studies (17-19), but in contrast with others (20,21). 
Studies which reported no difference in vascular tone used plethysmography to 
measure calf (17,18) or upper leg blood flow ( 19). Interestingly, studies that reported a 
difference in leg vascular tone (20,21), used Doppler ultrasound to measure whole leg 
blood flow. In contrast to plethysmography, Doppler does not correct for the 
differences in leg volume, which are likely to be present between these groups (22). In 
addition, Fu et al. (18) found no difference in calf blood flow between older and young 
men, although a higher sympathetic activity level was present in older men. This 
suggests that sympathetic activity can be increased, without an attenuated calf blood 
flow.
The augmented increase in total peripheral resistance during orthostatic 
challenges with advancing age is a well documented characteristic (8-11). In these 
studies, total peripheral resistance was studied, including the splanchnic vascular bed
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that accounts for approximately one-third of the total peripheral resistance, we have 
assessed peripheral vascular responses of the calf and forearm that also accounts for 
approximately one-third of the total peripheral resistance. Minson et al. (11), 
demonstrated that older men increased their splanchnic vascular resistance to a 
greater extent than young men during 60° HUT, which was hypothesized to be a 
compensation for the attenuated cardiac output and diminished increase in 
vasoconstriction of the forearm vascular bed. In contrast, we found no differences in 
forearm vascular resistance in young and older men during 30° HUT. Interestingly, we 
demonstrated a lower ability to increase calf vascular resistance during 30° HUT in 
older compared with young men. Although a different tilt angle was used, this has no 
effect on leg blood flow ( 16). The attenuated increase in calf vascular resistance, 
therefore, may initiate or contribute, at least partly, to the orthostatic intolerance 
observed in older men.
We can only speculate about the possible mechanisms that explain the 
attenuated vasoconstriction response in the calf during 30° HUT in older men 
compared with young men. Recently, Smith et al. (23) demonstrated that leg 
postjunctional a-adrenergic vasoconstrictor responsiveness to noradrenalin is reduced 
with advancing age, and thereby can impede sympathetic control of vascular 
resistance and negatively influence blood pressure control to orthostatic challenges. In 
young men, a larger response in the calf to a-adrenergic receptor stimulation is 
present than in the forearm (24). Accordingly, it is possible that the lower limb is 
prone, especially with advancing age, to the reduction in a-adrenergic vasoconstrictor 
responsiveness and could explain the difference in tilt-induced calf vascular resistance 
increase between older and young men.
Another possible explanation for the tilt-induced attenuated increase in calf 
vascular resistance could be the attenuated vasoconstrictor reserve (25) in advancing 
age, possibly caused by an increase in basal sympathetic activity (18,26). In other 
words, older men cannot increase their calf vascular resistance during an orthostatic 
challenge to the same extent as young men, who have a larger vasoconstrictor reserve. 
In addition, arterial and venous blood vessel stiffening may contribute to the 
orthostatic hypotension in older men (2,27). Blood vessel stiffening with advancing 
age is associated with decreased baroreflex sensitivity (2,28). The attenuated heart rate 
response during orthostatic challenges in older men (8,28), as present in our study, 
supports the decreased baroreflex sensitivity. On the contrary, blood vessel stiffening
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could also blunt venous pooling and thereby limit the fall in venous return (27) during 
orthostatic challenges. However, since cardiac output in older men during orthostatic 
challenges is compromised (8-10), the vascular stiffening clearly is not sufficient 
enough to prevent venous pooling.
Another hypothesized mechanism is the decreased total blood volume in 
advancing age (29). During orthostatic challenges a translocation of blood into the 
compliant peripheral venous system occurs, leading to a decreased cardiac filling (7). 
In older men the lower total blood volume could lead to a relatively exaggerated 
decrease in cardiac filling during orthostatic challenges.
The objective of the present study was not to elucidate the mechanism causing 
the differences in tilt-induced responses between young and older men, for this 
additional research is needed. Nonetheless, the attenuated increase in calf vascular 
resistance during 30° HUT in older men seems to be part of the explanation of 
orthostatic hypotension in older men.
C linical relevance
Individuals, who suffer from severe orthostatic hypotension, can promote venous 
return and thereby raise cardiac output by applying physical counter-manoeuvres
(2,7,30). These physical counter-manoeuvres exist of leg crossing and/or leg muscle 
tensing, which are typically directed towards the lower limb vascular bed and have 
been demonstrated to be beneficial to counteract orthostatic hypotension. Based on 
our findings of an attenuated increase in calf vascular resistance in older men during 
30° HUT, we suggest that applying these physical counter-manoeuvres could be 
helpful in counteracting orthostatic hypotension, especially with advancing age. 
Additional research is needed to evaluate the efficacy of these counter manoeuvres in 
the aging population.
Conclusion
In conclusion, the present study demonstrates that 30° head-up tilt leads to an 
attenuated increase in vascular resistance of the calf, but not of the forearm in older 
compared with young men. The lower ability to increase calf vascular resistance in 
older men during orthostatic challenges cannot explain the augmented total 
peripheral resistance during orthostatic challenges, but may be part of the explanation 
of orthostatic hypotension with advancing age.
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ABSTRACT
Background: The pathophysiology of orthostatic hypotension in Parkinson’s disease 
(PD) is incompletely understood. The primary focus has thus far been on central 
mediated vasoconstrictor mechanisms. Here, we test the role of two peripheral factors: 
( 1) a reduced peripheral vasoconstriction (which may contribute because PD includes 
a generalized sympathetic denervation); and (2) an inadequate plasma volume (which 
may explain why plasma volume expansion can manage orthostatic hypotension in 
PD).
Methods: We included 11 PD patients with orthostatic hypotension (PD+OH), 14 PD 
patients without orthostatic hypotension (PD-OH) and 15 age-matched healthy 
controls. Leg blood flow was examined using duplex ultrasound during 60° head-up 
tilt. Leg vascular resistance was calculated as the arterial-venous pressure gradient 
divided by blood flow. In a subset of 9 PD+OH, 9 PD-OH and 8 controls, plasma 
volume was determined by indicator dilution method with radio-labelled albumin 
(125I-HSA).
Results: The basal leg vascular resistance was significantly lower in PD+OH (0.7±0.3 
mmHg/ml/min) compared to PD-OH (1.3±0.6 mmHg/ml/min) and controls (1.3±0.5 
mmHg/ml/min). Leg vascular resistance increased significantly during 60° head-up 
tilt with no significant difference between the groups (35% in PD+OH; 47% in PD- 
OH and 57% in controls). Plasma volume was significantly larger in PD+OH 
(3869±265 ml) compared to PD-OH (3123±377 ml) and controls (3204±537 ml). 
Conclusions: These results indicate that PD+OH have a lower basal leg vascular 
resistance in combination with a larger plasma volume compared with PD-OH and 
controls. Despite the increase in leg vascular resistance during 60° head-up tilt, 
PD+OH are unable to maintain their blood pressure.
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IN TRO D U CTIO N
Symptomatic and asymptomatic orthostatic hypotension (OH) is present in up to 60% 
of patients with Parkinson’s disease (PD) ( 1) and negatively correlated with quality of 
life (2). In elderly, OH is associated with cardiovascular morbidity and mortality (3-5). 
The pathophysiology of OH in PD remains incompletely understood. Until now, the 
focus has been primarily on impairment of central mediated vasoconstrictor 
mechanisms. PD patients have a reduced baroreflex cardio-vagal function (6), 
denervation of the heart (6,7), low noradrenaline levels and no increment in 
noradrenaline levels during orthostatic challenges (6,8). However, baroreflex failure 
and cardiac sympathetic denervation contribute to but cannot fully explain OH in PD 
(6,9).
During orthostatic challenges peripheral vasoconstriction contributes to 
maintain blood pressure via a central vasoconstrictor mechanism, i.e. baroreflex, and 
local vasoconstrictor mechanisms, such as the veno-arteriolar axon reflex (10) and the 
myogenic response ( 11). Since in PD a generalized rather than a central sympathetic 
denervation is present (12), central and local mediated peripheral vasoconstriction 
might be affected and, thereby, might play an important role in the pathophysiology 
of OH in PD.
Furthermore, a lower plasma volume may be another contributing factor to 
OH in PD. This assumption is based on the important role of the sympathetic nervous 
system in volume homeostasis via renal innervation and the renin-angiotensin system
( 13). In addition, a relation is present between baroreflex mediated vascular control
( 14), time to presyncope (15) and blood pressure during orthostatic challenges in 
autonomic failure ( 16). In addition, plasma volume expansion is considered an 
effective therapy in PD patients with OH (17,18). However, data on possible baseline 
differences in plasma volume in PD are lacking.
The aim of this study was to assess peripheral vascular responses in PD patients 
with and without OH, as well as in controls. For this purpose, we measured leg 
vascular resistance at baseline and during 60° head-up tilt. In addition, we aimed to 
measure plasma volume in these three groups. We hypothesized that baseline leg 
vascular resistance, the leg vascular resistance increase during 60° head-up tilt and 
plasma volume are lower in PD patients with OH compared with PD patients without 
OH and controls.
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METHODS
Subjects
25 PD patients and 15 age- and gender matched controls participated. Patients had 
idiopathic PD ( 19) diagnosed by an experienced neurologist (R.A.J.E. or B.R.B.) and 
disease severity (Hoehn and Yahr stages (20)) and severity of motor symptoms 
(Unified Parkinson Disease Rating Scale (UPDRS part I I I  (21)) were assessed. PD 
patients were assigned to two groups according to the presence of OH. OH was 
defined as a decrease of >20 mmHg in systolic or >10 mmHg in diastolic blood 
pressure during the first 3 minutes of active standing or during a passive 60° head-up 
tilt (22). 11 PD patients fulfilled the consensus criteria of OH (PD+OH), leaving 14 
PD patients without OH (PD-OH) (Table 1). The two patient groups showed no 
significant differences for various important baseline variables, including disease 
duration, disease severity and levodopa equivalent dose (Table 1) (23,24). None of the 
controls fulfilled the OH criteria. Exclusion criteria were smoking, cardiovascular 
disease, diabetes and hypertension. None of the subjects used medication known to 
relevantly interfere with vascular function, except for Parkinson medication which 
was continued during the study. In a randomly selected subgroup, of the original 
study group, we determined plasma volume (Table 2).
The study was performed in accordance with the Declaration of Helsinki and 
approved by the medical ethical committee of our institution. All subjects gave written 
informed consent.
Experimental procedures and protocol
Prior to the head-up tilt experiment and the plasma volume measurement, all subjects 
refrained from caffeine-containing beverages, vitamin C supplements and alcohol for 
>12 hours and from heavy physical activity for >24 hours and had been fasting for >2 
hours. A ll head-up tilt experiments and plasma volume measurements were 
performed in the morning in a quiet, temperature-controlled room (23± 1°C).
Subjects laid down on a manually driven tilt-table with footboard. The subjects 
supported their body weight during the 60° head-up tilt by standing on the left leg, 
allowing the right leg to be relaxed for blood flow measurements. After a supine 
resting period of at least 30 minutes, subjects were tilted manually, within 5 seconds,
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to a passive 60° head-up tilt position for a 10-minute period. In the subgroup plasma 
volume was determined on a separate occasion.
Table 1. Subject characteristics.
Controls (n=15) PD-OH (n=14) PD+OH (n=11)
Gender (m/f) 9/6 6/8 10/1*
Age (yrs) 64±8 61±8 65±9
Height (cm) 175±8 172±10 179±9
Body mass (kg) 77±9 75±14 83±11
Systolic BP (mmHg) 126±15 130±13 131±12
Diastolic B P (mmHg) 81 ±7 81±9 80±6
Disease duration (yrs) 7±5 10±10
H & Y stage (median(range)) 2(1-3) 2(1.5-4)
UPDRS III (median(range)) 23(7-40) 26(13-63)
Dopaminergic medication
Levodopa (mg/day) 581±230 (n=8) 564±253 (n=7)
Ergoline dopamine agonist (mg/day) 3 (n=1)
Non-ergoline dopamine agonist (mg/day) 5±5 (n=6) 6±8 (n=9)
Levodopa equivalent dose (mg/day) 500±316 (n=11) 615±286 (n=8)
Values represent mean±SD. PD-OH, Parkinson disease without orthostatic hypotension. PD+OH,
Parkinson disease with orthostatic hypotension. BP, blood pressure. H & Y stage, Hoehn & Yahr stage
(range: 1-5). UPDRS III, Unified Parkinson Disease Rating Scale part III (range: 0-104).*significantly
different from PD-OH and controls.
Table 2. Subject characteristics of subgroup for plasma volume determinations.
Characteristics Controls (n==8) PD-OH (n=9) PD+OH (n=9)
Gender (m/f) 6/2 6/3 8/1
Age (yrs) 66±7 60±7 62±7
MAP (mmHg) 97±11 97±9 94±5
Body mass index (kg/m2) 25±2 26±4 26±3
Lean body mass (LBM) (kg) 60±6 58±8 62±3
Disease duration (yrs) 9±8 7±5
H & Y stage (median(range)) 2(1-2.5) 2(2-2.5)
UPDRS III (median(range)) 26(12-40) 26.5(15-39)
Dopaminergic medication
Levodopa (mg/day) 533±264 (n=6) 542±489 (n=7)
Ergoline dopamine agonist (mg/day) 3 (n=1)
Non-ergoline dopamine agonist (mg/day) 7±7 (n=3) 11±9 (n=4)
Levodopa equivalent dose (mg/day) 530±334 702±516
Values represent mean±SD. PD-OH, Parkinson disease without orthostatic hypotension. PD+OH,
Parkinson disease with orthostatic hypotension. BP, blood pressure. H & Y stage, Hoehn & Yahr stage
(range: 1-5). UPDRS III, Unified Parkinson Disease Rating Scale part III (range: 0-104).*significantly
different from PD-OH and controls.
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Measurements
Blood pressure was measured continuously using a non-invasive blood pressure 
device (Nexfin, BMEYE, The Netherlands). A finger cuff was attached to the middle 
phalanx of the left third finger to measure finger arterial blood pressure, which 
accurately reflects intra-arterial blood pressure changes (25). A build-in heart 
reference system was in operation to correct for hydrostatic influences. Mean arterial 
blood pressure (MAP) was derived beat to beat and heart rate was the inverse of the 
interbeat interval.
Upper leg blood flow during the last minute of supine rest and 60° head-up tilt 
was measured using duplex ultrasound. Mean red blood cell velocity (Vmean) and 
diameter of the right superficial femoral artery, ~2 cm distal of the bifurcation, were 
measured with a duplex ultrasound device (ARTLAB system, Pie Medical, The 
Netherlands; W AKI, Atys Medical, France). Vmean was calculated as the average of 
20 ultrasound waveforms and diameter was calculated as the average of 6 consecutive 
mean diameters. Leg blood flow was calculated as (n • r2 • Vmean) • 60 (r = ^  • 
diameter of the superficial femoral artery).
Calf venous pooling was determined by measuring the calf volume change 
using plethysmography. Mercury-in-silastic strain gauges were placed around the 
thickest part of the right calf and connected to a plethysmograph (Hokanson Inc, 
USA). To avoid any direct contact with the tilt-table, the calf was supported by small 
cushions. The difference in calf volume between 60° head-up tilt and supine was 
determined and expressed as percentage increase.
Venous blood samples during supine rest and 60° head-up tilt were taken to 
determine plasma noradrenaline levels as described previously (26).
Plasma volume was determined by indicator dilution method using radio­
labelled albumin (125I-HSA) (27). A known quantity of 125I-HSA was injected into an 
antecubital vein in supine position. Subsequently, venous blood samples from the 
contra-lateral antecubital vein were drawn after 10, 20, 30 and 40 minutes.
Data analysis
Leg vascular resistance was calculated as the arterial-venous pressure gradient divided 
by leg blood flow. Supine venous pressure was set at 9 mmHg and during 60° head-up 
tilt the arterial-venous pressure gradient was replaced by MAP, since hydrostatic
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pressure makes an identical contribution to leg venous as well as leg arterial pressure 
(28).
Plasma volume was determined by dividing the total injected radioactivity by 
the virtual volume-specific radioactivity at time 0, which corresponds with the 
injection of 125I-HSA (27). Measured plasma volume was expressed according to the 
calculated lean body mass (29) and a predicted plasma volume was calculated (30).
Statistical analysis
Data are presented as mean±SD, unless otherwise stated. The level of statistical 
significance was set at a=0.05. Unpaired t-tests were used to assess differences in 
predicted and measured plasma volume within the groups. ANOVAs were used to 
assess differences in subject characteristics, baseline supine values, 60° head-up tilt 
values and plasma volume. Repeated measures ANOVAs were used to assess the effect 
of 60° head-up tilt. Bonferroni’s correction was used to correct for multiple 
comparisons. Post-hoc t-tests were performed when the ANOVA reported a 
significant effect.
Table 3. Central and peripheral hemodynamic during supine and 60° head-up tilt.
Controls (n=15) PD-OH (n=14) PD+OH (n=11) ANOVA
Supine 60°HUT Supine 60°HUT Supine 60°HUT Ptime P time*group
SBP (mmHg) 129±22 125±24 129±10 131±11 130±11 100±18*f <0.01 <0.01
DBP (mmHg) 83±7 85±9 82±8 87±11 84±4 78±10 0.68 <0.01
MAP (mmHg) 99±11 98±12 97±8 101±9 99±6 86±12*f <0.01 <0.01
Heart rate (bpm) 58±7 71±13 68±7** 83±9* 60±7 74±10 <0.01 0.64
SFA (mm) 7.7±1.2 7.5±1.2 6.7±0.8** 6.6±0.7** 8.2±0.7 8.0±0.7 <0.01 0.55
LBF (ml/min) 85±32 64±36 88±35 77±62 184±76*f 111±66 <0.01 0.01
LVR
(mmHg/ml/min)
1.32±0.51 2.07±1.25 1.30±0.58 1.91±1.10 0.66±0.34*f 0.89±0.28*f <0.01 0.22
NA (nmol/l) 1.97±0.70 2.60±0.87 1.94±0.89 2.25±1.17 1.79±0.56 1.76±0.61 <0.01 0.02
Calf volume change (%) 3.0±0.6 2.7±0.8 2.1± 0.6*
Values represent mean±SD. PD-OH, Parkinson disease without orthostatic hypotension. PD+OH, 
Parkinson disease with orthostatic hypotension. HUT, head-up tilt. SBP, systolic blood pressure. DBP, 
diastolic blood pressure. MAP, mean arterial blood pressure. SFA, superficial femoral artery diameter. 
LBF, leg blood flow. LVR, leg vascular resistance. NA, noradrenaline. *, significantly different from 
controls. f, significantly different from PD-OH. *' significantly different from PD+OH
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RESULTS
In the PD+OH group, baseline leg blood flow was significantly higher and leg vascular 
resistance was significantly lower compared with PD-OH (p<0.01 for both 
parameters) and controls (p<0.01 for both parameters) (Table 3, Figure 1). The 
diameter of the superficial femoral artery in PD+OH (p<0.01) and controls (p=0.02) 
was significantly larger compared with PD-OH (Table 3). Heart rate in PD-OH was 
significantly higher compared to PD+OH (p=0.02) and controls (p<0.01) (Table 3). 
No differences in baseline systolic and diastolic blood pressure, MAP or noradrenaline 
levels were observed (Table 3).
Figure 1. Leg vascular resistance in supine and 60° head-up tilt position in controls, 
Parkinson’s disease patients without and with orthostatic hypotension.
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Values represent mean+SE. C, controls (n=15). PD-OH, Parkinson’s disease without orthostatic 
hypotension (n=14). PD+OH, Parkinson’s disease with orthostatic hypotension (n=11). HUT, head- 
up tilt. *, significantly different from supine position. f, significantly different from C and PD-OH.
During 60° head-up tilt, systolic blood pressure and MAP significantly decreased in 
PD+OH (Table 3). Heart rate significantly increased in all groups with a similar 
magnitude (Table 3). Leg blood flow decreased significantly in all groups during 60°
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head-up tilt, with a higher decrease in PD+OH (40%) compared with PD-OH (13%) 
and controls (25%) (Table 3). Leg vascular resistance significantly increased during 
60° head-up tilt in PD+OH (35%), PD-OH (47%) and controls (57%), with no 
significant difference between the groups (Table 3, Figure 1). Leg vascular resistance 
during 60° head-up tilt in PD+OH was significantly lower compared with PD-OH 
(p<0.01) and controls (p=0.01) (Table 3, Figure 1). The superficial femoral artery 
diameter significantly decreased during 60° head-up tilt in PD+OH and controls but 
not in PD-OH (Table 3). Noradrenaline levels significantly increased during 60° head- 
up tilt in controls and PD-OH but not in PD+OH (Table 3).
Calf volume increased during 60° head-up tilt in all groups, with a significant 
lower calf volume increase in PD+OH compared with controls (Table 3).
Figure 2 . Plasma volume expressed per lean body mass in controls, Parkinson’s 
disease patients without and with orthostatic hypotension.
Values represent mean+SE. C, controls (n=8). PD-OH, Parkinson’s disease without orthostatic 
hypotension (n=9). PD+OH, Parkinson’s disease with orthostatic hypotension (n=9). *, significantly 
different from PD-OH and C.
Plasma volume was significantly larger in PD+OH compared with PD-OH (p<0.01) 
and controls (p<0.01) (Table 4). In PD+OH the measured plasma volume was
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significantly larger (p<0.01) compared with predicted (Table 4). Plasma volume 
corrected for lean body mass was significantly larger in PD+OH compared with PD- 
OH (p<0.01) and controls (p<0.01) (Table 4, Figure 2).
Table 4 . Plasma volume.
Controls (n=8) PD-OH (n=9) PD+OH (n=9)
Predicted plasma volume (ml) 3003±295 2957±372 3190±100
Plasma volume (ml) 3204±537 3123±377 3869±265*f
Plasma volume / LBM (ml/kg) 53.8±7.6 54.1±5.6 62.0±3.1*
LVR (mmHg/ml/min) 1.17±0.40 1.28±0.65 0.88±0.31
Values represent mean±SD. PD-OH, Parkinson disease without orthostatic hypotension. PD+OH, 
Parkinson disease with orthostatic hypotension. LVR, baseline leg vascular resistance. *, significantly 
different from controls and PD-OH. f, significantly different from predicted plasma volume.
DISCUSSION
The major findings of this study are that PD+OH have a lower basal leg vascular 
resistance, in combination with a larger plasma volume, as compared with both PD- 
OH and controls. The leg vascular resistance increase during 60° head-up tilt was not 
different between the three groups. Despite the leg vascular resistance increase during 
60° head-up tilt PD+OH are unable to maintain their blood pressure.
The present study is the first to demonstrate a lower basal leg vascular resistance in 
PD+OH compared with PD-OH and controls. This novel finding is in agreement with 
our hypothesis and in line with the accepted pathophysiology of OH in PD. Since PD 
is associated with a generalized rather than a central sympathetic denervation (12), an 
attenuated sympathetic activity may explain the lower leg vascular resistance in 
PD+OH. Muscle sympathetic nerve activity (MSNA) in PD decreases with age, disease 
duration and severity (31). This might indicate that generalized sympathetic 
denervation is more pronounced in PD+OH than in PD-OH. However, denervation 
of sympathetic fibers to the heart has been shown to exist not only in PD+OH but also 
in PD-OH and even in early PD (6,7,32). A second explanation could be the lower 
noradrenaline levels in PD+OH. We did not find a significant difference in basal 
noradrenaline levels between the groups, in contrast to other studies (1,6,8,12), 
although noradrenaline in our study tended to be lower in PD+OH. The lack of a 
noradrenaline difference could be due to larger standard deviations of noradrenaline
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levels in our PD patients who are treated with levodopa (9), Although noradrenaline is 
a potent vasoconstrictor, vascular tone is regulated by a combination of several 
vasoconstrictors and dilators. The effect of lower noradrenaline levels in PD+OH on 
vascular tone and leg vascular resistance is unknown. A decrease in a-adrenoceptors 
or in their sensitivity to noradrenaline could be a third explanation, especially in 
combination with lower noradrenaline levels. However, in PD+OH there is evidence 
for a-adrenoceptor supersensitivity caused by sympathetic denervation (33). The 
explanation for the lower basal leg vascular resistance in PD+OH is, therefore, most 
likely an attenuated sympathetic activity to the legs.
In contrast to our hypothesis leg vascular resistance increased during 60° head- 
up tilt in PD+OH, and to a similar extent as in PD-OH and controls. During 
orthostatic challenges an immediate drop in blood pressure is sensed by 
baroreceptors. This increases heart rate, cardiac contractility and peripheral vascular 
resistance via an increase in sympathetic outflow and a decrease in vagal-nerve activity 
(34,35). One previous study measured local vascular resistance of the anterior tibial 
muscle and subcutaneous tissue of the calf in PD+OH during 45° head-up tilt using 
the 133-Xenon washout method, but did not find a significant increase (36). The 
smaller experimental vascular bed, lower tilt angle and small number of subjects could 
explain the difference with our study. The leg vascular resistance increase during 60° 
head-up tilt in PD+OH in our study might be explained by spared sympathetic fibers. 
However, noradrenaline levels in PD+OH did not increase during 60° head-up tilt, in 
concordance with previous studies (6,8). An increase in sympathetic activity is, 
therefore, unlikely to explain the leg vascular resistance increase in PD+OH. Another 
explanation might be the local vasoconstrictor mechanisms involved in maintaining 
blood pressure during orthostatic challenges, i.e. the veno-arteriolar axon reflex 
(VAR) and the myogenic response. Preserved local vasoconstriction mechanisms have 
been previously demonstrated in a small number of PD+OH and allocated to the VAR 
(36). The VAR is a local axon reflex triggered by an >25 mmHg increase in venous 
pressure which results in constriction of the corresponding arteriole and assumed to 
be a-adrenergic mediated (10). Since in PD+OH there is no increase in noradrenaline 
levels, it is unlikely that the VAR contributes to the leg vascular resistance increase 
during 60° head-up tilt. More likely, the myogenic response is responsible for the 
observed leg vascular resistance increase in PD+OH. The myogenic response is a 
smooth muscle vasoconstrictor response to increments in transmural pressure
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independent of the sympathetic nervous system (11). The myogenic response is 
thought to play a major role during orthostatic challenges in autonomic failure (11). 
The myogenic response can, therefore, at least partly explain the leg vascular 
resistance increase in PD+OH during 60° head-up tilt whether or not accompanied by 
a partly spared central mediated a-adrenergic vasoconstriction.
Although the increase in leg vascular resistance during 60° head-up tilt was not 
significantly lower in PD+OH compared to PD-OH and controls, the leg 
vasoconstriction in PD+OH is insufficient to counteract the decrease in blood 
pressure during 60° head-up tilt. The compensatory local vasoconstrictor mechanisms 
are unable to increase leg vascular resistance in PD+OH during 60° head-up tilt to a 
satisfactory level that can prevent the development of OH. A lack of appropriate leg 
vasoconstriction might, therefore, play a role in the pathophysiology of OH in PD. 
Especially in combination with the lower basal leg vascular resistance in PD+OH.
A larger calf volume increase is associated with a larger decrease in venous 
return and, thereby, can contribute to OH (34). In contrast, during 60° head-up the 
calf volume increase was lower in PD+OH compared to controls and tended to be 
lower compared to PD-OH. Excessive venous pooling of the calf does, therefore, not 
contribute to OH in PD. However, venous pooling in other vascular beds, especially 
the splanchnic vascular bed, might still play a role in a decreased venous return in 
PD+OH.
Besides central and local mediated vasoconstrictor mechanisms, an adequate 
plasma volume is essential for orthostatic tolerance (35,37). In contrast to our 
hypothesis, the plasma volume in PD+OH was larger compared to PD-OH and 
controls. The larger plasma volume in PD+OH could be a compensation for the lower 
leg vascular resistance. As a result of the lower leg vascular resistance, vascular 
capacity is increased and w ill result in a relative low plasma volume (37) which could 
lead to a reduced renal arterial pressure. Consequently, renin will be released and 
more angiotensin II  will be formed leading to aldosterone release, and thereby 
increasing plasma volume (38). However, plasma renin concentration in PD seems to 
be lower than in controls and PD patients show an inadequate rise in plasma renin 
during head-up tilt (39). Unfortunately, we do not know whether the renin- 
angiotensin-aldosterone system in PD+OH is activated. Vasopressin or antidiuretic 
hormone are unlikely to play a role, since plasma levels in a small group of PD+OH 
were comparable to controls (40) and vasopressin treatment had no effect (41).
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Despite the larger plasma volume, PD+OH are not able to maintain their blood 
pressure in an upright position. Possibly, they still have a relative low plasma volume 
as a result of the lower basal leg vascular resistance (37). We controlled for other 
causes of plasma volume increase (38,42,43), e.g. none of the subjects had a high 
dietary salt intake, slept in a head-up tilt position, used volume expanders and there 
were no differences in physical activity between the groups. Another, more technical, 
explanation could be related to the plasma volume measurement. Considerable 
endothelial damage could cause leakage of 125I-HSA into the extravascular space which 
w ill cause an overestimation of plasma volume. In PD endothelial function and 
possible damage is unknown. Since the renal endothelium is especially vulnerable, 
proteinuria should be one of the first symptoms. None of the PD+OH had known 
proteinuria and, therefore, the dilution method with 125I-HSA is considered to be the 
golden standard (27).
Limitations
The PD+OH group included more men, and patients tended to be more severely 
affected compared with PD-OH and controls. They also used a higher levodopa 
equivalent dose, although the difference with PD-OH was not significant. OH in PD is 
associated with gender, age, disease duration and severity (44), however this does not 
explain the demonstrated lower basal leg vascular resistance in combination with the 
larger plasma volume.
We measured plasma volume in a subgroup for practical reasons. We randomly 
selected the subjects from the original study group in order to avoid bias. The results 
of the plasma volume determination are convincing, even in our relatively small 
sample size. We do not believe that a larger sample size would change our results.
C linical Perspective
Despite several published recommendations on the treatment of OH in PD, they are 
scarcely evidenced based (17,18). Several non-pharmacological interventions have 
presumed efficacy by increasing venous return or plasma volume, i.e. elastic stockings, 
physical counter manoeuvres, salt and fluid intake, sleeping in the head-up position or 
increase physical activity (17,18). Fludrocortisone (9a-fluorohydrocortisone) and 
midodrine (a-adrenoceptor agonist) are most commonly used in the pharmacological 
management of OH in PD (17,18). The results of the present study, i.e. a lower basal
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leg vascular resistance with low noradrenaline levels and a larger plasma volume in 
PD+OH, support the use of midodrine as a vasoconstrictive agent and, at the same 
time, question the use of fludrocortisone as a volume expanding agent. More evidence 
is, therefore, needed in non- and pharmacological management of OH in PD in order 
to optimally manage OH in PD.
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Leg vasoconstriction during head-up tilt in patients with 
autonomic failure is not abolished
Jan  G ro o th u is  
D ic k  T h ijssen  
Jacq u es  L en d e rs  
Jaap  D e in u m  
M a r ia  H o p m a n
Jo u rn a l o f  A p p lie d  P h y s io lo g y  2010  D ec  2 (E p u b  a h e a d  o f  p r in t)

A B S T R A C T
M a in ta in in g  b lo o d  p re s s u re  d u r in g  o r th o s ta t ic  c h a llen g es  is p r im a r i ly  a c h ie v e d  b y  
b a ro r e c e p to r  m e d ia te d  a c tiv a tio n  o f  th e  sy m p a th e t ic  n e rv o u s  sy s tem , w h ic h  c a n  b e  
d iv id e d  in to  a  p re g a n g lio n ic  a n d  p o s tg a n g lio n ic  p a r t .  D e sp ite  th e i r  p re g a n g lio n ic  
a u to n o m ic  fa ilu re , sp in a l c o rd - in ju r e d  in d iv id u a ls  d e m o n s tra te  a p re s e rv e d  p e r ip h e ra l  
v a s o c o n s tr ic t io n  d u r in g  o r th o s ta t ic  ch a llen g es . W h e th e r  th is  a lso  a p p lie s  to  p a tie n ts  
w ith  p o s tg a n g lio n ic  a u to n o m ic  fa ilu re  is u n k n o w n . T h e re fo re , w e  a ssessed  leg 
v a s o c o n s tr ic t io n  d u r in g  60° h e a d -u p  t i l t  in  five p a tie n ts  w ith  p u re  a u to n o m ic  fa ilu re  
(P A F ) a n d  in  tw o  p a tie n ts  w ith  a u to n o m ic  fa ilu re  d u e  to  d o p a m in e -f i-h y d ro x y la se  
(D B H ) de fic ien cy . T e n  h e a lth y  su b je c ts  se rv ed  as c o n tro ls . Leg b lo o d  flo w  w as 
m e a s u re d  u s in g  d u p le x  u l t r a s o u n d  in  th e  r ig h t  su p e rf ic ia l fe m o ra l a r te ry . Leg v a sc u la r  
re s is ta n c e  w as  c a lc u la te d  as th e  a r te r ia l-v e n o u s  p re s s u re  g ra d ie n t  d iv id e d  b y  b lo o d  
flow . D B H  d e fic ie n c y  p a tie n ts  w e re  te s te d  o ff  a n d  o n  th e  n o ra d r e n a l in  p r o - d r u g  L- 
D O P S . D u r in g  60° h e a d -u p  tilt , leg  v a sc u la r  re s is ta n c e  in c re a se d  s ig n if ic a n tly  in  PA F 
(0 .4 0 ± 0 .3 8  (+ 30% ) m m H g /m l /m in ) .  T h e  in c re a se  in  leg  v a sc u la r  re s is ta n c e  w as n o t  
s ig n if ic a n tly  d if fe re n t f ro m  c o n tro ls  (0 .8 8 ± 1 .0 4  (+ 72% ) m m H g /m l /m in ) .  In  D B H  
d e fic ie n c y  leg  v a sc u la r  re s is ta n c e  in c re a se d  b y  0 .49± 0 .01  (+ 153% ) a n d  1 .52± 1 .47  
(+ 234% ) m m H g /m l /m in  o f f  a n d  o n  L -D O P S , re sp ec tiv e ly . D e sp ite  th e  in c re a se  in  leg  
v a sc u la r  re s is ta n c e , o r th o s ta t ic  h y p o te n s io n  w as p re s e n t in  P A F  a n d  D B H  d e fic ie n t 
p a tie n ts . O u r  re s u lts  d e m o n s tra te  th a t  leg  v a s o c o n s tr ic t io n  d u r in g  o r th o s ta t ic  
ch a llen g es  in  p a tie n ts  w ith  PA F  o r  D B H  d e fic ie n c y  is n o t  ab o lish e d . T h is  in d ic a te s  
th a t  th e  sy m p a th e tic  n e rv o u s  sy s tem  is n o t  th e  so le  o r  p iv o ta l m e c h a n is m  in d u c in g  leg  
v a s o c o n s tr ic t io n  d u r in g  o r th o s ta t ic  ch a llen g es . A d d itio n a l v a s o c o n s tr ic to r  
m e c h a n is m s  m a y  c o m p e n s a te  fo r  th e  lo ss  in  sy m p a th e tic  n e rv o u s  sy s tem  c o n tro l.
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I N T R O D U C T I O N
T h e  u p r ig h t  p o s tu re  in  h u m a n s  le ad s  to  a g ra v i ta t io n a l d is p la c e m e n t o f  b lo o d  in to  th e  
d e p e n d e n t  v a sc u la tu re  o f  th e  s p la n c h n ic  a re a  a n d  lo w e r lim b s , le a d in g  to  a d e c re a se  in  
v e n o u s  r e tu r n  to  th e  h e a r t  a n d  a n  im m e d ia te  d ro p  in  b lo o d  p re s s u re  (1 ,2 ). T h e  
d e c re a se  in  b lo o d  p re s s u re  w ill u n lo a d  b a ro re c e p to r s  re s u lt in g  in  a  d e c re a se d  vagal- 
n e rv e  a c tiv ity  a n d  in c re a se d  s y m p a th e t ic  o u tf lo w  (1 ,2). T h e  a c tiv a tio n  o f  th e  
s y m p a th e t ic  n e rv o u s  sy s tem  w ill in c re a se  h e a r t  ra te , c a rd ia c  c o n tra c ti l i ty  a n d  
p e r ip h e ra l  v a sc u la r  re s is ta n c e  (1,2).
T h e  s y m p a th e t ic  n e rv o u s  sy s tem  can  b e  a n a to m ic a l ly  a n d  fu n c t io n a l ly  d iv id e d  
in  a p re g a n g lio n ic  a n d  p o s tg a n g lio n ic  p a r t  (1 ,3 ). D e sp ite  p re g a n g lio n ic  a u to n o m ic  
fa ilu re , sp in a l c o rd - in ju r e d  in d iv id u a ls  d e m o n s tra te  a n  in c re a se  in  leg  v a sc u la r  
re s is ta n c e  d u r in g  o r th o s ta t ic  c h a llen g es  (4 -7 ). T h e se  re s u lts  su g g es t th a t  th e  
s y m p a th e t ic  n e rv o u s  sy s tem  is n o t  o b lig a to ry  fo r  p e r ip h e ra l  v a s o c o n s tr ic t io n  d u r in g  
o r th o s ta t ic  ch a llen g es . W h e th e r  th is  a lso  a p p lie s  to  p a tie n ts  w ith  p o s tg a n g lio n ic  
a u to n o m ic  fa ilu re  is u n k n o w n . W e , th e re fo re , a sse ssed  leg  v a s o c o n s tr ic tio n  d u r in g  an  
o r th o s ta t ic  ch a llen g e  in  tw o  d is tin c tiv e  p a t ie n t  g ro u p s  w ith  a u to n o m ic  d is o rd e rs  w h o  
d e m o n s tra te  se lec tiv e  fa ilu re  o f  th e  p o s tg a n g lio n ic  p a r t  o f  th e  s y m p a th e t ic  n e rv o u s  
sy s tem .
T a b le  1. P a th o p h y s io lo g ic a l c la ss if ic a tio n .
PA F D B H
Sym pathetic nerves D egenerative In tact
Baseline no rad renaline Low A bsent
N orad rena line  response d u ring  tilt Low A bsent
R esponse to  no radrenaline Increased Increased
PAF, pure autonomic failure. DBH, dopamine -fi-hydroxylase deficiency. SNS, sympathetic nervous
system.
F o r  th is  p u rp o s e , w e  m e a s u re d  leg  v a sc u la r  re s is ta n c e  a t  b a se lin e  a n d  d u r in g  60° h e a d -  
u p  t i l t  in  p a tie n ts  w ith  p u re  a u to n o m ic  fa ilu re  (P A F ) a n d  d o p a m in e -f i-h y d ro x y la se  
(D B H ) d e fic ie n c y  as w ell as a g ro u p  o f  h e a lth y  c o n tro ls . P A F  re p re s e n ts  a c h ro n ic  
p r im a ry  a u to n o m ic  d is o rd e r  w ith  a p o s tg a n g lio n ic  le s io n  w ith  sy m p a th e tic  
d e n e rv a t io n  (T ab le  1) (8 ,9 ). D B H  d e fic ie n c y  is a n  e x tre m e ly  ra r e  h e re d i ta ry  
a u to n o m ic  d is o rd e r  c h a ra c te r iz e d  b y  a c o m p le te  a b se n c e  o f  n o ra d r e n a l in e  w ith  an  
in ta c t  sy m p a th e t ic  n e rv o u s  sy s tem  (T ab le  1) (10). W e  h y p o th e s iz e d  th a t  leg 
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vasoconstriction will be present in patients with PAF and DBH deficiency, which 
supports the idea that the sympathetic nervous system is not obligatory for leg 
vasoconstriction during orthostatic challenges.
METHODS 
Subjects
Seven patients with chronic autonomic failure, including 5 PAF and 2 DBH deficient 
patients, and 10 age-matched healthy controls (7 males and 3 females) participated in 
this study (Table 2). PAF is characterised by reduced levels of noradrenaline and 
widespread autonomic failure with no other neurological features present (11) (Table 
1) and was diagnosed by an experienced internist (J.D. or J.W.M.L.). Diagnosis of 
DBH deficiency was confirmed by a complete absence of plasma and urine 
noradrenaline and adrenaline (Table 1), increased dopamine levels, a significant 
improvement of clinical symptoms of autonomic failure upon L-threo- 
dihydroxyphenylserine (L-DOPS, droxidopa) treatment and verification of the genetic 
disorder (10,12). None of the subjects smoked. A ll PAF patients continued their 
medication (Table 2) and four of them were put on extra sodium intake. DBH 
deficiency patients were measured before and 2 weeks after cessation of their daily L- 
DOPS treatment, which was confirmed by undetectable plasma and urine 
noradrenaline levels. Autonomic failure in PAF patients was confirmed by Valsalva 
manoeuvre testing.
This study was performed in accordance with the Declaration of Helsinki and 
approved by the medical ethical committee of our institution. All subjects gave written 
informed consent.
Experimental procedures and protocol
A ll subjects refrained from caffeine-containing food and beverages, vitamin C 
supplements, nicotine and alcohol for >12 hours and from heavy physical activity for 
>24 hours prior to the experiment. Subjects had been fasting for >2 hours before the 
experiment. A ll experiments were performed in the morning in a quiet, temperature- 
controlled (23±1 °C) room.
Subjects rested in the supine position on a manually driven tilt-table with 
footboard. After a supine resting period of at least 30 minutes, subjects were tilted
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manually, within 5 seconds, to a passive 60° HUT position for a 10-minute period. 
The subjects supported their body weight during the 60° head-up tilt (HUT) by 
standing on the left leg, allowing the non-weight bearing right leg to be relaxed for 
blood flow measurements.
Table 2 . Subject and group characteristics.
Subject G ender se ^ H eight
(cm)
W eight
(kg)
SBP
(m mHg)
DBP
(m mHg)
HR
(bpm )
Drugs
DBH1 f 26 159 60 136 72 52 L-DOPS
DBH2 f 41 167 55 120 90 56 L-DOPS
DBH (n=2) 34±11 163±6 58±4 128±11 81±3 54±3
PAF1 f 69 154 52 140 76 85 1,2
PAF2 m 75 184 61 120 86 78
PAF3 f 76 172 60 144 86 68 1,2
PAF4 f 64 167 74 192 98 68 1,2,
PAF5 m 67 172 54 180 90 68 2
PAF (n=5) 70±5 170±11 60±9* 155±30* 87±8 73±8
C (n=8) 69±4 177±9 80±9 128±18 81±8 60±8
Values represent individual values and mean±SD. DBH, dopamine-ß-hydroxylase deficiency. PAF, 
pure autonomic failure. C, controls. SBP, systolic blood pressure. DBP, diastolic blood pressure. HR, 
heart rate. L-DOPS, L-threo-dihydroxyphenylserine. 1, midodrine. 2, fludrocortisone. *, significantly 
different from controls. Blood pressure and heart rate values for DBH are after a 14 days interruption 
of L-DOPS treatment.
Measurements
Blood pressure was measured continuously using a non-invasive blood pressure 
device (Nexfin, BMEYE). A finger cuff was attached to the middle phalanx of the right 
third finger to measure finger arterial blood pressure, which accurately reflects intra- 
arterial blood pressure changes (13). A built-in heart reference system was in 
operation to correct for hydrostatic influences. Mean arterial blood pressure (MAP) 
was derived beat to beat and heart rate was the inverse of the interbeat interval. Stroke 
volume and systemic vascular resistance was determined by a three-element model of 
arterial input impedance using Modelflow (14). Cardiac output was calculated as 
stroke volume times heart rate.
Superficial femoral arterial blood flow during supine rest and 60° HUT was 
measured using duplex ultrasound. Mean red blood cell velocity (Vmean) and systolic 
and diastolic diameter of the right superficial femoral artery, ~2 cm distal of the 
bifurcation, were measured with a duplex ultrasound device (Picus, ESAOTE; W AKI, 
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Atys Medical). Vmean was calculated as the average of 20 consecutive Doppler 
waveforms. Automated software was used for operator-independent analyses of 
waveforms (Matlab 6.1; Mathworks). For diameter measurements the average of six 
consecutive mean diameters was obtained. Real-time automated analyses were 
performed using the ARTLAB system (Pie Medical). Leg blood flow was calculated 
with the following formula: (n • r2 • Vmean) • 60 (r = ^  • diameter of the superficial 
femoral artery).
Data analysis
Leg vascular resistance was calculated as the arterial-venous pressure gradient (Pa-Pv) 
divided by blood flow. Supine venous pressure was set at 9 mmHg and during 60° 
HUT the arterial-venous pressure gradient was replaced by MAP, since hydrostatic 
pressure makes an identical contribution to leg venous as well as leg arterial pressure
(15).
Statistical analysis
Statistical analyses were performed using SPSS 16.0 (SPSS) software. Data are 
presented as mean±SD, unless otherwise stated. The level of statistical significance was 
set at a<0.05. Differences in baseline parameters between PAF and controls were 
assessed using independent t-tests. Repeated measures ANOVAs were used to assess 
differences in the effect of 60° HUT on leg vascular resistance between PAF and 
controls. Post hoc t-tests were performed when the ANOVA reported a significant 
effect. Bonferroni correction was used to correct for multiple comparisons. Baseline 
values and the effect of 60° HUT in DBH deficiency patients were not statistically 
analyzed.
RESULTS
Baseline leg vascular resistance, leg blood flow and superficial femoral artery diameter 
were not significantly different between PAF and controls, whereas MAP and heart 
rate were significantly higher in PAF compared to controls (p=0.01 and p<0.001, 
respectively) (Table 3). In DBH deficiency patients baseline supine leg vascular 
resistance was lower compared to controls (Table 3). Baseline supine MAP and heart 
rate were comparable between DBH deficiency and controls (Table 3). Although leg
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vascular resistance increased during L-DOPS treatment, leg vascular resistance 
remained lower in DBH deficiency compared to controls (Table 3).
Table 3 . Basal and 60° head-up tilt systemic and peripheral cardiovascular 
parameters.
Subject MAP (mmHg)
Basal 60° H U T
Heart rate (bpm)
Basal 60° H U T
LBF (m l/m in)
Basal 60° H U T
LVR (m m H g/m l/m in)
Basal 60° H U T
SFA
(mm)
DBH1 99 81 51 58 332 109 0.27 0.77 6.8
on L-DOPS 95 82 47 55 140 35 0.62 3.17 6.1
DBH2 86 52 56 78 199 59 0.39 0.87 5.3
on L-DOPS 101 87 68 69 111 67 0.83 1.31 5.7
PAF1 97 86 85 89 55 45 1.66 1.77 9.0
PAF2 119 98 79 94 72 54 1.53 1.87 6.2
PAF3 133 54 63 69 80 22 1.61 2.66 6.5
PAF4 150 64 70 63 180 61 0.79 1.06 9.5
PAF5 121 80 69 75 104 62 1.08 1.32 9.0
PAF (n=5) 124±19* 76±18*t 73±9* 78±13 98±49 49±16t 1.33±0.38 1.74±0.61t 8.0±1.6
C (n=8) 101±12 101±13 59±8 71±12t 96±33 63±30t 1.17±0.39 2.04±1.23t 8.0±1.2
Time Interact Time Interact Time Interact Time Interact
ANOVA <0.01 <0.01 <0.01 0.12 <0.01 0.34 0.02 0.34
Values represent individual values and mean±SD, respectively. DBH, dopamine-fi-hydroxylase 
deficiency. PAF, pure autonomic failure. C, controls. MAP, mean arterial blood pressure. LBF, leg 
blood flow. LVR, leg vascular resistance. SFA, superficial femoral artery diameter. HUT, head-up tilt. 
L-DOPS, L-threo-dihydroxyphenylserine. ANOVA, indicates the P-values of the repeated measures 
ANOVA between PAF and controls. *, p o st hoc significantly different from controls. f, significantly 
different from baseline.
60° head-up tilt
A ll subjects completed the 10-minute period of 60° HUT. During 60° HUT, leg 
vascular resistance significantly increased in PAF (30±22%) and controls (72±69%) 
(post hoc p=0.04 and p=0.01, respectively), whilst the increase in leg vascular 
resistance was not significantly different between groups (Table 3, Figure 1). Controls 
showed no change in MAP (Table 3, Figure 1), whilst MAP significantly decreased 
during 60° HUT in PAF (post hoc p=0.02) (Table 3, Figure 2). Heart rate increased 
significantly during 60° HUT in PAF and controls (Table 3). The increase in heart rate 
was not significantly different between groups (Table 3). In the DBH deficient 
patients, off and on L-DOPS treatment, leg vascular resistance increased during 60° 
HUT (DBH1 184% and 413%; DBH2 123% and 57%, respectively) (Table 3, Figure 2). 
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The DBH deficient patients (off and on L-DOPS) showed a decrease in MAP during 
60° HUT (Table 3, Figure 2). Heart rate increased in DBH deficient patients off and on 
L-DOPS (Table 3).
Figure 1. Group and individual mean arterial blood pressure and leg vascular 
resistance at baseline and during 60° head-up tilt in pure autonomic failure patients 
and controls.
PAF
Controls
8
Diamonds indicate group values (mean±SE) and solid lines indicate individual values. MAP, mean 
arterial blood pressure. LVR, leg vascular resistance. HUT, head-up tilt. PAF, pure autonomic failure 
*, significantly different from baseline.
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Figure 2 . Mean arterial blood pressure and leg vascular resistance at baseline and 
during 60° head-up tilt in dopamine-fi-hydroxylase deficient patients, off and on L- 
DOPS.
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DBH, dopamine-fi-hydroxylase deficient patient. MAP, mean arterial blood pressure (MAP). LVR, leg 
vascular resistance. HUT, head-up tilt.
Stroke volume decreased significantly during 60° HUT in PAF and controls (Table 4). 
Systemic vascular resistance decreased significantly in PAF but did not change in 
controls during 60° HUT (Table 4). Controls showed no change in cardiac output, 
whilst cardiac output decreased during 60° HUT in PAF (post hoc p=0.02) (Table 4). 
The DBH deficient patients showed a decrease in stroke volume and cardiac output
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during 60° HUT off and on L-DOPS (Table 4). Systemic vascular resistance decreased 
during 60° HUT only in DBH2 off L-DOPS (Table 4).
Table 4 . Systemic cardiovascular parameters at baseline and during 60° head-up tilt. 
Subject Stroke volume (ml) Cardiac output (l/min) SVR (dyn.s/cm5)
Baseline 60° HUT Baseline 60° HUT Baseline 60° HUT
DBH1 152 106 7.8 6.1 767 799
with L-DOPS 129 85 6.0 4.7 961 1050
DBH2 93 47 5.2 3.7 1312 1134
with L-DOPS 97 75 6.6 5.2 1249 1343
PAF1 56 46 3.8 3.2 2892 1847
PAF2 53 42 4.2 4.0 2285 1988
PAF3 39 29 2.5 2.0 4416 2175
PAF4 61 48 4.3 3.1 2794 1655
PAF5 68 55 4.7 4.2 2064 1584
PAF (n=5) 55±13 44±11t 3.9±0.9 3.3±0.9f 2890±920* 1850±242t
Controls (n=10) 70±14 59±14f 4.1±1.1 4.2±1.0* 2158±608 2100±597
Time Interaction Time Interaction Time Interaction
ANOVA <0.01 0.85 0.02 <0.01 <0.01 0.01
Values represent individual values and mean±SD, respectively. DBH, dopamine-fi-hydroxylase 
deficiency. PAF, pure autonomic failure. SVR, systemic vascular resistance. 60° HUT, 60° head-up tilt. 
L-DOPS, L-threo-dihydroxyphenylserine. ANOVA, indicates the P-values of the repeated measures 
ANOVA between PAF and controls. *, p o st hoc significantly different from controls. f, significantly 
different from baseline.
8
DISCUSSION
To study the importance of the sympathetic nervous system during orthostatic 
challenges, we examined leg vascular responses during 60° HUT in two distinct 
groups of chronic postganglionic autonomic disorders. The major findings are 1) an 
increase in leg vascular resistance during 60° HUT was observed in both 
postganglionic autonomic failure groups 2) the increase in leg vascular resistance in 
PAF patients seemed to be lower, although not significantly different from healthy 
controls, and 3) orthostatic hypotension during 60° HUT was still present in the 
postganglionic autonomic failure groups, despite the preserved leg vasoconstriction.
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These findings indicate that the sympathetic nervous system is not the sole or pivotal 
mechanism for leg vasoconstriction during orthostatic challenges.
Leg vasoconstrictor mechanisms
To maintain blood pressure during orthostatic challenges, peripheral vasoconstriction 
is induced by baroreceptor mediated activation of the sympathetic nervous system
(1.2), which can be anatomically divided in a preganglionic and postganglionic part
(1.3). We demonstrated that leg vasoconstriction in patients with PAF and DBH 
deficiency is not abolished. In parallel to our findings, a preserved leg vasoconstriction 
was demonstrated in spinal cord-injured individuals (4-7) with preganglionic 
autonomic failure due to disruption of the spinal cord. Indeed, the increase in leg 
vascular resistance during HUT in spinal cord-injured individuals, but also in healthy 
controls, was unaffected during intra-arterial infusion of phentolamine (a-adrenergic 
antagonist) (7). The major finding of our study is that an intact sympathetic nervous 
system is not obligatory for leg vasoconstriction during orthostatic challenges in 
humans, which reinforces the findings of the previous studies.
As an intact sympathetic nervous system is not obligatory, one may question 
which mechanism(s) contribute to the leg vasoconstriction in our subjects during 60° 
HUT. In autonomic disorders with intact sympathetic nerve endings, as in DBH 
deficiency (10), non-adrenergic neurotransmitters, such as adenosine triphosphate 
(ATP) and neuropeptide Y (NPY) (16) may contribute to the demonstrated leg 
vasoconstriction. DBH deficient patients have an intact sympathetic nervous system 
with a normal increase in baroreflex mediated sympathetic activity during 60° HUT 
(Table 1) ( 17). Non-adrenergic neurotransmitters may, therefore, induce 
vasoconstriction during head-up tilt in DBH deficiency (Table 5). In PAF patients, 
however, non-adrenergic neurotransmitters are unlikely to contribute to the leg 
vasoconstriction, given the generalized sympathetic denervation and consequent loss 
of sympathetic nerve terminals (Tables 1 and 5) (8,9,18). The non-adrenergic 
neurotransmitters ATP and NPY are co-stored with norepinephrine, simultaneously 
released from the sympathetic nerve terminal into the synaptic cleft and thought to 
have a coordinated action with norepinephrine (19). Animal studies have 
demonstrated the vasoconstrictor capacities of ATP, whereas NPY modulates the 
action of norepinephrine and ATP ( 19,20). However, the exact role of noradrenergic 
neurotransmitters in humans is still unclear.
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Also local vasoconstrictor mechanisms may induce vasoconstriction, such as 
the veno-arteriolar axon reflex (VAR). The VAR is triggered when venous pressure 
exceeds 25 mmHg, which results in vasoconstriction of the corresponding arteriole, 
and may importantly contribute to peripheral vasoconstriction during orthostatic 
challenges (21). The VAR runs through a sympathetic axon and is thought to be a- 
adrenergic mediated (22). Due to the denervation of the sympathetic postganglionic 
axons in PAF the VAR cannot contribute to leg vasoconstriction during 60° HUT 
(Table 1 and 5). In DBH deficiency, based on the absence of norepinephrine, the VAR 
may only contribute to leg vasoconstriction if it is mediated by non-adrenergic 
neurotransmitters (Table 1 and 5). This would challenge the general view of the VAR 
being a-adrenergic mediated (22). However, recent studies suggest that the VAR is not 
fully a-adrenergic mediated (7,23).
Finally, peripheral vasoconstriction may also be induced via the myogenic 
response, which is triggered by an increase in transmural pressure across an arteriole 
(22,24), and is independent of humoral or neuronal influences (25). Therefore, the 
myogenic response is independent of the sympathetic nervous system. The myogenic 
response may explain the observed leg vasoconstriction in both PAF and DBH 
deficiency (Table 5). Similarly, the myogenic response is hypothesized to be 
responsible for the leg vasoconstriction during HUT and limb dependency in spinal 
cord-injured individuals (7,26). This redundant local vasoconstrictor mechanism may 
compensate for the loss of sympathetic mediated vasoconstriction and explain the 
preserved leg vasoconstriction in patients with autonomic failure.
The results of our study clearly demonstrate that the sympathetic nervous 
system is important but is not obligatory for leg vasoconstriction during orthostatic 
challenges. Whilst alternative vasoconstrictor mechanisms may compensate for the 
loss of sympathetic a-adrenergic vascular control, it is unknown whether and to which 
extend these mechanisms are present during normal situations or only become active 
when the sympathetic nervous system fails. Most likely, leg vasoconstriction during 
orthostatic challenges is caused by a combination of central and local vasoconstrictor 
mechanisms. When one of these mechanisms fails, the other vasoconstrictor 
mechanisms can compensate for its loss. The results demonstrate that without control 
of the sympathetic nervous system, leg vascular resistance can increase by 30% in PAF 
patients. This 30% increase in leg vascular resistance may be considered as the 
maximal capacity of non-adrenergic vasoconstrictor mechanisms, most likely the
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myogenic response, to contribute to leg vasoconstriction. However, this needs to be 
studied in detail in future studies.
Table 5 . Possible peripheral vasoconstrictor mechanisms in pure autonomic failure 
and dopamine-fi-hydroxylase deficiency.
Vasoconstrictor mechanisms PAF DBH
Baroreflex - —
N on-adrenergic neurotransmission* - +
Veno-arteriolar axon reflex (VAR) — +
Myogenic response + +
PAF, pure autonomic failure. DBH, dopamine-fi-hydroxylase deficiency. *, adenosine triphosphate 
(ATP) and neuropeptide Y (NPY).
Orthostatic hypotension
Despite the leg vasoconstriction during 60° HUT, orthostatic hypotension (>20 
mmHg decrease in systolic or >10 mmHg decrease in diastolic pressure within 3 
minutes of standing or a 60° HUT (11)) was present in all PAF and DBH deficient 
patients. Interestingly, the increase in leg vascular resistance during 60° HUT in DBH 
deficient patients was even larger compared to controls. Orthostatic hypotension in 
autonomic failure can, therefore, only be partly attributed to changes in the leg 
vascular response. Potential contributing mechanisms for the orthostatic hypotension 
in autonomic failure could relate to alterations in the splanchnic vascular bed, an 
attenuated venoconstriction and/or inadequate plasma volumes. In PAF patients the 
large decrease in systemic vascular resistance suggests a lack of vasoconstriction in 
other vascular beds, in contrast to the increase in leg vascular resistance. The vascular 
resistance of the superior mesenteric artery does not change during head-up tilt in 
PAF patients, nor does the forearm vascular resistance (27). Suggesting a lack of 
vasoconstriction of the upper limb and splanchnic vascular bed, although the superior 
mesenteric artery is only one of three large splanchnic blood vessels. However, 
systemic vascular resistance decreases, indicating that there should be vasodilation in 
other vascular beds in PAF patients. Which vascular beds actually demonstrate 
vasodilation is unknown. Nevertheless, the decrease in systemic vascular resistance 
during 60° HUT seems to be the major cause of orthostatic hypotension in PAF 
patients (27-29). Future studies should further examine the exact mechanism 
explaining the orthostatic hypotension in autonomic failure, which may contribute to 
the clinical management of these patients.
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Baseline values
The baseline leg vascular resistance was not different between PAF and controls, 
despite generalized sympathetic denervation and low norepinephrine levels in PAF. 
This could be explained by the use of midodrine (a-adrenoceptor agonists) and to a 
lesser extend fludrocortisone in PAF, which both increase baseline leg vascular 
resistance. Similarly, the higher MAP in PAF compared to controls may be explained 
by increased blood volume by prescribed fludricortisone and sodium. Alternatively, 
PAF patients may demonstrate physiological adaptations in order to try to prevent 
orthostatic intolerance (30,31).
Limitations
In our 60° HUT protocol the subjects support their body weight on one leg, allowing 
the non-weight bearing leg to be relaxed for blood flow measurements. This protocol 
has been used before (4,32,33), but might increase muscle tensing in the weight­
bearing leg (34) and, thereby, increase muscle sympathetic nerve activity (MSNA) by 
the exercise pressor reflex (35). We have tried to minimize the muscle tensing during 
60° HUT by supporting the thigh of the weight-bearing leg by a strap to keep it 
extended and supporting straps around the waist and chest. Muscle tensing in the 
weight-bearing leg might result in vasoconstriction in this leg, although it seems to 
decrease systemic vascular resistance in controls and PAF patients (34). It could, 
therefore, be that muscle tensing in the weight-bearing leg leads to vasoconstriction 
and at the same time to systemic vasodilation, explaining our lack of increase in 
systemic vascular resistance in controls. The demonstrated increase in leg vascular 
resistance of the non weight-bearing leg could, in that case, be underestimated. 
Nevertheless, the differences between standing on one or two legs during 60° HUT on 
central and peripheral vascular responses are unknown.
Our small group sizes resulted in less powerful statistical analyses, especially in 
DBH deficiency. However, both disorders represent rare autonomic disorders with 
often serious co-morbidities, while DBH deficient patients rarely cease their 
medication. Moreover, these unique and carefully selected groups demonstrated 
comparable cardiovascular responses during 60° HUT. Therefore, increasing our 
sample size w ill unlikely change the major outcomes of our study.
Four out of five PAF patients used medication to manage their orthostatic 
hypotension (Table 2). The use of an a-adrenoceptor agonist (midodrine) increases
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basal vascular tone. However, whether this drug altered the vascular tone during 
orthostatic challenges is unknown. Fludrocortisone and sodium have an effect on 
circulating volume and fludricortisone has also a lesser effect on vascular tone. It is, 
therefore, unlikely that the observed leg vasoconstriction during 60° HUT in PAF is a 
result of medication. Furthermore, one PAF patient did not use any medication but 
demonstrated similar results as the other PAF patients.
C linical relevance
The initial cardiovascular responses to orthostatic challenges, i.e. increase in heart 
rate, cardiac contractility and peripheral vascular resistance, have been allocated to the 
sympathetic nervous system (2,3,29,36,37). Our results challenge this widely adopted 
view, since an increase in leg vascular resistance was observed in specific disorders of 
the postganglionic part of the sympathetic nervous system. Alternative 
vasoconstrictor mechanisms may compensate for the loss of sympathetic a-adrenergic 
mediated vasoconstriction in patients with autonomic failure. Furthermore, our 
results indicate that, despite the increase in leg vascular resistance and optimal 
pharmacotherapy, orthostatic hypotension was still present in all PAF and DBH 
deficient patients. This suggests that orthostatic intolerance is unlikely caused by 
changes in leg vascular resistance.
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In human evolution, maintaining blood pressure during changes in posture has been 
an important circulatory achievement. The Autonomic nervous system is thought to 
play a principal role in the control of blood pressure regulation ( 1-3). Failure of the 
autonomic nervous system to control blood pressure regulation may result in an 
immediate decrease in blood pressure when adopting the upright position, known as 
orthostatic hypotension ( 1,3). The baroreceptor mediated increase in sympathetic 
nervous system activity w ill result in an increase in heart rate, cardiac contractility and 
peripheral vascular resistance ( 1,2). The increase in peripheral vascular resistance in 
order to maintain blood pressure during the transition from supine to the upright 
position is scarcely studied. Therefore, we examined the changes in peripheral 
vascular resistance during the upright posture in individuals with autonomic failure. 
We also examined the role of peripheral vascular resistance in the episode of 
hypertension during exaggerated sympathetic activity, i.e. autonomic dysreflexia, in 
individuals with a spinal cord lesion. In this final chapter, our results are summarized 
and the consequences of our findings will be discussed and related to other studies.
LEG VASCULAR RESPONSES IN  SPINAL CORD INJURY
Basal leg vascular resistance
A spinal cord injury leads to numerous cardiovascular adaptations below the level of 
the spinal cord lesion (4-6). Supraspinal sympathetic nervous system control of the leg 
vascular bed is lost in spinal cord injured individuals (SCI) and one might expect a 
decreased basal leg vascular resistance due to autonomic failure. In contrast, SCI 
individuals demonstrate an increased basal leg vascular resistance (Chapters 3 -5 ) (7­
12). We demonstrated in Chapter 4  a contribution of angiotensin I I  to the increased 
basal leg vascular resistance in SCI individuals. Previous studies have demonstrated 
that the increased basal leg vascular resistance in SCI individuals cannot be explained 
by adaptations in sympathetic tone (12) or an impaired availability of endothelium- 
derived NO (7), whereas the vasoconstrictor endothelin-1 contributed significantly 
( 10). Interestingly, endothelin-1 and angiotensin II  are closely linked in the regulation 
of vascular tone. Angiotensin II  stimulates endothelin-1 release in cultured 
endothelial cells (13). The hypertensive effects of angiotensin II  in humans might be 
mediated by stimulation of renal endothelin-1 receptors (14,15). In addition 
angiotensin II-induced hypertension in rats can be attenuated by endothelin-1
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receptor antagonists (16). Therefore, the contribution of angiotensin II  and 
endothelin-1 to the increased basal leg vascular resistance in SCI individuals, could 
share a common pathway.
We demonstrated in Chapter 4  that angiotensin II  contributed to vascular 
resistance only in the paralysed and extremely inactive legs and not in the non­
paralysed active arms of SCI individuals. Similarly, we demonstrated no contribution 
of angiotensin II  to vascular resistance in healthy active controls. We, therefore, 
hypothesize that the demonstrated contribution of angiotensin II  to the increased 
basal leg vascular tone in SCI individuals relates to extreme inactivity of the 
deconditioned legs. Indeed, increased levels of angiotensin II  have been demonstrated 
in bed rest studies (17,18). More importantly, our hypothesis is supported by the 
consistently demonstrated normalisation of basal leg vascular resistance and the 
diminished contribution of endothelin-1 to leg vascular resistance after electrical 
stimulation-assisted exercise in SCI individuals (9,10,19).
The increased basal leg vascular resistance in SCI individuals is not in 
agreement with the typical finding in autonomic failure. For instance, basal leg 
vascular resistance in patients with Parkinson’s disease (PD) with autonomic failure 
(C h apter 7 ) and dopamine-C-hydroxylase deficiency (C h apter 8) is lower than in 
controls (20,21). The lower basal leg vascular resistance in these groups is probably 
due to a decrease in sympathetic a-adrenergic tone due to sympathetic denervation 
(PD) (20,22) or the inability to produce noradrenaline (DBH deficiency) (21). This is 
supported by the fact that the noradrenaline prodrug L-DOPS increased basal leg 
vascular resistance in DBH deficiency and that the a-adrenoceptor agonist midodrine 
had a similar effect in pure autonomic failure (PAF) patients (C h apter 8). In contrast, 
the increased basal leg vascular resistance in SCI individuals is not explained by 
adaptations in sympathetic a-adrenergic tone (12) but by adaptations in the 
contribution of the humoral vasoconstrictors angiotensin II  (C h apter 4 )  and 
endothelin-1 (10) related to extreme inactivity. The extreme inactivity in SCI 
individuals and consequent deconditioning of the legs also leads to structural 
adaptations (vascular atrophy) which may contribute to the increased basal leg 
vascular resistance. Physical activity level in most individuals with autonomic failure 
is decreased, however not even close to the extent of the extreme inactivity in SCI 
individuals. Inactivity, therefore, seems to influence leg vascular tone more than the 
loss of supraspinal control. More importantly, the effect of inactivity on leg vascular
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resistance, i.e. increase in leg vascular resistance, is contrary to the effect of the loss of 
supraspinal sympathetic control, i.e. decrease in leg vascular resistance.
One might suggest that the increased basal leg vascular resistance in SCI 
individuals protects them from orthostatic hypotension. In the initial phase after a 
spinal cord injury (‘spinal shock’) orthostatic hypotension is present in most SCI 
individuals and in some SCI individuals the orthostatic hypotension persists over time 
(23). The increased basal leg vascular resistance in Chapters 3, 4 a n d  5  was 
demonstrated in chronic SCI individuals with low and high spinal cord lesion, but 
none of these SCI individuals demonstrated orthostatic hypotension. Whether the SCI 
individuals with orthostatic hypotension have a lower leg vascular resistance is 
unknown. In line with this, a decrease in leg vascular resistance may increase the 
susceptibility for orthostatic hypotension in SCI individuals. There are some 
unpublished cases from our laboratory of SCI individuals who developed orthostatic 
hypotension after an electrical-stimulation assisted cycling training program aimed to 
counteract the leg deconditioning. The effects of an electrical-stimulation assisted 
cycling program on blood pressure responses during orthostatic challenges in SCI 
individuals are unknown (24).
Autonomic dysreflexia
The clinically interesting phenomenon of autonomic dysreflexia can occur in SCI 
individuals with a spinal cord lesion above the sixth thoracic spinal segment (T6) (4), 
since a large part of the sympathetic nervous system is without central inhibitory 
pathways (5,6). Autonomic dysreflexia is characterised by an episode of hypertension 
induced by exaggerated sympathetic activity caused by a stimulus below the level of 
the spinal cord lesion (4,6,25,26). Because autonomic dysreflexia is induced by 
exaggerated sympathetic activity, the widely adopted view is that the vasoconstrictor 
response is entirely a-adrenergic mediated (5,6,26,27). However, we demonstrated in 
C hapter 5 that a residual leg vasoconstriction was present during a-adrenoceptor 
blockade with intra-arterial phentolamine (a-adrenoceptor antagonist) infusion 
during autonomic dysreflexia in SCI individuals. We, therefore, believe that 
autonomic dysreflexia is not entirely a-adrenergic mediated. The rapid and instant 
increase in blood pressure during autonomic dysreflexia makes other slower 
vasoconstrictor mechanisms, such as the renin-angiotensin II system (RAS), unlikely. 
Moreover, plasma levels of renin and angiotensin II did not change during autonomic
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dysreflexia (C hapter 5), nor does vasopressin (28). Since leg vasoconstriction was still 
present during a-adrenoceptor blockade, other sympathetic neurotransmitters have to 
be involved, such as adenosine triphosphate (ATP) and neuropeptide Y (NPY)
(29,30). In contrast to SCI individuals, a-adrenoceptor blockade with phentolamine 
infusion completely blocked the leg vasoconstriction response during exaggerated 
sympathetic activity evoked by a cold pressor test of the hand in healthy controls 
(C hapter  5). This indicates that supraspinal control of the sympathetic nervous system 
suppresses the role of non-adrenergic transmission during exaggerated sympathetic 
activity. Or vice versa, the loss of supraspinal control arouses the role of non- 
adrenergic transmission to leg vasoconstriction during exaggerated sympathetic 
activity.
The management of autonomic dysreflexia remains a challenge in clinical 
practice (25,31). Non-pharmacological strategies, such as removing the visceral, 
noxious or non-noxious stimulus and a head-up tilt position, remain the first choice 
followed by pharmacological measures (26,31). In earlier days, a-adrenoceptor 
antagonists were used (26). Although these drugs are the first choice from a 
theoretical point of view, serious adverse reactions and the strong vasodilator effect 
and consequent reduction in blood pressure in the periods in between episodes of 
autonomic dysreflexia have contributed to the limited use of a-adrenoceptor 
antagonists. Currently, nifedipine (calcium channel blocker) is used as a primary 
agent (26,31) and may prevent or control autonomic dysreflexia indicated by a lower 
blood pressure response (31,32). However, we demonstrated in C hapter 5  that an a- 
adrenoceptor antagonist has a more pronounced effect compared to a calcium 
channel blocker on both the increase in blood pressure and leg vascular resistance. 
Interestingly, an angiotensin-converting enzyme (ACE) inhibitor (captopril) is also 
used in the management of autonomic dysreflexia and appears to be safe and effective 
(33). We demonstrated in C hapter 4  a contribution of angiotensin II to the increased 
basal leg vascular resistance in SCI individuals, therefore an ACE inhibitor could also 
lower leg vascular resistance during autonomic dysreflexia. We, recently, studied the 
effect of an ACE inhibitor on the leg vasoconstriction during autonomic dysreflexia 
and demonstrated an attenuated increase in leg vascular resistance (Figure 1). Similar 
to a calcium channel blocker, the effect of an ACE inhibitor is less pronounced 
compared to an a-adrenoceptor antagonist. We demonstrated in C hapter 5  that 
sympathetic non-adrenergic neurotransmitters contribute to the increase in leg
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vascular resistance during autonomic dysreflexia, therefore the development of 
antagonists of non-adrenergic transmitters might be a target for future management 
of autonomic dysreflexia. Perhaps these antagonists may appear to be effective in 
reducing the blood pressure increase during autonomic dysreflexia without 
significantly lowering the blood pressure in the periods in between episodes of 
autonomic dysreflexia in SCI individuals. This is a general problem that exists with all 
available pharmacological agents used nowadays in the management of autonomic 
dysreflexia.
Figure 1. Leg vascular resistance during autonomic dysreflexia without and with an 
ACE inhibitor.
Leg vascular resistance during supine rest and during evoked autonomic dysreflexia in 5 spinal cord- 
injured individuals under control situation and 90 minutes after an oral dose of captopril (25 mg). 
AU, arbitrary units. *, significantly difference. Groothuis, unpublished data.
LEG VASCULAR RESPONSES IN AUTONOMIC FAILURE
The sympathetic nervous system is thought to play a principal role in the control of 
blood pressure regulation (1-3) and can be anatomically and functionally divided in a 
preganglionic and postganglionic (1,34). Autonomic disorders demonstrate selective 
failure of the different parts of the sympathetic nervous system (Figure 2). The
157
baroreceptor mediated increase in sympathetic activity, triggered by a drop in blood 
pressure upon an orthostatic challenge, will result in an increase in heart rate, cardiac 
contractility and peripheral vascular resistance (1-3). Although the changes in heart 
rate and cardiac output have been extensively studied during head-up tilt, changes in 
leg vascular resistance have been scarcely studied. We have, therefore, examined the 
change in leg vascular resistance during head-up tilt in individuals with autonomic 
failure due to selective autonomic disorders.
Figure 2. The level of autonomic failure within the sympathetic nervous system of the 
different autonomic disorders studied in this thesis.
SCI, spinal cord lesion (Chapters 3-5). PD, Parkinson’s disease (Chapter 7). PAF, pure autonomic 
failure (Chapter 8). DBH, dopamine-fi-hydroxylase deficiency (Chapter 8).
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Non-invasive assessment of leg vascular resistance during head-up tilt
Leg vascular resistance is calculated as the arterial-venous pressure gradient (Pa-Pv) 
divided by leg blood flow. In the supine position with the leg at or above heart level, 
the venous pressure is assumed to be close to 0 mmHg. However, during orthostatic 
challenges a hydrostatic pressure is added to leg arterial as well as to leg venous 
pressure (3,35,36). The question is how the upright posture affects the arterial-venous 
pressure gradient. At the onset of an orthostatic challenge, the venous valves will 
prohibit venous backflow and, thereby, interrupt the formation of a continuous 
hydrostatic column. However, continued venous filling with blood from the arterioles 
will, after some time, result in the formation of a continuous hydrostatic column (35­
37). Only when continuous hydrostatic columns are formed in both the leg arteries 
and the leg veins, the assumption can be made that the hydrostatic pressure 
contributes equally to leg arterial as well as to leg venous pressure (36). The finding in 
Chapter 2 , that leg venous pressure during head-up tilt is similar to the calculated 
hydrostatic pressure after 3-4 minutes of head-up tilt, is of importance to calculate leg 
vascular resistance with non-invasive measurement techniques during orthostatic 
challenges. We have, therefore, used these results in the calculation of leg vascular 
resistance during head-up tilt in this thesis.
Leg vascular responses during head-up tilt
In this thesis we studied the leg vascular responses during head-up tilt in different 
autonomic disorders with autonomic failure of specific parts of the sympathetic 
nervous system (Figure 2). In Chapters 3 and 4  we studied SCI individuals with 
preganglionic autonomic failure (Table 1). Despite their loss of supraspinal control of 
the sympathetic nervous system, we demonstrated a preserved increase in leg vascular 
resistance during head-up tilt. In Chapter 7  Parkinson’s disease (PD) patients with 
orthostatic hypotension were studied and we demonstrated a preserved increase in leg 
vascular resistance during head-up tilt. Sympathetic denervation, due to a 
postganglionic lesion is present in PD with autonomic failure (20,22) (Table 1). 
Similarly, patients with pure autonomic failure (PAF) have generalised sympathetic 
denervation due to a postganglionic lesion of the sympathetic nervous system (Table 
1), causing widespread autonomic failure (38-40). Despite the loss of sympathetic 
fibres, we demonstrated in Chapter 8 a preserved increase in leg vascular resistance in 
PAF during head-up tilt. In Chapter 8 we also studied patients with dopamine-C-
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hydroxylase (DBH) deficiency who have a complete absence of noradrenaline with an 
intact sympathetic nervous system with normal supraspinal control (21,41,42) (Table
1). Surprisingly, we demonstrated in Chapter 8 a preserved increase in leg vascular 
resistance during head-up tilt in DBH deficiency despite the absence of noradrenaline. 
In summary, in autonomic disorders, with autonomic failure due to a lesion in the 
preganglionic and postganglionic part of the sympathetic nervous system, the increase 
in leg vascular resistance during head-up tilt is preserved.
Vasoconstrictor mechanisms
The baroreflex mediated increase in sympathetic activity, is thought to be the most 
important vasoconstrictor mechanism during orthostatic challenges (1-3). However, 
we have demonstrated in this thesis that individuals with baroreflex failure, due to 
specific autonomic disorders, have preserved increases in leg vascular resistance 
during head-up tilt (Chapters 3, 4, 7  and 8). This indicates that other vasoconstrictor 
mechanisms can compensate for the loss of baroreflex mediated leg vasoconstriction. 
Possible vasoconstrictor mechanisms are non-adrenergic neurotransmission (29,30), 
humoral factors such as the RAS (3) and local vasoconstrictor mechanisms, such as 
the veno-arteriolar axon reflex (VAR) (43) and the myogenic response (44,45).
Non-adrenergic neurotransmission
In autonomic disorders with intact sympathetic nerve terminals, such as in SCI 
individuals (Chapters 3 and 4) and DBH deficiency (Chapter 8), non-adrenergic 
neurotransmitters, such as ATP and NPY (29,30), may be involved in the 
demonstrated increase in leg vascular resistance (Table 1). ATP and NPY are co­
stored with noradrenaline, simultaneously released from the sympathetic nerve 
terminal into the synaptic cleft and thought to have a coordinated action with 
noradrenaline (30). Animal studies have demonstrated the vasoconstrictor capacities 
of ATP, whereas NPY modulates the action of noradrenaline and ATP (30,46). 
However, the exact role of non-adrenergic neurotransmitters in humans is still 
unclear. Since there is no increase in sympathetic activity during head-up tilt in SCI 
individuals, indicated by a lack of noradrenaline increase (47,48), it is unlikely that 
non-adrenergic neurotransmitters are released from the sympathetic nerve terminal. 
On the contrary, in DBH deficiency there is a normal increase in baroreflex mediated 
sympathetic activity during head-up tilt (49) and, therefore, non-adrenergic
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neurotransmitters may induce leg vasoconstriction in DBH deficiency (Table 1). 
However, non-adrenergic neurotransmitters should contribute to widespread 
vasoconstriction but total peripheral resistance decreased during head-up tilt in DBH 
deficiency (Table 2). It is, therefore, unlikely that non-adrenergic neurotransmission 
contributes to the demonstrated preserved leg vasoconstriction in DBH deficiency.
Humoral vasoconstrictors
During prolonged orthostatic challenges (>25 min.), the RAS is activated and 
angiotensin II probably contributes to peripheral vasoconstriction (3,50). However, 
we demonstrated in Chapter 4  that angiotensin II does not contribute to the increase 
in leg vascular resistance during a 10-minute head-up tilt in SCI individuals and 
controls. Similarly, the vasoconstrictors endothelin-1, vasopressin and aldosterone are 
unlikely to contribute to the increase in leg vascular resistance during head-up tilt, as 
they do not increase during short term orthostatic challenges (50,51).
Veno-arteriolar axon reflex
The VAR is a local vasoconstrictor mechanism which may contribute up to 45% of 
peripheral vasoconstriction during orthostatic challenges in controls (43). The VAR is 
triggered when venous pressure exceeds 25 mmHg, which results in vasoconstriction 
of the corresponding arteriole (43). The VAR runs through a sympathetic axon and is 
thought to be a-adrenergic mediated (44,52). Therefore, the VAR cannot be 
responsible for the leg vasoconstriction during head-up tilt in autonomic disorders 
with sympathetic denervation, such as in PD and PAF (Chapters 7  and 8) (Table 1). It 
is unlikely that the VAR plays a role in the increase in leg vascular resistance during 
head-up tilt in SCI, since the leg vasoconstriction response is still present during a- 
adrenoceptor blockade (53) (Table 1). Similarly, it is unlikely that the VAR induces leg 
vasoconstriction in DBH deficiency with a complete absence of noradrenaline 
(Chapter 8). Leg vasoconstriction induced by the VAR, however, could also be due to 
non-adrenergic neurotransmission, challenging the general view of an a-adrenergic 
mediated mechanism (52,53). This might be a possibility in SCI individuals and DBH 
deficiency due to the intact sympathetic nerve endings, although the concerns about 
non-adrenergic neurotransmitters have been discussed previously.
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Table 1. Pathophysiological classification and possible vasoconstrictor mechanisms of
the different autonomic disorders
PAF PD DBH SCI
SNS lesion Postganglionic Postganglionic Postganglionic Preganglionic
Sympathetic nerves Degenerative Degenerative Intact Intact
Baseline noradrenaline Low Low Absent Normal
Noradrenaline release Low Low Absent Low
Response to noradrenaline Increased Increased Increased Increased
Baroreflex - - - -
Non-adrenergic transmission - - + +
Veno-arteriolar axon reflex - - +* +*
Myogenic response + + + +
Spinal cord injury (SCI), Parkinson’s disease with autonomic failure (PD), pure autonomic failure 
(PAF) and dopamine-fi-hydroxylase deficiency (DBH). SNS, sympathetic nervous system. *, via non- 
adrenergic neurotransmission.
Myogenic response
Another local vasoconstrictor mechanism is the myogenic response, which is triggered 
by an increase in transmural pressure across an arteriole (44,45). The myogenic 
response is independent of humoral and neuronal influences (54), and, thus, 
independent of the sympathetic nervous system. In SCI individuals the myogenic 
response is responsible for the increase in leg vascular resistance during limb 
dependency (55). The autonomic disorders studied in this thesis, all have an 
unimpaired myogenic response (Table 1) and, therefore, the myogenic response may 
be responsible for the demonstrated preserved increase in leg vascular resistance 
during head-up tilt in autonomic failure where baroreflex control is absent.
Orthostatic hypotension
Blood pressure is defined as the product of cardiac output (heart rate times stroke 
volume) and total peripheral resistance. Although the increase in peripheral resistance 
is important to maintain blood pressure during orthostatic challenges (2,56), the 
preserved increase in leg vascular resistance could not prevent orthostatic hypotension 
in PD, PAF and DBH deficiency (Chapters 7  and 8) (Table 2). There are some possible 
explanations for our findings.
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Table 2 . Changes in cardiovascular parameters during head-up tilt.
AMAP
(mmHg)
AHR
(bpm)
ASV
(ml)
ACO
(l/min)
ATPR
(dyn.s/cm5)
ALVR
(mmHg/min/ml)
30° head-up tilt
Controls 2±5 3±4 -8±6 -0.2±0.4 101±168 0.71±0.81
SCI 6±10 4±3 -5±6 0.0±0.4 69±176 0.63±0.50
60° head-up tilt
PD-OH 4±9 9±4 -6±7 0.0±0.6 27±648 0.88±0.56
PD+OH -14±8 9±4 -19±5 -0.7±0.2 -9.4±133 0.34±0.37
DBH -26±12 14±11 -46±0 -1.6±0.1 -89±126 0.49±0.01
PAF -48±34 5±8 -11±2 -0.6±0.4 -1040±879 0.40±0.38
SCI, spinal cord-injured individuals. PD-OH, Parkinson’s disease without orthostatic hypotension. 
PD+OH, Parkinson’s disease with orthostatic hypotension. DBH, dopamine-fi-hydroxylase deficiency 
PAF, pure autonomic failure. MAP, mean arterial blood pressure. HR, heart rate. SV, stroke volume. 
CO, cardiac output. TPR, total peripheral resistance. LVR, leg vascular resistance.
The increase in leg vascular resistance during head-up tilt was attenuated in PD with 
orthostatic hypotension, PAF and DBH deficiency (Table 2). This attenuated leg 
vasoconstriction could contribute to orthostatic hypotension. More importantly, we 
determined leg vascular resistance and not total peripheral vascular resistance. Besides 
the leg vascular bed, the splanchnic vascular bed importantly contributes to total 
peripheral vascular resistance. The vascular responses of the splanchnic vascular bed 
in autonomic failure are unknown. However, we found small to large decreases in 
total peripheral vascular resistance during head-up tilt (Table 2). Especially in PAF, 
the decrease in total peripheral vascular resistance was large and might contribute to 
their orthostatic hypotension. Since leg vascular resistance increased in these groups, 
the decrease in total peripheral resistance must be due to vasodilation in other 
vascular beds. It is unknown in which vascular beds vasodilation occurs during 
orthostatic challenges in autonomic failure, but it might be that the splanchnic 
vascular bed plays an important role.
Basal leg vascular resistance was lower in PD with orthostatic hypotension and 
DBH deficiency compared to healthy controls (Chapters 7  and 8). Therefore, despite 
the preserved leg vasoconstriction, the leg vascular resistance during head-up tilt was 
still lower in PD with orthostatic hypotension and DBH deficiency compared to 
healthy controls. As a result of the lower leg vascular resistance, vascular capacity is 
increased and will result in a relative low plasma volume (57). Despite the increased 
plasma volume in PD with orthostatic hypotension (Chapter 7), it might still be a
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relative low plasma volume. The relative low plasma volume could contribute to the 
lower stroke volume in PD with orthostatic hypotension and DBH deficiency (Table 
2) and, consequently, contribute to orthostatic hypotension.
Blood pressure is defined as the product of cardiac output and total peripheral 
resistance. Therefore, blood pressure is not only depending on peripheral resistance 
but also on cardiac output. A decrease in cardiac output may, therefore, contribute to 
orthostatic hypotension in autonomic failure. Cardiac output is defined as heart rate 
times stroke volume and especially stroke volume seems to be essential to maintain 
cardiac output. Heart rate increased in all groups during head-up tilt, but still cardiac 
output decreased in PD with orthostatic hypotension, DBH deficiency and PAF (Table
2). Stroke volume decreased in PD with orthostatic hypotension, PAF and DBH 
deficiency (Table 2) and may contribute to orthostatic hypotension. Since stroke 
volume depends on the venous return of blood to the heart, a larger decrease in 
venous return might contribute to orthostatic hypotension in autonomic failure. An 
absent increase in cardiac contractility, due to sympathetic denervation of the heart in 
autonomic failure, may also contribute to a lower stroke volume during (Figure 2).
Figure 2 . Schematic representation of blood pressure control.
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In summary, the orthostatic hypotension in autonomic failure may be explained by an 
attenuated increase in leg vascular resistance, vasodilation in other vascular beds, a 
low basal leg vascular resistance, an absent increase in cardiac contractility, a 
decreased venous return or a combination of these options. Interestingly, it may well 
be that the contributions of the aforementioned possibilities are different for each 
autonomic disorder.
Contribution of the venous system
In this thesis we have focused on the arterial leg vasoconstriction during head-up tilt. 
However, as mentioned in the previous paragraph, the venous system might play a 
principal role in orthostatic hypotension in autonomic failure. During orthostatic 
challenges blood is translocated to the dependent venous vasculature (3,35), lowering 
stroke volume and consequently cardiac output (figure 2). The mechanism of a 
decrease in venous return in autonomic failure may have different causes. First, 
baroreflex mediated sympathetic activity does not only result in arterial 
vasoconstriction but also in venoconstriction (Figure 2), which is mainly directed to 
the splanchnic vascular bed (3,58). Baroreflex failure will probably result in an absent 
venoconstriction of the splanchnic vascular bed, thereby reducing the venous return 
(3). Secondly, an increase in venous pooling can reduce venous return, however in 
Chapter 7  we demonstrated no increase in venous pooling in the lower legs of PD 
patients with orthostatic hypotension. Finally, an inadequate plasma volume may 
contribute to a reduction in venous return (1,57) (Figure 2). Autonomic failure might 
influence plasma volume since the sympathetic nervous system plays an important 
role in volume homeostasis via direct renal innervation and via an increase in RAS 
activity (59). In Chapter 7 , however, we demonstrated a higher plasma volume in PD 
patients with orthostatic hypotension, similarly to one previous study in autonomic 
failure (60). The increased plasma volume in PD patients with orthostatic hypotension 
might be a compensatory mechanism for the lower basal leg vascular resistance, which 
is supported by a strong correlation (Figure 3). Nonetheless, the PD patients were 
unable to maintain blood pressure during an orthostatic challenge. In summary, 
although the exact mechanism of orthostatic hypotension in autonomic failure is 
unknown, we have demonstrated that adaptations in leg vascular resistance are not 
the main cause.
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Figure 3 . Correlation between basal leg vascular resistance and plasma volume.
Basal leg vascular resistance (mmHg/ml/min)
Controls (C; n=8), Parkinson’s disease patients w ithout (PD-OH; n=9) and with orthostatic 
hypotension (PD+OH; n=9). The P value refers to the Pearson’s correlation coefficient (R) calculated 
for all subjects (n=26).
IS THE SYM PATHETIC NERVOUS SYSTEM  OBLIGATORY FOR STANDING?
The results described in this thesis demonstrate that in autonomic disorders with 
selective failure of different levels of the autonomic nervous system (Figure 1), an 
increase in leg vascular resistance is still present during orthostatic challenges despite 
sympathetic nervous system failure. This indicates that alternative vasoconstrictor 
mechanisms, most likely the myogenic response, can compensate for the loss of 
baroreflex mediates sympathetic vasoconstriction. Even in acute autonomic failure, 
simulated by a-adrenoceptor blockade in healthy controls, leg vasoconstriction was 
preserved during head-up tilt (53). This suggests that alternative vasoconstrictor 
mechanisms are present in the legs. It seems that the supraspinal control of the 
sympathetic mediated a-adrenergic leg vasoconstriction overrules the alternative local 
vasoconstrictor mechanisms. This is illustrated by the attenuated increase in leg 
vascular resistance in situations with an increased sympathetic nervous system
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activity, such as in aging (Chapter 6). Furthermore, during exaggerated sympathetic 
activity with supraspinal control the vasoconstrictor response was completely 
abolished with a-adrenoceptor blockade, in contrast to sympathetic activity without 
supraspinal control (Chapter 5).
However, in autonomic failure the increase in leg vascular resistance is 
inadequate to maintain blood pressure in the upright posture. This suggests that the 
baroreflex mediated increase in sympathetic activity resulting in vasoconstriction in 
vascular beds, other than the legs, cardiac contractility and venoconstriction is 
obligatory to maintain blood pressure in the upright posture. It might be that the 
evolutionary process of maintaining blood pressure in the upright position in humans 
is not yet completely accomplished. Most systems in the human body do not depend 
on one physiological mechanism. Maintaining blood pressure in the upright position 
in humans seems to rely mainly on the sympathetic nervous system, although other 
mechanisms try to compensate for the loss of sympathetic nervous system control of 
blood pressure regulation.
IM PLICATIONS OF THE STUDIES AND FUTURE DIRECTIONS
Secondary complications of a spinal cord injury are of significance for the quality of 
life of a SCI individual. Understanding the pathophysiological mechanisms of these 
secondary complications is, therefore, essential for the clinical management of SCI 
individuals. Pressure sores and poor wound healing is a major problem in SCI 
individuals. The increased basal leg vascular resistance in SCI individuals may 
importantly contribute to the development of these secondary complications. In 
combination with previous research of our department we have now indentified two 
major vasoconstrictor pathways which contribute to the increased basal leg vascular 
resistance. These two vasoconstrictors, angiotensin II and endothelin-1, are closely 
connected in the regulation of vascular tone. We hypothesise that lowering the basal 
leg vascular resistance with receptor antagonists of angiotensin II or endothelin-1 may 
lower or prevent the development of pressure sores and improve wound healing. Since 
the contribution of these vasoconstrictors seems to be related to extreme physical 
inactivity, one might also try to improve physical activity by, for instance, electrical 
stimulation-assisted exercise. To prove this hypothesis we first have to assess leg 
vascular resistance in SCI individuals with pressure sores. More ideally, we should
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assess whether the SCI individuals with high basal leg vascular resistance have an 
increased risk in developing pressure sores. One step further is to assess whether 
angiotensin II and endothelin-1 antagonists or physical activity can improve or 
accelerate wound and pressure sores healing. The final step would be to try to prevent 
the development of pressure sores by treating the SCI individuals at risk. We should 
make one important remark, angiotensin II and endothlein-1 receptor antagonists can 
induce hypotension and, therefore, blood pressure monitoring is of utmost 
importance.
Autonomic dysreflexia is another serious secondary complication of a spinal 
cord injury. Prevention of the development of autonomic dysreflexia by informing the 
patient, patient carers and medical personnel is the primary action in autonomic 
dysreflexia management. The first step during autonomic dysreflexia is removing the 
triggering factor and start non-pharmacological strategies. Only when these strategies 
fail to lower blood pressure, pharmacological measures are indicated. However, the 
management of autonomic dysreflexia remains a challenge. Our results suggest a new 
target for future autonomic dysreflexia management, i.e. non-adrenergic 
neurotransmitters.
Patients with autonomic failure often complain of orthostatic hypotension 
being the most disabling symptom. Treatment of orthostatic hypotension in 
autonomic failure is a challenge and hardly evidence based (1,61). Our results suggest 
that an attenuated increase in leg vascular resistance does not contribute to orthostatic 
hypotension in autonomic failure. However, in some autonomic disorders basal leg 
vascular resistance is low and, despite leg vasoconstriction, remains lower during 
orthostatic challenges as compared to controls. It might be that the low basal leg 
vascular resistance contributes to the orthostatic hypotension. Increasing the basal leg 
vascular resistance could, therefore, be an effective strategy, although the results in 
PAF patients, with a-adrenergic agonist treatment, suggest otherwise. We 
demonstrated that a compensatory vasoconstrictor mechanism, the myogenic 
response, might be responsible for the observed increase in leg vascular resistance in 
autonomic failure. Future research should focus on trying to improve the 
vasoconstrictor capacities of this compensatory mechanism in order to try to manage 
orthostatic hypotension. Non-pharmacological interventions, such as physical 
activity, or pharmacological interventions in order to improve the vasoconstrictor 
capacities of the myogenic response could be studied. As discussed, a decrease in
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cardiac output, probably due to a decrease in venous return, is an important 
additional factor in orthostatic hypotension in individuals with autonomic failure. 
The mechanism of the decreased cardiac output in autonomic failure is unclear and, 
therefore, of interest for future studies. As a first step, interventions that increase 
venous return should be studied for their efficacy to treat orthostatic hypotension in 
autonomic failure.
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SUM M ARY
The upright posture of humans greatly challenges the control of blood pressure 
regulation. The autonomic nervous system plays a principal role in the control of 
blood pressure regulation via changes in sympathetic nervous system activity. 
Baroreflex mediated increases in sympathetic nervous system activity leads to changes 
in heart rate, cardiac contractility and peripheral vascular resistance. Surprisingly, the 
changes in peripheral vascular resistance are scarcely studied. Therefore, the general 
aim of this thesis was to examine the role of the autonomic nervous system in a 
specific part of the blood pressure regulation, i.e. peripheral vascular control, in 
individuals with autonomic failure, with a special interest in individuals with a spinal 
cord lesion.
Throughout this thesis we have calculated leg vascular resistance, as measure for 
peripheral vascular control, during head-up tilt as the arterial-venous pressure 
gradient divided by blood flow. In Chapter 2  we have examined the changes in 
intravenous pressure during head-up tilt in healthy controls. Intravenous pressure 
measured in the great saphenous vein was similar to the calculate hydrostatic pressure 
during 30° and 70° head-up tilt. The hydrostatic pressure contributes, therefore, 
equally to leg arterial as well as to leg venous pressure during head-up tilt.
In Chapter 3 we examined the changes in leg vascular resistance during 30° head-up 
tilt in spinal cord-injured (SCI) individuals. Despite their central autonomic failure, 
due to the disruption of the spinal cord, SCI individuals had a preserved leg 
vasoconstriction during 30° head-up tilt. This finding demonstrates that humans are 
able to increase their leg vascular resistance independently of supraspinal sympathetic 
control.
Although SCI individuals have central autonomic failure they demonstrate an 
increased basal leg vascular resistance. In Chapter 4 , we demonstrated a contribution 
of angiotensin II to the increased basal leg vascular resistance in SCI individuals. 
Angiotensin II did not contribute to forearm vascular resistance in SCI individuals 
nor to leg and forearm vascular resistance in healthy controls. The contribution of 
angiotensin II to the increased leg vascular resistance in SCI individuals might, 
therefore, relate to the extreme inactivity of the paralyzed legs. Furthermore, we
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demonstrated in Chapter 4  that angiotensin II does not contribute to the preserved leg 
vasoconstriction in SCI individuals during 30° head-up tilt. Nor does it contribute to 
leg vasoconstriction during 30° head-up tilt in healthy controls.
Because SCI individuals have an intact sympathetic nervous system with no 
supraspinal control, the interesting clinical phenomenon of autonomic dysreflexia can 
occur. This episode of hypertension in SCI individuals was thought to be a-adrenergic 
mediated. We demonstrated in Chapter 5  that the increase in leg vascular resistance 
during autonomic dysreflexia in SCI individuals is not entirely a-adrenergic mediated. 
This finding demonstrates that the leg vasoconstriction during autonomic dysreflexia 
in SCI individuals is partly explained by non-adrenergic neurotransmitters, such as 
adenosine triphosphate (ATP) and neuropeptide Y. The increase in leg vascular 
resistance during a cold pressure test of the hand in healthy controls was completely 
a-adrenergic mediated, suggesting that non-adrenergic neurotransmission is 
suppressed by supraspinal control.
Older men have an augmented increase in total peripheral resistance during head-up 
tilt despite their chronically elevated sympathetic nervous system activity. However, in 
Chapter 6 we demonstrated an attenuated increase in leg vascular resistance during 
30° head-up tilt in older men compared to young controls. The attenuated increase in 
leg vascular resistance may be part of the explanation of orthostatic hypotension with 
advancing age.
In Chapter 7  we examined the changes in leg vascular resistance during 60° head-up 
tilt and measured plasma volume in Parkinson’s disease patients with and without 
orthostatic hypotension. Parkinson’s disease patients with orthostatic hypotension 
demonstrated a lower basal leg vascular resistance in combination with a larger 
plasma volume compared to Parkinson’s disease patients without orthostatic 
hypotension and healthy controls. Parkinson’s disease patients with orthostatic 
hypotension demonstrated a preserved leg vasoconstriction during 60° head-up tilt, 
which was not different from Parkinson’s disease patients without orthostatic 
hypotension and healthy controls. These findings demonstrate that orthostatic 
hypotension in Parkinson’s disease is not due to an attenuated leg vasoconstriction or 
an inadequate plasma volume, but may partly be explained by a lower basal leg 
vascular resistance.
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In Chapter 8 we examined the changes in leg vascular resistance during 60° head-up 
tilt in two selective autonomic disorders with autonomic failure of the postganglionic 
(pure autonomic failure) and neurotransmitter (dopamine-fi-hydroxylase deficiency) 
part of the sympathetic nervous system. Despite their autonomic failure, we 
demonstrated a preserved leg vasoconstriction during 60° head-up tilt in pure 
autonomic failure and dopamine fi-hydroxylase deficient patients. This finding 
indicate that the sympathetic nervous system is not obligatory for leg vasoconstriction 
during orthostatic challenges.
10
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Eén van de belangrijkste momenten in de evolutie van de mens is het gaan staan en 
lopen op twee benen. De rechtopstaande houding geeft de mens een groot voordeel, 
maar tegelijkertijd is het een uitdaging voor de regelsystemen die noodzakelijk zijn om 
de bloeddruk te kunnen handhaven. Het autonoom zenuwstelsel heeft in dit proces 
een belangrijke rol.
Wanneer wij rechtop gaan staan zal onder invloed van de zwaartekracht meer 
bloed de bloedvaten onder het niveau van het hart instromen. Hierdoor wordt het 
hart minder gevuld met bloed en kan er minder bloed vanuit het hart de grote 
lichaamsslagader (aorta) worden gepompt. Dit leidt tot een bloeddrukdaling die 
opgemerkt zal worden door bloeddruksensoren in de halsslagaders en de aorta. Deze 
sensoren verhogen de activiteit van het sympathische zenuwstelsel, een onderdeel van 
het autonoom zenuwstelsel. Deze verhoogde activiteit leidt tot een toename van de 
pompkracht van het hart, een toename van de hartslag en een toename van de perifere 
vaatweerstand. Binnen enkele hartslagen zal hierdoor de bloeddrukdaling worden 
tegengegaan en de bloeddruk gehandhaafd blijven.
Wanneer het bloeddrukregelsysteem faalt kan dit leiden tot een 
bloeddrukdaling tijdens het rechtop gaan staan, wat orthostatische hypotensie wordt 
genoemd. Dit proefschrift beschrijft het onderzoek naar de rol van veranderingen in 
de perifere vaatweerstand in het handhaven van de bloeddruk bij personen met een 
aandoening van het sympathisch zenuwstelsel (autonoom falen), met speciale 
aandacht voor personen met een dwarslaesie.
Als maat voor de perifere vaatweerstand, maken we in dit proefschrift gebruik van de 
vaatweerstand in de benen. De vaatweerstand in de benen kan tijdens zogenaamde 
kantelproef berekend worden door het verschil in druk tussen slagader en ader te 
delen door de bloedstroom. In Hoofdstuk 2  hebben we de veranderingen in 
intraveneuze druk gemeten tijdens een kantelproef bij gezonde personen. Hieruit 
kwam naar voren dat bij kantelhoeken van 30° en 70° de intraveneuze druk gelijk was 
aan de berekende hydrostatische druk. Tijdens een kantelproef heeft de hydrostatisch 
druk dus eenzelfde invloed op de druk in de slagader als op de druk in de ader van het 
been.
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In Hoofdstuk 3 hebben we de veranderingen in de vaatweerstand in de benen bij 
personen met een dwarslaesie gemeten. Deze personen hebben door schade aan het 
ruggenmerg geen centrale controle over het sympathische zenuwstelsel onder het 
niveau van de dwarslaesie. Ondanks verlies van controle over het sympathisch 
zenuwstelsel vinden wij tijdens een kantelproef een toename in de vaatweerstand in de 
benen bij personen met een dwarslaesie. Dit resultaat toont aan dat de mens de 
vaatweerstand in de benen kan verhogen, onafhankelijk van centrale controle over het 
sympathisch zenuwstelsel.
Personen met een dwarslaesie hebben in rust een hogere vaatweerstand in de 
benen in vergelijking met gezonde controles. In Hoofdstuk 4  laten we zien dat 
angiotensine II, een vaatweerstand verhogende stof, een rol speelt in deze verhoogde 
vaatweerstand bij personen met een dwarslaesie. Angiotensine II speelt echter geen rol 
in de vaatweerstand in de armen van personen met een dwarslaesie en ook niet in de 
vaatweerstand in de armen en benen van gezonde personen. De verhoogde bijdrage 
van angiotensine II aan de vaatweerstand in de benen van personen met een 
dwarslaesie kan daarom gerelateerd zijn aan de extreme inactiviteit van de verlamde 
benen. Tevens laten we in Hoofdstuk 4  zien dat angiotensine II geen rol speelt in de 
toename van de vaatweerstand in de benen tijdens een kantelproef bij zowel personen 
met een dwarslaesie als gezonde personen.
Personen met een dwarslaesie hebben onbeschadigde sympathische 
zenuwvezels onder het niveau van de dwarslaesie. Overactiviteit van deze zenuwvezels 
kan zorgen voor het optreden van het interessante klinische fenomeen van autonome 
dysreflexie. Dit betreft een episode van een verhoogde bloeddruk in personen met een 
dwarslaesie, veroorzaakt door een pijnprikkel onder het niveau van de dwarslaesie, 
zoals bijvoorbeeld een overvolle blaas of een blaasontsteking. Gedacht wordt dat een 
overactiviteit van het sympathische zenuwstelsel onder het niveau van de dwarslaesie 
leidt tot een forse toename in vaatweerstand en daarmee een stijging van de 
bloeddruk. Aangenomen wordt dat de toename in vaatweerstand ontstaat via het 
vrijkomen van noradrenaline uit de uiteinden van de sympathische zenuwvezels. In 
Hoofdstuk 5  tonen we aan dat de toename van de vaatweerstand in de benen tijdens 
autonome dysreflexie bij personen met een dwarslaesie niet alleen door het vrijkomen 
van noradrenaline veroorzaakt wordt. Ook de non-adrenerge neurotransmitters 
adenosine trifosfaat (ATP) en neuropeptide Y, stoffen die ook vrijkomen uit de 
uiteinden van sympathische zenuwvezels, kunnen voor een deel de toename van de
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vaatweerstand in de benen tijdens autonome dysreflexie verklaren. Bij gezonde 
personen was de toename van de vaatweerstand tijdens een verhoging van de activiteit 
van het sympathisch zenuwstelsel door middel van een pijnprikkel wel geheel te 
verklaren door het vrijkomen van noradrenaline. Deze resultaten suggereren dat 
centrale controle over het sympathisch zenuwstelsel het vrijkomen van non-adrenerge 
neurotransmitters onderdrukt.
Ondanks een chronisch verhoogde activiteit van het sympathisch zenuwstelsel, 
hebben ouderen een verhoogde toename van de totale perifere vaatweerstand tijdens 
een kantelproef. In Hoofdstuk 6 laten wij echter zien dat tijdens deze kantelproeven 
gezonde oudere mannen een verminderde toename van de vaatweerstand in de benen 
hebben in vergelijking met gezonde jonge mannen. De verminderde toename van de 
vaatweerstand in de benen kan een verklaring zijn voor het frequenter optreden van 
orthostatische hypotensie bij het ouder worden.
In Hoofdstuk 7  hebben we naast de veranderingen in de vaatweerstand in de benen 
tijdens een kantelproef bij personen met de ziekte van Parkinson met en zonder 
orthostatische hypotensie ook het plasma volume gemeten. In vergelijking met 
personen met de ziekte van Parkinson zonder orthostatische hypotensie en gezonde 
personen hebben personen met de ziekte van Parkinson met orthostatische hypotensie 
in rust een lagere vaatweerstand in de benen gecombineerd met een hoger plasma 
volume. Tijdens een kantelproef is er bij personen met de ziekte van Parkinson met 
orthostatische hypotensie een toename in de vaatweerstand in de benen. Echter deze 
toename is niet verschillend van personen met de ziekte van Parkinson zonder 
orthostatische hypotensie en gezonde personen. Deze resultaten laten zien dat 
orthostatische hypotensie in personen met de ziekte van Parkinson niet veroorzaakt 
wordt door een verminderde toename van de vaatweerstand in de benen of door een 
inadequaat plasma volume, maar deels te verklaren is door een verlaagde 
vaatweerstand in de benen in rust.
In Hoofdstuk 8 hebben we de veranderingen in de vaatweerstand in de benen tijdens 
een kantelproef gemeten bij personen met twee selectieve aandoeningen van het 
sympathisch zenuwstelsel. Deze personen hebben autonoom falen door een 
aandoening van de post-ganglionaire sympathische zenuwvezels (puur autonoom
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falen) en door een afwezigheid van noradrenaline (dopamine-ß-hydroxylase 
deficiëntie). Ondanks het falen van het sympathisch zenuwstelsel, vinden we bij deze 
personen een toename van de vaatweerstand in de benen tijdens een kantelproef. Deze 
resultaten wijzen erop dat het sympathische zenuwstelsel niet noodzakelijk is voor een 
toename van de vaatweerstand in de benen tijdens rechtop gaan staan.
Dit proefschrift laat zien dat ondanks autonoom falen door verschillende 
aandoeningen van het sympathisch zenuwstelsel de mens tijdens een kantelproef een 
toename heeft van de vaatweerstand in de benen. Deze toename van de vaatweerstand 
wordt waarschijnlijk veroorzaakt door lokale regelsystemen in de bloedvaten van de 
benen en is onafhankelijk van het autonoom zenuwstelsel. Deze lokale regelsystemen 
proberen de bloeddruk te handhaven tijdens rechtop gaan staan wanneer het 
sympathisch zenuwstelsel faalt. Echter de toename van de vaatweerstand in de benen 
bij mensen met autonoom falen is onvoldoende om de bloeddruk te handhaven.
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